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Definition
Community-acquired pneumonia is an infection of the lung tissue acquired outside of the
hospital.
Epidemiology
CAP is a common and potentially serious illness with considerable morbidity. Globally, CAP
accounts for 15% of deaths in children under 5-years-old (WHO, 2015). CAP is a clinical diagnosis
defined as being caused by a community-acquired infection in a previously healthy child.
Streptococcu S. pneumoniae is the most common bacterial cause of pneumonia in children of all
ages (Barnson, 2018). Other bacterial pathogens that may be considered in children with CAP
include Streptococcus aureus (including Methicillin-resistant Staphylococcus aureus),
Streptococcus pyogenes (group A Streptococcus), Haemophilus influenzae type b (if
unimmunized), non-typeable Haemophius influenzae, and Moraxella catarrhalis (Branson, 2018).
Objective of Guideline
The objective of this guideline is to improve and standardize the care of children with an exam
indicative of CAP that are cared for in the Emergency Department (ED), Urgent Care Clinic (UCC),
Ambulatory, and Inpatient setting.
Perspective of Guideline
• Provider
• Patient
• Families
• Health System (CMKC)
• Community
• Payors
Target Users
• ED/UCC physicians
• Inpatient physicians
• General Pediatricians
• Residents and Fellow Trainees
• Nurse Practitioners
Target Population
Guideline Inclusion Criteria
•
Children 3 months to 18 years of age
•
No underlying medical condition
Guideline Exclusion Criteria
•
Children < 3 months of age
•
Underlying medical condition
Potential Cost Implications
•
Improved antibiotic selection leading to reduction in exposure to costly antibiotics
•
Reductions in unnecessary lab testing
Potential Organizational Barriers and Facilitators
Barriers
•
Guideline uptake by providers
•
Drug shortages
•
Limited antibiotic access in the community (e.g. Cefpodoxime)
Facilitators
•
Provider engagement
•
Provider adherence
* These guidelines do not establish a standard of care to be followed in every case. It is recognized
that each case is different, and those individuals involved in providing health care are expected to use
their judgment in determining what is in the best interests of the patient based on the circumstances
existing at the time. It is impossible to anticipate all possible situations that may exist and to prepare
guidelines for each. Accordingly, these guidelines should guide care with the understanding that
departures from them may be required at times.
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• Algorithm (see page 1)
• Power Plan (see Appendix A)
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Existing documents that guided the development of this CPG:
• The Infectious Diseases Society of America/Pediatric Infectious Diseases Society (IDSA/PIDS)
Guideline 2011
• The British Thoracic Society (BTS) Guideline 2011
• American College of Radiology (ACR) Appropriateness Criteria Pneumonia In The
Immunocompetent Child 2019
Clinical Questions Answered by this CPG:
IDSA/PIDS and BTS guidelines provided guidance to the CAP CPG team (Bradley et al., 2011;
Harris et al., 2011). American College of Radiology was used to answer question one
(Chan et al., 2019).
See Table 1 for AGREE II. Additional questions posed by the CPG Team follow:
1. In pediatric patients with suspected CAP, when is imaging necessary and what type is
needed for the diagnosis of CAP?
2. In pediatric patients with suspected CAP, what is the predictive value of a CBC or
inflammatory marker laboratory tests (CRP, Procalcitonin, ESR) to assist in the diagnosis of
CAP?
3. In pediatric patients with CAP, when should blood cultures be obtained?
4. In pediatric patients with suspected CAP, when should rapid viral testing be used to help
distinguish between viral and bacterial pneumonia?
5a. In pediatric patients with uncomplicated CAP, what treatment regimen is recommended?
• Antibiotic selection, dosing, and duration
5b. In pediatric patients with complicated CAP, what treatment regimen is recommended?
•
Antibiotic selection, dosing, and duration
5c. In pediatric patients with CAP and a penicillin allergy, what treatment regimen is
recommended?
• Serious/Type I hypersensitivity
• Non-serious/Non-type I hypersensitivity
6. In pediatric patients with suspected CAP, what clinical features suggest atypical
pneumonia?
Table 1
AGREE IIa Summary for the IDSA Guideline (Bradley et al., 2011) and British Thoracic Society
Guideline (BTS) (Harris et al., 2011)
Percent Agreement
Percent Agreement
Domain
IDSA Guideline
BTS Guideline
Scope and purpose
96%
100%
Stakeholder involvement

65%

57%

Rigor of development

56%

83%

Clarity and presentation

94%

86%

Applicability

38%

55%

Editorial independence

65%

73%

Overall guideline assessment

82%

82%

Team’s recommendation for guideline use
Yes
Yes
Note: Four EBP Scholars completed the AGREE II on both guidelines.
aBrouwers, M.C. et al. for the AGREE Next Steps Consortium. (2010) AGREE II: Advancing guideline
development, reporting and evaluation in healthcare. Canadian Medical Association
Journal, 182, E839-842. Retrieved from https://www.agreetrust.org/wpcontent/uploads/2017/12/AGREE-II-Users-Manual-and-23-item-Instrument-2009-Update-2017.pdf
* These guidelines do not establish a standard of care to be followed in every case. It is recognized
that each case is different, and those individuals involved in providing health care are expected to use
their judgment in determining what is in the best interests of the patient based on the circumstances
existing at the time. It is impossible to anticipate all possible situations that may exist and to prepare
guidelines for each. Accordingly, these guidelines should guide care with the understanding that
departures from them may be required at times.
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Practice Recommendations
1. Evaluation in the ED, UCC, and Ambulatory Setting
a. Clinical exam for uncomplicated CAP

i. Uncomplicated CAP is the absence of significant effusion, empyema, severe or
impending respiratory failure, and/or signs and symptoms of sepsis or shock
(Bradley, Byington et al. 2011).
ii.

The British Thoracic Society guideline recommends consideration of bacterial
pneumonia in patients with persistent fever >38.5 with intercostal retractions
and increased respiratory rate (Harris, Clark et al. 2011).

iii.

Patients more likely to have bacterial pneumonia, as compared to viral lower
respiratory tract disease, will have fever specifically longer duration of fever,
focal auscultatory findings, tachypnea, and no wheezing on
auscultation (Mathews, Shah et al. 2009; Neuman, Monuteaux et al. 2011;
Neuman, Scully et al. 2010; Shah, Bachur et al. 2010; Tanen and Trocinski,
2002).

iv. No gold standard currently exists for the diagnosis of bacterial pneumonia,
including chest X-ray (CXR) (Lynch, Bialy et al. 2010) limiting the
methodology of studies attempting to develop prediction tools to link clinical
symptoms with bacterial disease.
v. Children initially felt to have uncomplicated bacterial CAP on adequate
antibiotic therapy are expected to show signs of improvement within 48-72
hours (Bradley et al. 2011; Harris, Clark et al. 2011).
b. Clinical exam for complicated CAP
i. Complicated pneumonia is a pulmonary parenchymal infection with
parapneumonic effusions, multilobar disease, abscess, or cavities; necrotizing
pneumonia, empyema, pneumothorax, or bronchopleural fistula; or
pneumonia that is a complication of bacteremic disease that includes other
sites of infection (Bradley et al., 2011).
ii.

Patients more likely to have effusion or empyema may be older than 3 years
of age and have prolonged fever, greater than 7 days (Byington, Spencer et
al. 2002; Schultz, Fan et al. 2004).

iii.

The PIDS/IDSA guideline indicated that prolonged fever with abdominal and
chest pain have been associated with pneumonia complications with
concerning physical exam findings that includes dullness to percussion,
decreased/diminished breath sounds, change in quality of breath sounds and
transmitted speech (Bradley, Byington et al. 2011).

iv. For children that do not show improvement within 48-72 hours of antibiotic
therapy, further investigation should be performed, and complicated
pneumonia should be considered.
a) Re-evaluate clinical exam and vital signs.
b) Consider diagnostic imaging with chest x-ray or ultrasound in addition
to evaluate for the presence of a clinically significant pleural effusion
that would alter antibiotic choice and possible surgical management of
the patient.
c) Consideration of alternative diagnosis including viral lower respiratory
tract infection, foreign body aspiration, aspiration pneumonia, tumor
or mass, tuberculosis or histoplasmosis, or other uncommon lung
infection.
d) Consideration of an Infectious Diseases consult is recommended for a
patient with concern for an infectious process that is not clinically
improving.
* These guidelines do not establish a standard of care to be followed in every case. It is recognized
that each case is different, and those individuals involved in providing health care are expected to use
their judgment in determining what is in the best interests of the patient based on the circumstances
existing at the time. It is impossible to anticipate all possible situations that may exist and to prepare
guidelines for each. Accordingly, these guidelines should guide care with the understanding that
departures from them may be required at times.
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Clinical exam findings for atypical pneumonia

i. There are no strong clinical features to differentiate atypical pneumonia from
other organisms. Pediatric patients suspected of lower respiratory tract
infections caused by Mycoplasma pneumoniae are typically school-aged
children (age 5-18 years) (Clinical Question 6).
d. Imaging
i. The American College of Radiology (ACR) guidelines recommend no imaging
(including chest x-rays) for immunocompetent children 3 months of age and
older with suspected uncomplicated CAP in a well-appearing child who does
not require hospitalization (Chan et al. 2019).
e. Lab diagnostics
i. A strong recommendation is made against routinely obtaining labs, including
CBC and inflammatory markers, for patients with suspected bacterial CAP
(Clinical Question 2).
ii.

A conditional recommendation is made for blood cultures in patients requiring
admission with any of the following criteria (Clinical Question 3):
a) < 6months with fever,
b) not fully immunized,
c) central line,
d) immunocompromised,
e) admitted to the ICU,
f) complex/chronic medical conditions (Feudtner et al., 2014), and
g) effusion or empyema on chest radiograph
2. Treatment ED, Urgent Care, and Ambulatory for Uncomplicated and Penicillin
Hypersensitivity
a. Uncomplicated
i. A strong recommendation is made for amoxicillin to be used for ambulatory
treatment of uncomplicated CAP (Question 5a).
ii. Treatment with high dose amoxicillin 80-100 mg/kg/day divided into two or
three doses per day for 5-7 days.
b. Penicillin hypersensitivity
i. A strong recommendation is made for clindamycin or anti-pneumococcal
cephalosporin antibiotics for treatment of CAP patients with a penicillin allergy
(Question 5c).
a) Non-serious/Not-Type I Hypersensitivity (rash and itching):
1. Oral clindamycin 30-40 mg/kg/day divided every 8 hours (max
1800 mg/day) or an anti-pneumococcal cephalosporin.
2. Anti-pneumococcal cephalosporins are cefuroxime, cefpodoxime,
and cefprozil (preparations may be challenging to find in the
community).
a. Cefuroxime 250 – 500 mg PO q12h (available in tablet form
only)
b. Cefpodoxime 5 mg/kg/dose PO q12h (max 200 mg/dose)
c. Cefprozil 15 mg/kg/dose PO q12h (max 500 mg/dose)
b) Serious/Type I Hypersensitivity (hives and anaphylaxis)
1. Clindamycin 30-40 mg/kg/day divided every 8 hours (max
1800 mg/day).
c) Cefdinir is not recommended for oral therapy due to poor lung tissue
penetration.

* These guidelines do not establish a standard of care to be followed in every case. It is recognized
that each case is different, and those individuals involved in providing health care are expected to use
their judgment in determining what is in the best interests of the patient based on the circumstances
existing at the time. It is impossible to anticipate all possible situations that may exist and to prepare
guidelines for each. Accordingly, these guidelines should guide care with the understanding that
departures from them may be required at times.
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c.

Atypical pneumonia

i. Current care standard was guided by the parent guidelines
ii. A weak recommendation is made for macrolide in patients suspected of
atypical pneumonia.
a) Treatment recommendations for this patient population include the use
of macrolides based on retrospective and adult studies as well as the
effectiveness of this antibiotic class against this pathogen (Bradley,
Byington et al. 2011).
b) Significant macrolide resistance exists for Streptococcus pneumoniae
isolates making antibiotics such as azithromycin a poor choice for
patients suspected of typical bacterial CAP. The 2018 CMH antibiogram
demonstrated that 50% of S. pneumoniae were resistant to
macrolides.
c) The British Thoracic Society guideline promotes the use of macrolide
antibiotics at any age if no response is seen to first-line empirical
therapy or if Mycoplasma or Chlamydia is suspected (Harris, Clark et
al. 2011).
d) Review of primary literature suggests that there is insufficient
evidence to conclude that treatment with a macrolide antibiotic either
decreases the severity of symptoms or shortens the course of CAP
caused by atypical pathogens (Harris, Kolokathis et al. 1998; Bradley,
Arguedas et al. 2007)
3. Admission Criteria
a. Current care standard was guided by the parent guidelines.
b. A recommendation to hospitalize the following infants and children presenting with:
i. Moderate to severe CAP: respiratory distress including tachypnea for age,
dyspnea, retractions, grunting, nasal flaring, apnea, altered mental status
and/or hypoxemia.
ii. Less than 6 months of age suspected of bacterial pneumonia.
iii. Infants/children suspected of pneumonia with Staphylococcus aureus as a
pathogen.
iv. Infants/children with concerns for compliance with therapy.
v. Recommendations for admission to the ICU include respiratory failure or
impending respiratory failure, need for pharmacologic support of blood
pressure or perfusion, patient remains hypoxic on >0.50 inspired O2 or a
patient with altered mental status (Bradley, Byington et al. 2011).
4. Evaluation Inpatient Uncomplicated CAP
a. Imaging
i. The ACR recommends chest radiograph as the initial imaging for
immunocompetent children 3 months of age and older with communityacquired pneumonia that do not respond to initial outpatient treatment or
requires hospital admission (Chan et al. 2019).
ii. The ACR guidelines state that chest ultrasound may be appropriate for the
initial imaging of immunocompetent children 3 months of age and older with
community-acquired pneumonia that does not respond to initial outpatient
treatment or requires hospital admission (Chan et al. 2019). However, chest
ultrasound is very operator dependent and its effectiveness decreases quickly
in untrained hands.
iii. Currently, diagnostic ultrasound is limited to Adele Hall and Children’s Mercy
Kansas campuses, and so we recommend the majority of patients continue to
be screened for CAP using CXR.

* These guidelines do not establish a standard of care to be followed in every case. It is recognized
that each case is different, and those individuals involved in providing health care are expected to use
their judgment in determining what is in the best interests of the patient based on the circumstances
existing at the time. It is impossible to anticipate all possible situations that may exist and to prepare
guidelines for each. Accordingly, these guidelines should guide care with the understanding that
departures from them may be required at times.
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b. Lab diagnostics
i. A strong recommendation is made against routinely obtaining labs, including
CBC and inflammatory markers, for patients with suspected bacterial CAP
(Clinical Question 2).
ii.

A conditional recommendation is made for blood cultures in patients requiring
admission with any of the following criteria (Clinical Question 3):
a) < 6months with fever,
b) not fully immunized,
c) central line,
d) immunocompromised,
e) admitted to the ICU,
f) complex/chronic medical conditions (Feudtne et al., 2014), and
g) effusion or empyema on chest radiograph.
5. Treatment Inpatient Uncomplicated and Penicillin Hypersensitivity
a. Uncomplicated
i. A strong recommendation is made for first-line therapy of ampicillin for
inpatient treatment of uncomplicated CAP (Clinical Question 5a).
a) Ampicillin 50 mg/kg/dose IV q6h (max 2 gm/dose)
1. High dose ampicillin overcomes the resistance of S.
pneumoniae
b. Penicillin Hypersensitivity
i. Non-serious/Not-Type I Hypersensitivity (rash and itching) (Clinical Question
5c):
a) Ceftriaxone 50 mg/kg/dose IV q24h (max 2 gm/dose)
1. Ceftriaxone must not be administered simultaneously with
calcium-containing IV solutions, including continuous calciumcontaining infusions such as parenteral nutrition via a Y-site.
However, in patients other than neonates, ceftriaxone and
calcium-containing solutions may be administered sequentially
of one another if the infusion lines are thoroughly flushed
between infusions with a compatible fluid (FDA, 2014).
ii. Serious/Type I Hypersensitivity (hives and anaphylaxis)
a) Clindamycin 13.3 mg/kg/dose IV q8h (max 600 mg/dose)
1. At CMH 10% of Streptococcus pneumonia (pneumococcus)
isolates were resistant to clindamycin in 2018.
6. Evaluation inpatient Complicated CAP
a. Imaging
i. The ACR recommends chest radiograph as the initial imaging for
immunocompetent children 3 months of age and older with communityacquired pneumonia that do not respond to initial outpatient treatment or
requires hospital admission (Chan et al. 2019).
ii. ARC recommends further imaging with ultrasound (US) or chest computed
tomography (CT) may be appropriate in a patient with moderate to large
parapneumonic effusion by CXR (Chan, 2019).
7. Treatment Inpatient Complicated CAP
a. A strong recommendation is made for ampicillin/sulbactam to be used for patients with
complicated CAP (Clinical Question 5b).
i. Antibiotics for inpatient treatment of complicated CAP.
a) Treatment with ampicillin/sulbactam 50 mg of ampicillin
component/kg/dose IV every 6 hours (max 2 g of ampicillin
component/dose) is recommended when pneumonia is complicated.
* These guidelines do not establish a standard of care to be followed in every case. It is recognized
that each case is different, and those individuals involved in providing health care are expected to use
their judgment in determining what is in the best interests of the patient based on the circumstances
existing at the time. It is impossible to anticipate all possible situations that may exist and to prepare
guidelines for each. Accordingly, these guidelines should guide care with the understanding that
departures from them may be required at times.
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b) If concerns for methicillin-resistant Staphylococcus aureus or severe
disease, the addition of vancomycin 15 mg/kg/dose IV every 6 to 8
hours is recommended.
c) Recommend consideration of further evaluation, including repeat CXR
or other diagnostic imaging, change in antibiotics or ID consultation in
a patient without clinical improvement after 48-72 hours of therapy.
d) Children with bacterial pneumonia on adequate antibiotic therapy
should show signs of improvement within 48 to 72 hours (Bradley,
Byington et al. 2011; Harris, Clark et al. 2011). For children that do
not show this improvement, further investigation should be performed.
8. IR/Surgical Consult

a. Recommend consultation with interventional radiology or surgery for evaluation of
clinically significant effusion/empyema for drainage with thoracentesis
b. Prompt evaluation of effusion by thoracentesis is essential in the diagnosis and
management of complicated CAP.
c. Evaluation of the fluid should include laboratory analysis to assist in diagnosis with
recommendations to obtain gram stain and culture, cell count with differential and PCR
if available.
d. For patients with a simple parapneumonic effusion, with fluid evaluation indicating
effusion without empyema, thoracentesis alone maybe sufficient management,
although the risk of fluid re-accumulate is a concern.
e. The PIDS/IDSA guideline recommends:
i. size of the effusion is an important factor in determining management
strategies
ii. small, uncomplicated effusions be treated with antibiotics alone.
f. The PIDS/IDSA guideline defines significant effusion as a >10mm rim of fluid on a
lateral decubitus film or greater than one-fourth of the hemithorax opacified on an
upright chest radiograph (Bradley, Byington et al. 2011).
g. Large effusions or effusions associated with respiratory distress require drainage.
h. Utilization of chest tube with fibrinolytic agents is our recommended first-line
intervention.
i. Chest tube with fibrinolysis has been shown to pose less risk of clinical deterioration
without any decrease in therapeutic response for patients identified with empyema (St
Peter, Tsao et al. 2009). The PIDS/IDSA guideline identifies that utilization of VATS or
chest tube with fibrinolytic agents have been shown to decrease morbidity compared
to chest tube alone including reductions in the duration of fever and hospital length of
stay (Bradley, Byington et al. 2011)
j. VATS are rarely indicated and should be considered in discussion with surgery only
after demonstrated treatment failure with chest tube + fibrinolysis (Kelly et al. 2018).
9. Alternative Diagnosis with No clinical Improvement Without Parapneumonic
Effusion.
a.
b.
c.
d.
e.

Foreign body aspiration
Aspiration pneumonia
Tuberculosis or histoplasmosis
Other uncommon infections of the lungs
Tumor

10. Discharge planning
a.

Transition to oral antibiotics
i. The PIDS/IDSA guideline has the same recommendation; amoxicillin as first-line
therapy in patients suspected of bacterial disease. In addition to amoxicillin’s
effectiveness, treating with a limited spectrum antimicrobial will help decrease the
development of antibiotic resistance (Bradley, Byington et al. 2011). Patients
discharged on amoxicillin did not have significant treatment failures identified as
either readmission to the hospital or necessitating a change in antibiotic therapy
after discharge (Newman, Hedican et al. 2012). Patients with mild to moderate

* These guidelines do not establish a standard of care to be followed in every case. It is recognized
that each case is different, and those individuals involved in providing health care are expected to use
their judgment in determining what is in the best interests of the patient based on the circumstances
existing at the time. It is impossible to anticipate all possible situations that may exist and to prepare
guidelines for each. Accordingly, these guidelines should guide care with the understanding that
departures from them may be required at times.
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b.

pneumonia may receive the same benefit from oral antibiotics as parenteral
therapy if they can tolerate oral fluids and show compliance with oral therapy
(Atkinson, Lakhanpaul et al. 2007). The British Thoracic Society guideline reserves
IV antibiotics for patients unable to tolerate oral fluids or patients presenting with
septicemia or complicated pneumonia (Harris, Clark et al. 2011).
ii. For uncomplicated pneumonia, transition to oral high dose amoxicillin (80-100
mg/kg/day divided twice a day), when clinically indicated, and at discharge to
complete a total course of antibiotics of 5 to7 days.
iii. Treatment with high-dose amoxicillin (80-100 mg/kg/day divided twice a day) is
recommended when bacterial pneumonia is suspected (Kabra, Lodha et al. 2006).
High-dose amoxicillin has high lung tissue penetration and can overcome S.
pneumoniae resistance (Deeks, Palacio et al. 1999), which has been identified in
multiple studies as the most common bacterial pathogen in children (HeiskanenKosma, Korppi et al. 1998; Wubbel, Muniz et al. 1999; Juven, Mertsola et al. 2000;
Michelow, Olsen et al. 2004; Madhi, Kuwanda et al. 2005).
iv. For patients with non-serious/not-type I hypersensitivity (rash and itching)
and uncomplicated CAP, oral transition to clindamycin (30-40 mg/kg/day
divided every 8 hours; max 1800 mg/day), cefuroxime (250 – 500 mg PO
q12h), cefpodoxime (5 mg/kg PO q12h, max 200 mg/dose), or cefprozil (15
mg/kg PO q12h, max 500 mg/dose) can be considered.
v. For patients with serious/type I hypersensitivity (hives and anaphylaxis) and
uncomplicated CAP, oral transition to clindamycin (30 – 40 mg/kg/day divided
every 8 hours, max 1800 mg/day) is recommended.
vi. For complicated CAP, transition from ampicillin/sulbactam (IV) to high-dose
amoxicillin/clavulanate (80 – 100 mg/kg/day divided every 8 – 12 hours, max
4000 mg/day). The extra-strength (600 mg amoxicillin/5mL) oral suspension
or XR capsules should be utilized when using high-dose
amoxicillin/clavulanate. For oral regimens providing coverage against
methicillin-resistant Staphylococcus aureus, contact Infectious Diseases or
Antimicrobial Stewardship for oral transition regimens.
Discharge Criteria
i.
ii.
iii.
iv.
v.

Overall clinical improvement after a minimum of 12-24 hours
Consistent pulse oximetry >90% on room air for at least 12-24 hours
Stable baseline mental status
Resolved work of breathing/tachypnea
Documented toleration of oral antibiotics and/or parents have demonstrated
the ability to administer antibiotics

How guideline was placed into practice

Once approved, the guideline was presented to appropriate care teams and implemented. Care
measurements will be assessed and shared quarterly with appropriate care teams to determine if
changes need to occur.

Guideline Preparation

This guideline was prepared by the Evidence Based Practice (EBP) Department in collaboration
with content experts at Children’s Mercy Kansas City. Development of this guideline supports of
the Improvement Center to promote care standardization that builds a culture of quality and
safety that is evidenced by measured outcomes. If a conflict of interest was identified the conflict
would be disclosed next to the team members name.

Team Members and Representation
Team Leader
• Jessica Markham, MD, MSc; Hospitalists
Team Members
• Alaina Burns, Pharm.D., BCPPS; Pharmacy
• Jennifer Goldman, MD, MS-CR; Infectious Disease
* These guidelines do not establish a standard of care to be followed in every case. It is recognized
that each case is different, and those individuals involved in providing health care are expected to use
their judgment in determining what is in the best interests of the patient based on the circumstances
existing at the time. It is impossible to anticipate all possible situations that may exist and to prepare
guidelines for each. Accordingly, these guidelines should guide care with the understanding that
departures from them may be required at times.
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Scotti Brackett, APRN; Urgent Care
Sherwin Chan, MD, PhD; Radiology
Frances Turcotte, MD, MPH, FAAP; Emergency Department

EBP Team Members
• Jarrod Dusin, MS, RD, LD, CPHQ; EBP Program Manager, Team Facilitator
• Jeffrey Michael, DO; EBP (Past Medical Director during work on this CPG)
• Jacqueline A Bartlett, PhD, RN; EBP Director
• Nancy Allen, MS, MLS, RD, LD, CPHQ; EBP Program Manager

Guideline Development Funding

The development of this guideline was underwritten by EBP, Pharmacy, and the Divisions of
Pediatric Hospital Medicine, Emergency Medicine, Urgent Care, Infectious Disease, and Radiology.

Approval Process

Guidelines are reviewed and approved by J. Newland, MD (external review) and J. Julian, MD
(internal review), Content Expert Team, the EBP Department, and other appropriate hospital
committees as deemed suitable for the guidelines intended use. Guidelines are reviewed and
updated as necessary every 3 years within the EBP Department at CMKC. Content expert teams
will be involved with every review and update.

Disclaimer

The content experts and the Office of EBP are aware of the controversies surrounding CAP CPG
Guideline. When evidence is lacking or inconclusive, options in care are provided in the guideline
and the power plans that accompany the guideline.
These guidelines do not establish a standard of care to be followed in every case. It is recognized
that each case is different, and those individuals involved in providing health care are expected to
use their judgment in determining what is in the best interests of the patient based on the
circumstances existing at the time.
It is impossible to anticipate all possible situations that may exist and to prepare guidelines for
each. Accordingly, these guidelines should guide care with the understanding that departures
from them may be required at times.
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Specific Care Question In pediatric patients with suspected CAP, what is the predictive value of a complete blood count (CBC) or inflammatory marker
laboratory tests (c-reactive protein [CRP], procalcitonin [PCT], erythrocyte sedimentation rate [ESR]) to assist in the diagnosis of CAP?
Recommendations from the CAP CPG Team
A strong recommendation is made against routinely obtaining labs, including CDC and inflammatory markers, for patients with suspected bacterial
CAP, based on expert opinion and review of current literature of the CAP CPG Team. The overall certainty in the evidence is very lowd. See Summary by
Outcome for substantiation of recommendations.
Literature Summary
Background. Hospitalization for community-acquired pneumonia in childhood is common in the United States (Lee, Lorch, Sheffler-Collins, Kronman, &
Shah, 2010). It is difficult to differentiate between viral and bacterial CAP because an organism in not identified in many cases. Williams et al. (2015)
report viruses account for approximately 73% of CAP in childhood, but when stratified by age, children < 2 years old have much higher rates of viral
pneumonia (80%) compared with those > 2 years old (49%).
The Infectious Diseases Society of America/Pediatric Infectious Diseases Society (IDSA/PIDS) makes a strong recommendation based on high-quality
evidence that inflammatory markers such as the ESR, CRP, or PCT cannot be used as the only determinants to distinguish between viral and bacterial
causes of CAP (Bradley et al., 2011). The British Thoracic Society (BTS) recommends not routinely testing inflammatory markers as they are not of
clinical value in distinguishing viral from bacterial infections (Harris et al., 2011).
The IDSA/PIDS and BTS Guidelines were assessed with the AGREE IIa instrument to assist the team in determining the appropriateness to adopt as the
governing guideline for this CAT. IDSA/PIDS and BTS were selected with an overall AGREE II score of 82%, with the recommendation to be used with
modifications (see Table 1).
Study characteristics. The search for suitable studies was completed on July 2018, 2018. S. Chan, MD, and A. Burns, PharmD, BCPPS reviewed the
65 titles and abstracts and identified 12 articles that were believed to answer the question using the Rayyanb tool. After an in-depth review, 12 articles
answered the question. Flood, Badik, and Aronoff (2008) a systematic review (SR) and eleven diagnostic studies (Alcoba et al., 2017; Brauner,
Goldman, & Kozer, 2010; Don, Valent, Korppi, & Canciani, 2009; Elemraid et al., 2014; Esposito, Bianchini, et al., 2016; Esposito, Di Gangi, et al.,
2016; Galetto-Lacour et al., 2013; Guo, Wang, Zhu, & Hao, 2015; Higdon et al., 2017; Hoshina et al., 2014; Stockmann et al., 2017) (see Figure 1)
are included in this synopsis. Flood et al. (2008) included eight diagnostic studies (Babu, Ganguly, Singhi, & Walia, 1989; Isaacs, 1989; M. Korppi &
Kröger, 1993; T. H.-K. Korppi, Matti, 2000; Lala, Madhi, & Pettifor, 2002; Moulin et al., 2001; Nohynek, Valkeila, Leinonen, & Eskola, 1995; Virkki et
al., 2002).
There is no gold standard to diagnosis bacterial CAP. The studies included in this review used different reference standards (gold standard) in their
diagnosis of bacterial CAP.
Summary by Outcome
CRP. Eight diagnostic studies (Alcoba et al., 2017; Elemraid et al., 2014; Esposito, Bianchini, et al., 2016; Esposito, Di Gangi, et al., 2016; Flood et al.,
2008; Galetto-Lacour et al., 2013; Higdon et al., 2017; Hoshina et al., 2014) evaluated serum concentrations of CRP as a predictor of bacterial
pneumonia. Three studies (Elemraid et al., 2014; Flood et al., 2008; Hoshina et al., 2014) could not be included in the meta-analysis due to incomplete
data. Flood et al. (2008) was a meta-analysis of eight diagnostic studies (Babu et al., 1989; Isaacs, 1989; M. Korppi & Kröger, 1993; T. H.-K. Korppi,
Matti, 2000; Lala et al., 2002; Moulin et al., 2001; Nohynek et al., 1995; Virkki et al., 2002). Flood et al. (2008) reported a pooled study population of
1230 pediatric patients aged one month to 18 years, with the incidence of bacterial infection of 41%.
* These guidelines do not establish a standard of care to be followed in every case. It is recognized that each case is different, and those individuals involved
in providing health care are expected to use their judgment in determining what is in the best interests of the patient based on the circumstances existing at
the time. It is impossible to anticipate all possible situations that may exist and to prepare guidelines for each. Accordingly, these guidelines should guide
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Children with bacterial pneumonia were signiﬁcantly more likely to have serum CRP concentrations exceeding 3.5–6 mg/dL than children with
nonbacterial infections, OR = 2.58, 95% CI [1.20, 5.55]. The positive predictive value, for CRP values of 4-6 mg/L, was only 64%. There was signiﬁcant
heterogeneity among the eight studies, p = .001, I2 = 81.4%. Elemraid et al. (2014) found among children (< 16 years of age) admitted to the hospital
with pneumonia (N = 401), those with bacterial pneumonia versus viral had a higher median CRP level, 16.5mg/dL versus 4mg/dL, p < .001. Hoshina
et al. (2014) found among children (< 15 years old) admitted to the hospital with pneumonia, those with bacterial pneumonia versus viral had higher
mean CRP levels, 9.93 mg/dL versus 2.11 mg/dL, p < .02.
CRP > 0.74 mg/dL. Two studies (Esposito, Bianchini, et al., 2016; Esposito, Di Gangi, et al., 2016) evaluated serum concentrations of CRP, with a
cutoff value of > 0.74mg/dL, as a predictor of bacterial pneumonia (N = 534). Sensitivity ranged from 51% to 64% and specificity ranged from
69% to 81% (see Figure 3 & Table 3). For children < 2 years of age, a cutoff value of > 0.74mg/dL would result in nine to 12 false-negative
diagnoses of bacterial pneumonia per 100 patients and 14 to 23 false-positive diagnoses per 100 patients. For children > 2 years of age, a cutoff
value of > 0.74mg/dL would result in 18 to 24 false-negative diagnoses of bacterial pneumonia per 100 patients and nine to 15 false-positive
diagnoses per 100 patients. The evidence was of very low certainty based on serious risk of bias, serious inconsistency, and serious imprecision
(see Table 3). There is no gold standard test to determine bacterial pneumonia (risk of bias), the studies used different reference standards
(inconsistency), and there was a low number of participants (imprecision).
CRP > 4 mg/dL. Three studies (Alcoba et al., 2017; Galetto-Lacour et al., 2013; Higdon et al., 2017) evaluated serum concentrations of CRP, with
a cutoff value of > 4mg/dL, as a predictor of bacterial pneumonia (N = 937). Sensitivity ranged from 77% to 95% and specificity ranged from 32%
to 97% (see Figure 4 & Table 4). For children <2 years of age, a cutoff value of > 4mg/dL would result in one to six false-negative diagnoses of
bacterial pneumonia per 100 patients and 17 to 51 false-positive diagnoses per 100 patients. For children > 2 years of age, a cutoff value of >
4mg/dL would result in two to 11 false-negative diagnoses of bacterial pneumonia per 100 patients and 11 to 34 false-positive diagnoses per 100
patients. The evidence was of very low certainty based on serious risk of bias, serious inconsistency, and serious imprecision (see Table 4). There is
no gold standard reference test to determine bacterial pneumonia (risk of bias), the studies used different reference standards (inconsistency), and
the specificity range is wide (imprecision).
CRP > 8 mg/dL. Two studies (Alcoba et al., 2017; Galetto-Lacour et al., 2013) evaluated serum concentrations of CRP, with a cutoff value of >
8mg/dL, as a predictor of bacterial pneumonia (N = 217). Sensitivity ranged from 74% to 92% and specificity ranged from 61% to 70% (see Figure
5 & Table 5). For children < 2 years of age, a cutoff value of > 8mg/dL would result in two to six false-negative diagnoses of bacterial pneumonia
per 100 patients and 23 to 29 false-positive diagnoses per 100 patients. For children > 2 years of age, a cutoff value of > 8mg/dL would result in
four to 13 false-negative diagnoses of bacterial pneumonia per 100 patients and 15 to 19 false-positive diagnoses per 100 patients. The evidence
was of very low certainty based on serious risk of bias, serious inconsistency, and serious imprecision (see Table 5). There is no gold standard
reference test to determine bacterial pneumonia (risk of bias), the studies used different reference standards (inconsistency), and there was a low
number of participants (imprecision).
WBC. Seven diagnostic studies (Brauner et al., 2010; Don et al., 2009; Esposito, Bianchini, et al., 2016; Galetto-Lacour et al., 2013; Guo et al., 2015;
Hoshina et al., 2014) evaluated WBC as a predictor of bacterial pneumonia. Two studies (Elemraid et al., 2014; Guo et al., 2015) were not included in
the meta-analysis due to incomplete data.

* These guidelines do not establish a standard of care to be followed in every case. It is recognized that each case is different, and those individuals involved
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Elemraid et al. (2014) found among children (<16 years of age) admitted to the hospital with pneumonia (N = 401). WBC count could not differentiate
between bacterial and viral infection, OR = 1.04, 95% CI [0.94, 1.15], p = .467. Guo et al. (2015) found among children (<18 years of age) admitted
to the hospital with pneumonia (N = 126), WBC count could not differentiate between bacterial and viral infection, p > 0.05.
WBC > 10.10 x 103/uL. Three studies (Don et al., 2009; Esposito, Bianchini, et al., 2016; Hoshina et al., 2014) evaluated WBC, with a cutoff
value of > 10.10 103/uL, as predictor of bacterial pneumonia (N = 210). Sensitivity ranged from 62% to 80% and specificity ranged from 38% to
50% (see Figure 6 & Table 6). For children < 2 years of age, a cutoff value of > 10.10 103/uL would result in five to nine false-negative diagnoses
of bacterial pneumonia per 100 patients and 37 to 46 false-positive diagnoses per 100 patients. For children > 2 years of age, a cutoff value of >
10.10 103/uL would result in 10 to 19 false-negative diagnoses of bacterial pneumonia per 100 patients and 25 to 31 false-positive diagnoses per
100 patients. The evidence was of very low certainty based on serious risk of bias, serious inconsistency, and serious imprecision (see Table 6).
There is no gold standard reference test to determine bacterial pneumonia (risk of bias), the studies used different reference standards
(inconsistency), and there was a low number of participants (imprecision).
WBC > 15 x 103/uL. Two studies (Don et al., 2009; Galetto-Lacour et al., 2013) evaluated WBC, with a cutoff value of > 15 103/uL, as predictor
of bacterial pneumonia (N = 142). Sensitivity ranged from 57% to 65% and specificity ranged from 67% to 68% (see Figure 7 & Table 7). For
children < 2 years of age, a cutoff value of > 15 103/uL would result in nine to 11 false-negative diagnoses of bacterial pneumonia per 100 patients
and 24 to 25 false-positive diagnoses per 100 patients. For children > 2 years of age, a cutoff value of > 15 103/uL would result in 17 to 22 falsenegative diagnoses of bacterial pneumonia per 100 patients and 16 to 16 false-positive diagnoses per 100 patients. The evidence was of very low
certainty based on serious risk of bias, serious inconsistency, and serious imprecision (see Table 7). There is no gold standard reference test to
determine bacterial pneumonia (risk of bias), the studies used different reference standards (inconsistency), and there was a low number of
participants (imprecision).
WBC > 25 x 103/uL. Two studies (Brauner et al., 2010; Don et al., 2009) evaluated WBC, with a cutoff value of > 25 103/uL, as predictor of
bacterial pneumonia (N = 409). Sensitivity ranged from 11% to 60% and specificity ranged from 72% to 100% (see Figure 8 & Table 8). For
children < 2 years of age, a cutoff value of > 25 103/uL would result in 10 to 22 false-negative diagnoses of bacterial pneumonia per 100 patients
and zero to 21 false-positive diagnoses per 100 patients. For children > 2 years of age, a cutoff value of > 25 103/uL would result in 20 to 44 falsenegative diagnoses of bacterial pneumonia per 100 patients and zero to 14 false-positive diagnoses per 100 patients. The evidence was of very low
certainty based on serious risk of bias, serious inconsistency, and serious imprecision (see Table 8). There is no gold standard reference test to
determine bacterial pneumonia (risk of bias), the studies used different reference standards (inconsistency), and wide sensitivity and specificity
(imprecision).
ESR. One diagnostic study (Don et al., 2009) evaluated ESR as a predictor of bacterial pneumonia.
ESR > 40 mm/h. One study (Don et al., 2009) evaluated ESR, with a cutoff value of > 40mm/h, as predictor of bacterial pneumonia (N = 66).
Sensitivity and specificity were 74% and 35%, respectively (see Figure 9 & Table 9). For children < 2 years of age, a cutoff value of > 40mm/h
would result in three to 10 false-negative diagnoses of bacterial pneumonia per 100 patients and 31 to 64 false-positive diagnoses per 100 patients.
For children > 2 years of age, a cutoff value of > 40mm/h would result in seven to 20 false-negative diagnoses of bacterial pneumonia per 100
patients and 20 to 42 false-positive diagnoses per 100 patients. The evidence was of very low certainty based on serious risk of bias and very
serious imprecision (see Table 9). There is no gold standard reference test to determine bacterial pneumonia (risk of bias), and there was a low
number of participants (imprecision).
* These guidelines do not establish a standard of care to be followed in every case. It is recognized that each case is different, and those individuals involved
in providing health care are expected to use their judgment in determining what is in the best interests of the patient based on the circumstances existing at
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ESR > 65 mm/h. One study (Don et al., 2009) evaluated ESR, with a cutoff value of > 65mm/h, as predictor of bacterial pneumonia (N = 66).
Sensitivity and specificity were 59% and 70%, respectively (see Figure 10 & Table 10). For children < 2 years of age, a cutoff value of > 65mm/h
would result in seven to 14 false-negative diagnoses of bacterial pneumonia per 100 patients and nine to 40 false-positive diagnoses per 100
patients. For children > 2 years of age, a cutoff value of > 65mm/h would result in 13 to 28 false-negative diagnoses of bacterial pneumonia per
100 patients and six to 27 false-positive diagnoses per 100 patients. The evidence was of very low certainty based on serious risk of bias and very
serious imprecision (see Table 10). There is no gold standard reference test to determine bacterial pneumonia (risk of bias), and there was a low
number of participants (imprecision).
ESR > 90 mm/h. One study (Don et al., 2009) evaluated ESR, with a cutoff value of > 90mm/h, as predictor of bacterial pneumonia (N = 66).
Sensitivity and specificity were 33% and 95%, respectively (see Figure 11 & Table 11). For children < 2 years of age, a cutoff value of > 90mm/h
would result in 13 to 20 false-negative diagnoses of bacterial pneumonia per 100 patients and zero to 18 false-positive diagnoses per 100 patients.
For children > 2 years of age, a cutoff value of > 90mm/h would result in 25 to 40 false-negative diagnoses of bacterial pneumonia per 100
patients and zero to 12 false-positive diagnoses per 100 patients. The evidence was of very low certainty based on serious risk of bias and very
serious imprecision (see Table 11). There is no gold standard reference test to determine bacterial pneumonia (risk of bias), and there was a low
number of participants (imprecision).
ESR > 115 mm/h. One study (Don et al., 2009) evaluated ESR, with a cutoff value of > 115mm/h, as predictor of bacterial pneumonia (N = 66).
Sensitivity and specificity were 11% and 95%, respectively (see Figure 12 & Table 12). For children < 2 years of age, a cutoff value of > 115mm/h
would result in 19 to 24 false-negative diagnoses of bacterial pneumonia per 100 patients and zero to 19 false-positive diagnoses per 100 patients.
For children > 2 years of age, a cutoff value of > 115mm/h would result in 38 to 48 false-negative diagnoses of bacterial pneumonia per 100
patients and zero to 12 false-positive diagnoses per 100 patients. The evidence was of very low certainty based on serious risk of bias and very
serious imprecision (see Table 12). There is no gold standard reference test to determine bacterial pneumonia (risk of bias), and there was a low
number of participants (imprecision).
PCT. Six diagnostic studies (Alcoba et al., 2017; Don et al., 2009; Esposito, Bianchini, et al., 2016; Galetto-Lacour et al., 2013; Hoshina et al., 2014;
Stockmann et al., 2017) evaluated PCT as a predictor of bacterial pneumonia. One study (Stockman et al., 2017) could not be added to the metaanalysis due to incomplete data.
Stockman (2018) found among children (median 2.4 years of age) admitted to the hospital with pneumonia (N = 532), bacterial pneumonia had higher
PCT concentrations (median, 6.10; Interquartile range (IQR), 0.84–22.79 ng/mL) than those with viral pathogens only (n = 349; median, 0.33; IQR,
0.12–1.35 ng/mL), or no pathogen detected (n = 47; median, 0.44; IQR, 0.10–1.83 ng/mL) (p < .001 for all).
PCT > 0.188 ng/mL. Two studies (Esposito, Bianchini, et al., 2016; Hoshina et al., 2014) evaluated serum concentrations of PCT, with a cutoff
value of > 0.188mg/dL, as a predictor of bacterial pneumonia (N = 318). Sensitivity ranged from 67% to 86% and specificity ranged from 65% to
82% (see Figure 13 & Table 13). For children <2 years of age, a cutoff value of > 0.188mg/dL would result in three to eight false-negative
diagnoses of bacterial pneumonia per 100 patients and 13 to 26 false-positive diagnoses per 100 patients. For children > 2 years of age, a cutoff
value of > 0.188mg/dL would result in seven to 16 false-negative diagnoses of bacterial pneumonia per 100 patients and nine to 17 false-positive
diagnoses per 100 patients. The evidence was of very low certainty based on serious risk of bias, serious inconsistency, and serious imprecision
(see Table 13). There is no gold standard reference test to determine bacterial pneumonia (risk of bias), the studies used different reference
standards (inconsistency), and there was a low number of participants (imprecision).
* These guidelines do not establish a standard of care to be followed in every case. It is recognized that each case is different, and those individuals involved
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PCT > 0.4 ng/mL. Three studies (Alcoba et al., 2017; Don et al., 2009; Galetto-Lacour et al., 2013) evaluated serum concentrations of PCT, with
a cutoff value of > 0.4mg/dL, as a predictor of bacterial pneumonia (N = 284). Sensitivity ranged from 76% to 97% and specificity ranged from
29% to 47% (see Figure 14 & Table 14). For children <2 years of age, a cutoff value of > 0.4mg/dL would result in one to six false-negative
diagnosis of bacterial pneumonia per 100 patients and 40 to 53 false-positive diagnoses per 100 patients. For children > 2 years of age, a cutoff
value of > 0.4mg/dL would result in one to 12 false-negative diagnoses of bacterial pneumonia per 100 patients and 26 to 36 false-positive
diagnoses per 100 patients. The evidence was of very low certainty based on serious risk of bias, serious inconsistency, and serious imprecision
(see Table 14). There is no gold standard reference test to determine bacterial pneumonia (risk of bias), the studies used different reference
standards (inconsistency), and there was a low number of participants (imprecision).
Identification of Studies
Search Strategy and Results (see Figure 1)
("community acquired pneumonia" OR "community-acquired pneumonia" OR ("Community-Acquired Infections"[MeSH] AND "Pneumonia"[MAJR]))
AND (("inflammatory markers"[tw] OR "inflammatory marker"[tw] OR biomarker[tw] OR "Biomarkers/blood"[Mesh] OR biomarkers[tw] OR "Blood
Sedimentation"[Mesh] OR "C-Reactive Protein"[Mesh] OR Procalcitonin OR PCT[tw] OR "C-reactive protein" OR CRP[tw] OR "Protein
Precursors/blood"[Mesh] OR "Calcitonin Gene-Related Peptide"[MeSH] OR "Calcitonin/blood"[Mesh] OR "Interferon-alpha/blood"[MeSH] OR
WBC[tw] OR "white blood cell count" OR "Leukocyte Count"[MeSH] OR "Neutrophils"[Mesh]) AND ("Predictive Value of Tests"[MeSH] OR utility[tw]
OR "Diagnosis, Differential"[MeSH] OR sensitivity[tw] OR specificity[tw] OR "predictive value" OR differential[tw] OR value[tw] OR diagnosis[tw] OR
diagnostic[tw] OR "ROC Curve"[Mesh] OR "Sensitivity and Specificity"[Mesh] OR "Area Under Curve"[MeSH Terms])) AND (child OR children OR
infant OR adolescence OR pediatr* OR paediatr*) AND ("last 5 years"[PDat])
Records identified through database searching n = 65
Additional records identified through other sources n = 3
Studies Included in this Review
Citation
Alcoba et al. (2017)
Brauner et al. (2010)
Don et al. (2009)
Elemraid et al. (2014)
Esposito, Bianchini, et al. (2016)
Esposito, Di Gangi, et al. (2016)
Flood et al. (2008)
*Isaacs (1989)
*Babu et al. (1989)
*M. Korppi and Kröger (1993)
*Nohynek et al. (1995)
*T. H.-K. Korppi, Matti (2000)
*Moulin et al. (2001)
*Virkki et al. (2002)
*Lala et al. (2002)
Galetto-Lacour et al. (2013)

Study Type
Diagnostic
Diagnostic
Diagnostic
Diagnostic
Diagnostic
Diagnostic
Diagnostic
Diagnostic
Diagnostic
Diagnostic
Diagnostic
Diagnostic
Diagnostic
Diagnostic
Diagnostic
Diagnostic
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Guo et al. (2015)
Higdon et al. (2017)
Hoshina et al. (2014)
Stockmann et al. (2017)
*References marked with an asterisk

Diagnostic
Diagnostic
Diagnostic
Diagnostic
indicate studies included from previously published SR

Studies Not Included in this Review with Exclusion Rationale
Citation
Reason for exclusion
Gilbert (2016)
Adult patients
Kartal (2017)
Does not differentiate between viral and bacterial CAP
Ning (2016)
Does not differentiate between viral and bacterial CAP
Shah (2005)
Includes other bacterial infection
Methods Used for Appraisal and Synthesis
aThe Appraisal of Guidelines Research and Evaluation II (AGREE II) is an international instrument used to assess the quality and reporting of clinical practice
guidelines for this analysis (Brouwers et al. 2010).
bRayyan is a web-based software used for the initial screening of titles and / or abstracts for this analysis (Ouzzani, Hammady, Fedorowicz & Elmagarmid,
2017).
cReview Manager (Higgins & Green, 2011) is a Cochrane Collaborative computer program used to assess the study characteristics as well as the risk of bias
and create the forest plots found in this analysis.
dThe GRADEpro Guideline Development Tool (GDT) is the tool used to create the Summary of Findings table(s) for this analysis.
eThe Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) flow diagram depicts the process in which literature is searched,
screened, and eligibility criteria is applied (Moher, Liberati, Tetzlaff, & Altman, 2009).
fThe Quality Assessment of Diagnostic Accuracy Studies-2 (QUADAS-2) (Whiting et al., 2011) is was used to assess the sources of bias and variation in the
diagnostic studies found in this analysis.
aBrouwers,

M.C. et al. for the AGREE Next Steps Consortium. (2010) AGREE II: Advancing guideline development, reporting and evaluation in
healthcare. Canadian Medical Association Journal, 182, E839-842. Retrieved from https://www.agreetrust.org/wp-content/uploads/2017/12/AGREEII-Users-Manual-and-23-item-Instrument-2009-Update-2017.pdf
bOuzzani, M., Hammady, H., Fedorowicz, Z., & Elmagarmid, A. (2016). Rayyan-a web and mobile app for systematic reviews. Systematic Reviews, 5(1),
210. doi:10.1186/s13643-016-0384-4
cHiggins, J. P. T., & Green, S. e. (2011). Cochrane Handbook for Systematic Reviews of Interventions [updated March 2011] (Version 5.1.0 ed.): The
Cochrane Collaboration, 2011.
dGRADEpro GDT: GRADEpro Guideline Development Tool (2015). McMaster University, (developed by Evidence Prime, Inc.). [Software]. Available
from gradepro.org.
eMoher D, Liberati A, Tetzlaff J, Altman DG, The PRISMA Group (2009). Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA
Statement. PLoS Med 6(7): e1000097. doi:10.1371/journal.pmed1000097 For more information, visit www.prisma-statement.org.
fWhiting, P. F., Rutjes, A. W., Westwood, M. E., Mallett, S., Deeks, J. J., Reitsma, J. B., ... & Bossuyt, P. M. (2011). QUADAS-2: a revised tool for the quality
assessment of diagnostic accuracy studies. Annals of internal medicine, 155(8), 529-536.
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Figure 1. Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRIMSA)e
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Figure 2. Risk of Bias Summary

* These guidelines do not establish a standard of care to be followed in every case. It is recognized that each case is different, and those individuals involved
in providing health care are expected to use their judgment in determining what is in the best interests of the patient based on the circumstances existing at
the time. It is impossible to anticipate all possible situations that may exist and to prepare guidelines for each. Accordingly, these guidelines should guide
care with the understanding that departures from them may be required at times.

Department of Evidence Based Practice
Service and Performance Excellence
Date Finalized/Revised: 10/2018; 03/2020
Appendix C

24

Specific Care Question
In pediatric patients with CAP, when should blood cultures be obtained?
Recommendations from the CAP CPG Team
Conditional recommendation is made for blood cultures in patients requiring admission with any of the following criteria (adapted from Heine et al.
2013): (a) < 6months with fever, (b) not fully immunized, (c) central line, (d) immunocompromised, (e) admitted to the ICU, (f) complex/chronic
medical conditions, and (g) effusion or empyema on chest radiograph. The recommendation is based on the GRADE Evidence to Decision instrumentd.
The overall certainty in the evidence is very lowd (see Summary of study findings for substantiation of recommendations).
The included studies focusing on severe CAP (n = 5) had a higher rate of positive BCs than studies focusing on non-severe CAP (n = 24), 8.0% versus
2.8%, respectively (see Table 1). Positive BCs ranged from 0.7% to 17.4% for patients with severe CAP, while positive BCs ranged from 0.8% to 9.7%
in patients with non-serve CAP. There was a high rate of false posititves for both severe and non-severe patients with CAP of 2.0%, with a range of 0%
to 8.1%. For all patients with positive BCs a change in antibiotic management happened in 39.6% of patients.
Two study differentiated patient characteristics associated with positive BCs with CAP (Fritz et al., 2019, Senavonge, Hantragool, & Shotelersuk, 2016).
Fritz et al. (2019) reported characteristics associated with bacteremia included male sex, parapneumonic effusion, lack of chest indrawing or wheezing,
and no previous receipt of antibiotics. Senavonge et al. (2016) reported Body temperature >38.5 0C, severe sepsis, severe respiratory distress
requiring endotracheal intubation, leukocytosis >17,000/ul, and mechanical ventilation were more common in patients with positive BCs.
Andrews, Simpson, Heine, and Teufel II (2015) examined the cost-effectiveness of checking BCs on all children hospitalized with CAP versus those
children with CAP at high-risk for bacteremia. Testing all patients admitted with CAP would cost $5,178 per 100 patients, or $9,214,238, annually
versus only testing the high-risk CAP patients would cost $3,545 per 100 patients or $5,668,778 annually.
Literature Summary
Background. Globally, CAP accounts for 15% of deaths in children under 5-years-old (WHO, 2015). CAP is a clinical diagnosis, defined as being caused
by a community-acquired infection in a previously healthy child. StreptococcuS. pneumoniae is the most common bacterial cause of pneumonia in
children of all ages (Barnson, 2018). Other bacterial pathogens that may be considered in children with CAP include Streptococcus aureus (including
Methicillin-resistant Staphylococcus aureus), Streptococcus pyogenes (group A Streptococcus), Haemophilus influenzae type b (if unimmunized), nontypeable Haemophius influenzae, and Moraxella catarrhalis (Branson, 2018).
The Pediatric Infectious Disease Society and the Infectious Disease Society of America (PIDS/IDSA) and the British Thoracic Society (BTS) are the
governing guidelines for this review (Bradley et al., 2011; Harris et al., 2011). The PIDS/IDSA and the BTS do not recommend BCs for fully immunized
children with CAP managed in the outpatient setting (Bradley et al., 2011; Harris et al., 2011). Bradley et al. (2011) recommendS BCs for all patients
admitted to the hospital with moderate to severe CAP, including complicated pneumonia. This review will summarize identified literature to answer the
PICOT question
Study characteristics. The search for suitable studies was completed on July 27, 2018. J. Michael DO and J. Goldman MD, MS-CR reviewed the 79
titles and abstracts and identified 23 articles that were believed to answer the question. After an in-depth review, 11 articles were believed to answer
the question. Tam et al. (2015) a systematic review (SR) and nine cohort studies (Andrews et al., 2015; Davis et al., 2017; Fritz et al., 2019; Kwon et
al., 2017; Lai, Nathan, de Bruyne, & Chan, 2015; McCulloh et al., 2015; Neuman et al., 2017; Newman et al., 2012; Senavonge et al., 2016; Stankey
et al., 2018) (see Figure 1) are included in this synopsis. The SR included 21 cohorts.
* These guidelines do not establish a standard of care to be followed in every case. It is recognized that each case is different, and those individuals involved
in providing health care are expected to use their judgment in determining what is in the best interests of the patient based on the circumstances existing at
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Summary of study findings
The included studies used differing definitions of severe and non-serve CAP (see Table 1).
Blood cultures for severe and non-severe CAP. Twenty nine studies, including 21 from the meta-analysis (Davis et al., 2017; Kwon et al., 2017;
Lai et al., 2015; McCulloh et al., 2015; Neuman et al., 2017; Newman et al., 2012; Senavonge et al., 2016; Stankey et al., 2018; Tam et al., 2015),
reported BCs (N = 14,326) and positive BCs (n = 523) for patients admitted to the hospital with severe and non-severe CAP. Twelve studies, including
seven from the meta-analsis (Davis et al., 2017; Lai et al., 2015; McCulloh et al., 2015; Neuman et al., 2017; Newman et al., 2012; Tam et al., 2015),
reported false positive BCs (n = 116). The rate of positive BCs was 3.7% with a range of 0.4% to 16.8% and the rate of false positives was 2.0% with a
range of 0% to 8.1%. Five studies including three from the meta-analysis (Kwon et al., 2017; Lai et al., 2015; Tam et al., 2015), reported antibiotic
management changes in 21/53 (39.6%) of the patients with positive BCs or 21/3691 (0.6%) of the population with BCs drawn.
The evidence was of very low certainty based on serious risk of bias, serious inconsistency, and serious indirectness. The review had serious risk of
bias due to 14 of the 29 studies were retrospective chart reviews which could result in selection bias. This review had serious inconsistency due to the
heterogeneity of the included studies, including different definitions of CAP (see Table 1)and the reported I2 of 91.3% (Tam et al., 2015). There was
serious indirectness due to the regional difference in pneumonia prevalence and types of pneumonia (see Table 1).
Blood cultures for severe CAP. Five studies, including four from the meta-analysis (Stankey et al., 2018; Tam et al., 2015), reported BCs (N =
3,104) and positive BCs (n = 248) for patients admitted to the hosptial with severe CAP. False positives were not reported for these studies. The rate of
positive cultures was 8.0% with a range of 0.7% to 17.4%.
The evidence was of very low certainty based on serious inconsistency and serious indirectness. This review had serious inconsistency due to the
heterogeneity of the included studies, including different definitions of CAP (see Table 1) and a reported I2 of 91.3% (Tam et al., 2015). There was
serious indirectness due to the regional difference in pneumonia prevalence and types of pneumonia (see Table 1).
Blood cultures for non-severe CAP. Twenty four studies, including 17 from the meta-analysis (Davis et al., 2017; Kwon et al., 2017; Lai et al.,
2015; McCulloh et al., 2015; Neuman et al., 2017; Newman et al., 2012; Senavonge et al., 2016; Tam et al., 2015), reported BCs (N = 11,222) and
positive BCs (n = 275) for patients admitted to the hospital with non-severe CAP. Thirteen studies including eight from the meta-analysis (Davis et al.,
2017; Lai et al., 2015; McCulloh et al., 2015; Neuman et al., 2017; Newman et al., 2012; Tam et al., 2015) reported false positive BCs (n = 5,933).
The rate of positive BCs was 2.5% with a range of 0.8% to 9.7% and the rate of false positives was 2.0% with a range of 0% to 8.1%.
The evidence was of very low certainty based on serious risk of bias, serious inconsistency, and serious indirectness. The review had serious risk of
bias due to 13 of the 24 studies were retrospective chart reviews which could result in selection bias. This review had serious inconsistency due to the
heterogeneity of the included studies, including different definitions of CAP (see Table 1) and the reported I2 of 91.3% (Tam et al., 2015). There was
serious indirectness due to the regional difference in pneumonia prevalence and types of pneumonia (see Table 1).
Characteristics of positive blood culture. Two retrospective cohorts (Fritz et al., 2019, Senavonge et al., 2016) examined the characteristics of
positive blood cultures in children admitted to the hospital with CAP. Fritz et al. (2019) examined the number of BCs in children (N = 2358) admitted to
a hospital with CAP and the rate of positive BCs. Blood cultures were collected on 2143 children. Forty-six (2.2%) had a positive BC. Characteristics
associated with bacteremia included male sex (p = .008), parapneumonic effusion (p < .001), lack of chest indrawing or wheezing (p = .26), and no
previous receipt of antibiotics (p < .001). Children with bacteremia had longer lengths of stay (median: 5.8 vs 2.8 days; adjusted hazard ratio = 0.79,
95% CI [0.73,0.86]) and increased odds of ICU admission (43% vs 21%; OR = 5.21 [3.82, 6.84]) and invasive mechanical ventilation or shock (30%
vs 8%; OR = 5.28, 95% CI [2.41, 11.57]). Senavonge et al. (2016) examined the number of BCs in children (N = 152) admitted to a hospital with CAP
* These guidelines do not establish a standard of care to be followed in every case. It is recognized that each case is different, and those individuals involved
in providing health care are expected to use their judgment in determining what is in the best interests of the patient based on the circumstances existing at
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and the rate of positive BCs (Senavonge et al., 2016). Blood cultures were collected on 151 children. Thirteen cases (8.6%) had a positive BC, with six
cases being reported as true growth (3.9%). Bacteremia was significantly more common in severe sepsis, OR = 27.2, 95% CI [4.4, 167]; mechanical
ventilation, OR = 145, 95% CI [11.5, 1,830]; leukocytosis >17,000/ul, OR = 6.1, 95% CI [1.1, 34.7]; body temperature > 38.5°C, OR = 9.2, 95% CI
[1.6, 53.2]; and patchy infiltration, OR = 12.8, 95% CI [1.5, 113].
The evidence was of very low certainty as the study was non-randomzied (non-randomized start as low certainty evidence) and it is only one study
(imprecision).
Cost. A cost-effectiveness analysis occurred that compared all children hospitalized with CAP versus children with CAP at high-risk for bacteremia
(Andrews et al., 2015). Patients with CAP were identified as high-risk if they met any of the following criteria (a) < 6 months with fever or not fully
immunized, (b) central line, (c) immunocompromised, (d) toxic appearing or admitted to the intensive care unit, or (e) diagnosed with an effusion or
empyema on chest x-ray. When testing all patients admitted with CAP rather than only CAP patients at high-risk of bacteremia, 118 BCs would need to
be drawn to identify one patient with bacteremia. Testing only high-risk patients would result in .07 cases of missed bacteremia with treatment failure
per 100 patients. Testing all patients admitted with CAP would cost $5,178 per 100 patients or $9,214,238 annually. Testing only patients that are
high-risk would cost $3,545 per 100 patients or $5,668,778 annually.
The evidence was of very low certainty as the study was non-randomzied (non-randomized start as low certainty evidence) and it is only one study
(imprecision).
Identification of Studies
Search Strategy and Results (see Figure 1)
("community acquired pneumonia" OR "community-acquired pneumonia" OR ("Community-Acquired Infections"[MeSH] AND "Pneumonia"[MAJR]))
AND ("Blood Culture"[Mesh] OR "blood culture" OR "blood cultures" OR "blood/microbiology"[Mesh] OR "bacteremia/diagnosis"[Mesh] OR
"Bacteriological Techniques"[Mesh]) AND (child OR children OR infant OR adolescence OR pediatr* OR paediatr*) AND ("last 5 years"[PDat])
Records identified through database searching n = 79
Additional records identified through other sources n = 0
Studies Included in this Review
Citation
Andrews et al. (2015)
Davis et al. (2017)
Fritz et al. (2019)
Kwon et al. (2017)
Lai et al. (2015)
McCulloh et al. (2015)
Neuman et al. (2017)
Newman et al. (2012)
Senavonge et al. (2016)
Stankey et al. (2018)
Tam et al. (2015)
*Chen et al. (2012)

Study Type
Cohort
Cohort
Cohort
Cohort
Cohort
Cohort
Cohort
Cohort
Cohort
Cohort
SR
Cohort
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*Chong et al. (1997)
Cohort
*Delport et al. (2002)
Cohort
*Ferrero et al. (2010)
Cohort
*Heine et al. (2013)
Cohort
*Hickey et al. (1996)
Cohort
*Hijazi et al. (1997)
Cohort
*Isaacs (1989)
Cohort
*Juvén et al. (2000)
Cohort
*Kurz et al. (2013)
Cohort
*LaKhanI et al. (2013)
Cohort
*Laundy et al. (2003)
Cohort
*Leibovitz et al. (1990)
Cohort
*Moulin et al. (2001)
Cohort
*Myers et al. (2013)
Cohort
*Sandora et al. (2009)
Cohort
*Seçmeer et al. (2008)
Cohort
*Shah et al. (2011)
Cohort
*Sur et al. (2012)
Cohort
*Tajima et al. (2006)
Cohort
*Zhang, Guo, and MacDonald (2011)
Cohort
*References marked with an asterisk indicate studies included from previously published SR
Studies Not Included in this Review with Exclusion Rationale
Citation
Reason for exclusion
Barrett et al. (2016)
Antigen study
Bordon et al. (2015)
Only included positive samples
Ceccato et al. (2017)
Adults
Elemraid et al. (2014)
Blood cultures after vaccinations
Kurowski et al. (2015)
Qualitative study
Leyenaar et al. (2014)
Did not report positive BCs
Mathew et al. (2015)
Outpatient Study
Melzer and Welch (2013)
Did not report positive BCs
Menéndez et al. (2017)
Blood cultures not reported
Parikh et al. (2016)
Did not report positive BCs
Tagarro et al. (2016)
Vaccination study
Van Mes et al. (2015)
Did not report positive BCs
Yin et al. (2017)
Adults
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Methods Used for Appraisal and Synthesis
aThe Appraisal of Guidelines Research and Evaluation II (AGREE II) is an international instrument used to assess the quality and reporting of clinical practice
guidelines for this analysis (Brouwers et al. 2010).
bRayyan is a web-based software used for the initial screening of titles and / or abstracts for this analysis (Ouzzani, Hammady, Fedorowicz & Elmagarmid,
2017).
cReview Manager (Higgins & Green, 2011) is a Cochrane Collaborative computer program used to assess the study characteristics as well as the risk of bias
and create the forest plots found in this analysis.
eThe Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) flow diagram depicts the process in which literature is searched,
screened, and eligibility criteria is applied (Moher, Liberati, Tetzlaff, & Altman, 2009).
aBrouwers,

M.C. et al. for the AGREE Next Steps Consortium. (2010) AGREE II: Advancing guideline development, reporting and evaluation in
healthcare. Canadian Medical Association Journal, 182, E839-842. Retrieved from https://www.agreetrust.org/wp-content/uploads/2017/12/AGREEII-Users-Manual-and-23-item-Instrument-2009-Update-2017.pdf
bOuzzani, M., Hammady, H., Fedorowicz, Z., & Elmagarmid, A. (2016). Rayyan-a web and mobile app for systematic reviews. Systematic Reviews, 5(1),
210. doi:10.1186/s13643-016-0384-4
cHiggins, J. P. T., & Green, S. e. (2011). Cochrane Handbook for Systematic Reviews of Interventions [updated March 2011] (Version 5.1.0 ed.): The
Cochrane Collaboration, 2011.
eMoher D, Liberati A, Tetzlaff J, Altman DG, The PRISMA Group (2009). Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA
Statement. PLoS Med 6(7): e1000097. doi:10.1371/journal.pmed1000097 For more information, visit www.prisma-statement.org.
Question Originator
CAP CPG Team
Medical Librarian Responsible for the Search Strategy
Keri Swaggart, MLIS, AHIP
EBP Scholar’s Responsible for Analyzing the Literature
Teresa Bontrager, RN, BSN, MSN, CPEN
Justine Edwards, RN, MSN, CPEN
Rebecca Frederick, PharmD
Linda Martin, RN, BSN, CPAN
Helen Murphy, BHS, RRT, AE-C
Nicole Ratliff, BS RT(R)
Kim Robertson, MBA, MT-BC
Britney Snodgrass, MSN, RN, CPN
Hope Scott, RN, BSN, CPEN
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Acronyms Used in this Document
Acronym
Explanation
BTS
The British Thoracic Society
BC
Blood culture
CAP
Community-acquired pneumonia
CA-LRTI
Community-acquired lower respiratory tract infection
CI
Confidence interval
CBC
Complete blood count
CPG
Clinical Practice Guideline
CXR
Chest x-ray
EBP
Evidence Based Practice
ED
Emergency Department
EtD
Evidence to decision
FP
False Positive
IDSA
Infectious Disease Society of America
IQR
Interquartile range
MSSA
Methicillin-susceptible Staphylococcus aureus
MRSA
Methicillin-resistant Staphylococcus aureus
OR
Odds ratio
PHIS
Pediatric Health Information System
PIDS
The Pediatric Infectious Disease Society
PRISMA
Preferred Reporting Items for Systematic Reviews and Meta-Analyses
RCT
Randomized control trial
SR
Systemic review
TP
True positive
VATS
Video-assisted thoracoscopic surgery
WBC
White blood cell
WHO
World Health Organization
Date Developed/Updated
July 2019

* These guidelines do not establish a standard of care to be followed in every case. It is recognized that each case is different, and those individuals involved
in providing health care are expected to use their judgment in determining what is in the best interests of the patient based on the circumstances existing at
the time. It is impossible to anticipate all possible situations that may exist and to prepare guidelines for each. Accordingly, these guidelines should guide
care with the understanding that departures from them may be required at times.

Department of Evidence Based Practice
Service and Performance Excellence
Date Finalized/Revised: 10/2018; 03/2020

30

Figure 1. Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRIMSA)e
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Table 1
Overview of Studies
Study

Location

Study
Design and
Setting

Age (range)

Inclusion Criteria

Exclusion Criteria

Definition of CAP

BCs
TP BCs
FP BCs

Bacteria Isolated in
TP BCs, n (%)

Change in
Management

Developed Countries++
Andrews et
al. 2015

USA

Retrospectiv
e,

Not reported

Hospitalized
children with CAP

Not reported

Not reported

Not reported

Not reported

Not reported

Davis et al.
2016

Australi
a

Retrospectiv
e, inpatient

10months –
17 years

Admitted,
diagnosis code of
pneumonia, under
the age of 16

Not reported

Diagnosis code

177;
2 (1.1%)
7 (4%)

S. pneumoniae
2 (100%)

Not reported

Mean 4.9
years (0–18
years)

ICD-9 code of
pneumonia

Not reported

CXR diagnosis of
pneumonia,
inﬁltrate,
consolidation

CXR diagnosis of
bronchitis,
atelectasis, or
bronchiolitis

Not reported

409;
11 (2.7%);
33 (8.1%)

Not reported

Fever >37.5°C
and/ or
respiratory
symptoms and
positive CXR

*Heine et al.
2013

*Hickey et al.
1996

*Juven et al.
2000

*Kurz et al.
2013

USA

Retrospectiv
e, inpatient

USA

Retrospectiv
e,
Emergency
Department
(ED)

Median 27
months (0–
21 years)

Finland

Prospective,
inpatient

Mean 3.8
years (0.1–
16.7 years)

Austria

Prospective,
inpatient

Median 36
months (2
months– 17
years)

Children with CAP

Hospitalized with
diagnosis of CAP

Preexisting lung
disease,
immunodeﬁciency,
immunosuppressive
therapy

ICD-9 code of
pneumonia

Clinical features,
positive CXR

155;
5 (3.2%);
5 (3.2%)

S. pneumoniae
3 (30%),
E coli 1 (10%),
S pyogenes
1 (10%),
contaminants
5 (50%)

No reported

S. pneumoniae
10 (23%),
H parainfluenza
1 (2%),
contaminants
33 (75%)

No change in
therapy in all
cases

125;
1 (0.8%)

S. pneumoniae
1 (100%)

Not reported

173;
5 (2.9%);
2 (1.2%)

S. pneumoniae
2 (29%),
S aureus
1 (14%),
M catarrhalis
1 (14%),
Rothia 1 (14%),
coagulase-negative
Staphylococcus
2 (29%)

Narrowing of
treatment based
on test results
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Table 1 (cont.)
Study

*Isaacs et al.
1989

*Laundy et
al. 2003

McCulloh et
al. 2015

*Moulin et al.
200

*Myers et al.
2013

Neuman et
al. 2017

Location

Study
Design and
Setting

Age (range)

Inclusion Criteria

Exclusion Criteria

Definition of CAP

BCs
TP BCs
FP BCs

Bacteria Isolated in
TP BCs, n (%)

Change in
Management

Clinical features
and positive CXR

Hospital-acquired
pneumonia and
those with
underlying
pulmonary or
immunologic
disease

Positive
BC/pleural ﬂuid

57;
2 (3.5%)

S. pneumoniae
2 (100%)

Not reported

Fever ≥38.5°C
and tachypnea
per WHO criteria
± cough, with
positive clinical
exam/CXR

51;
4 (8%)

S. pneumoniae
3 (75%),
N meningitidis
1 (25%)

Not reported

390;
6 (1.5%);
9 (2.3%)

S. pneumoniae
5 (83%), nontypeable
Haemophilus
influenzae 1 (17%)

88;
10 (11.4%)

S. pneumoniae
10 (100%)

Not reported

39% had
therapy
broadened,
27% were
narrowed, 35%
had no change

Not reported

Prospective,
inpatient

Median 53
months, (1
month – 12
years)

UK

Prospective,
ED, outpatient

Median 1.3
years (2
weeks – 4.8
years)

Children ≤5 years
regardless of risk
factors

Young children
with obvious
bronchiolitis

USA

Retrospectiv
e, cohort,
inpatient

Mean 5.2
(months to
18 years)

ICD-9 code of
pneumonia,
general inpatient

Direct admission to
PICU, chronic
disease, admitted
from an outside
hospital

ICD-9

Severe febrile CAP
and
immunocompetent

Chronic disease,
antimicrobial 10
days before
admission, not
admitted to
hospital, or no BC

Chronic disease,
antimicrobial 10
d before
admission, not
admitted to
hospital, or no
BC

UK

France

Prospective,
inpatient

Mean 1.9
years (0.4-5
years)

USA

Multicenter
retro,
inpatient

Median 3.1
years (1.3 –
6.7 years)

USA

Retrospectiv
e, Cohort,
inpatient

1 year 18years;
72.5%

60 d–18 years,
ICD-9 code of
pneumonia/
effusion, positive
CXR and/or clinical
features and
laboratory results
Hospitalized;
diagnosis of
pneumonia (ICD 9
codes); diagnosis
of plural effusion;
Pediatric Health
Information
System plus
(PHIS+) database

Hospitalized since
birth, chronic
comorbid condition
or primary
diagnosis of
trauma

ICD-9 code

369;
26 (7.0%);
8 (2.2%)

S. pneumoniae
19 (56%),
H inﬂuenzae
1 (3%),
S aureus 6 (18%),
contaminants
8 (24%)

Transferred to
participating
hospitals; complex
chronic condition

ICD-9 code

2568;
65 (2.5%);
25; (1.0%)

S. pneumoniae
(78%),

Not reported
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Table 1 (cont.)
Study

Newman et
al. (2012)

*Sandora et
al. 2009

*Shah et al.
2011

Stankey et al.
2017

*Sur et al.
2012

Location

USA

USA

USA

USA

Romani
a

Study
Design and
Setting

Retrospectiv
e, inpatient

Retro
Cohort,
inpatient

Case-control
retro, ED

Retrospectiv
e, cohort,
inpatient

Prospective,
inpatient

Age (range)

2 months –
18 years

18 months 18 years;
56% <5
years

Median 2
years (0 –
18 years)

Median 57
months (4
months – 18
years)

1-18 years

Inclusion Criteria

Exclusion Criteria

Definition of CAP

BCs
TP BCs
FP BCs

Bacteria Isolated in
TP BCs, n (%)

Change in
Management

ICD-9 code

870;
23 (4%);
18 (2%)

S. pneumoniae
21 (91%),
Streptococcus
pyogenes
1 (4.3%);
S aureus 1 (4.3%)

Not reported

139;
2 (1.4%);
1 (0.7)

S. pneumoniae
1 (33%),
non-typeable H
inﬂuenzae
1 (33%), coagulasenegative
Staphylococcus
1 (33%)

17% had
appropriate
broadening,
67% had
appropriate
narrowing; 17%
had pathogen
not sensitive to
empirical
therapy

Hospitalized
children; diagnosis
of pneumonia (ICD
9 codes)

< 2 months; < 36
weeks' gestation;
diagnosed with
pneumonia three
days after
admission;
Immunocompromis
ed patients;
complex chronic
condition

ICD-9 code of
pneumonia

immunodeﬁciency,
chronic medical
conditions other
than asthma;
infants born <32
week; diagnosis of
bronchiolitis

Evaluated in ED
and ICD-9 code
with CA

Required
hospitalization ≤14
days before
diagnosis of
pneumonia;
immunocompromisi
ng/chronic medical
condition

ICD-9 code

291;
6 (2.1%);
3 (1%)

S. pneumoniae
4 (44%),
S aureus
1 (11%),
H inﬂuenzae
1 (11%), coagulasenegative
Staphylococcus
3 (33%)

Admitted with CAP
and empyema

Any syndromes,
impaired cough or
swallow, hospitalacquired
pneumonia,
oncology,
immunodeficient,
sepsis.

Positive for
empyema

310;
52 (16.7%)

Not reported for
blood cultures

Not reported

Clinical features,
positive CXR

Underlying lung
disease/malformati
on, nonacute/
recurrent
pneumonia

Clinical features

560;
38 (6.8%)

S. pneumoniae = 31
(82%),
K pneumoniae =
4 (11%),
H inﬂuenzae = 3
(8%)

Not reported

CXR ﬁndings
plus clinical
features in a
patient not
hospitalized or
long-term care
resident within
previous 14 days

Not reported

* These guidelines do not establish a standard of care to be followed in every case. It is recognized that each case is different, and those individuals involved
in providing health care are expected to use their judgment in determining what is in the best interests of the patient based on the circumstances existing at
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Table 1 (cont.)
Study

*Tajima et al.
2006

Location

Study
Design and
Setting

Age
(range)

Inclusion Criteria

Japan

Prospective
, inpatient

1 month 13years

Prospective
, inpatient

Median 4
years 3
months (7
months 16
years, 7
months)

Non-Developed Countries++
*Chen et al.
2012

*Chong et al.
1997

Taiwan

Singapo
re

Prospective
, inpatient

Mean 0.6
years (11
days – 11.8
years)

*Delport et
al. 2002

South
Africa

Prospective
, inpatient

Median 10
weeks (2
weeks – 5
years)

*Ferrero et
al. 2010

Argentin
a,
Brazil,
Dominic
an
Republic

Prospective
multicenter
observation
al,
inpatient

3–59
months;
majority
(37.2%)
were 12 –
23 months

Kuwait

Prospective
, inpatient

Median 14
months (10
days – 12
years)

Korea

Retrospecti
ve, cohort,
ED

*Hijazi et al.
1997

Kwon et al.
2017

1 year – 7
years

Exclusion Criteria

Definition of CAP

BCs
TP BCs
FP BCs

Bacteria Isolated in TP
BCs, n (%)

Change in
Management

Initial diagnosis of
pneumonia

Not reported

Clinical course
before
admission, CXR,
laboratory tests

157;
2 (1.3%)

H inﬂuenzae
1 (50%),
S. pneumoniae
1 (50%)

Not reported

Clinical features,
positive CXR

Chronic comorbid
disease, malignancy
immunodeﬁciency, or
immunosuppression

One clinical
symptom and
positive CXR

209;
2 (1%)

S. pneumoniae
2 (100%)

Not reported

Not reported

CA-LRTI

Nosocomial
pneumonia,
immunocompromised
host

Cough/fever <2
weeks duration,
clinical features
or positive CXR

121;
4 (3.3%)

Admitted to PICU;
intubated in ER;
RR >80– 90/min
with anticipated
apnea; positive
CXR

S. pneumoniae
1 (25%),
H inﬂuenzae
1 (25%), Enterobacter
1 (25%),
S. pneumoniae, H
inﬂuenzae
1 (25%)

Not reported

Not reported

23;
4 (17.4%)

K pneumoniae
2 (50%), not speciﬁed 2

Not reported

Hospitalized with
severe CAP

No evidence of CAP
on CXR

Presence of
cough/clinical
features

2536;
181 (7.1%)

S. pneumoniae
181 (100%)

Not reported

CA-LRTI, not
previously
admitted or visited
hospital in previous
8-weeks

Symptoms >1 week,
chronic disease,
bronchial asthma,
malnutrition

Cough and
clinical features

390;
38 (9.7%)

Not reported

Not reported

CAP diagnosis, BC

Cardiopulmonary
disease, viral
pneumonia, nonambulatory,
immunocompromise

Not reported

2705;
12 (0.4 %)

StreptococcuS.
pneumoniae 3 (25%),
Staphylococcus hominis
1 (8.3%), VCS 2
(16.7%)

No change in
antibiotic
regimen

* These guidelines do not establish a standard of care to be followed in every case. It is recognized that each case is different, and those individuals involved
in providing health care are expected to use their judgment in determining what is in the best interests of the patient based on the circumstances existing at
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Table 1 (cont.)
Study

Lai et al.
2015

*Lakhani et
al. 2013

*Leibovitz
et al. 1990

*Secmeer et
al. 2008

Location

Malaysi
a

India

Israel

Turkey

Study
Design and
Setting

Age (range)

Prospective,
cohort,
inpatient

Median 1
year 1
month
(38days to
10 years)

Prospective,
inpatient,
rural
population

1 months –
5 years;
majority
(48.5%)
were 12 –
60 months

Prospective,
inpatient,
outpatient

Average 3
years, 7
months (5
months 14.5 years)

Retrospectiv
e, inpatient

Mean 6.5 ±
3.5 years (2
– 16 years)

Senavonge et
al. 2016

Thailand

Prospective,
inpatient

Mean 1.9
years (60
days – 15
years)

*Zhang et al.
2011

China

Prospective,
inpatient

Mean 2.3
years (2 –
14 years)

BCs
TP BCs
FP BCs

Bacteria Isolated in
TP BCs, n (%)

Change in
Manageme
nt

Staphylococcus
(50%), Bacillus
(50%)

One out of
two
antibiotics
changed

Inclusion Criteria

Exclusion Criteria

Definition of
CAP

CAP diagnosis, BC

Congenital pneumonia,
Immunodeficiency,
Cardiac disorders,
Chronic respiratory
disorders, Nosocomial
pneumonia

171;
2 (1.1%)
3 (1.8%)

Clinically suspected
pneumonia

Critical/terminal illness,
acute bronchial asthma
exacerbation, chronic
lung
immunocompromise,
antimicrobial agents >48
h earlier

Fever ≥38°C,
Age adjusted
tachypnea,
clinical features
of pulmonary
infection, fever
ruled out for
other causes

WHO
classiﬁcation

66;
4 (6.1%)

Not reported

Not
reported

147;16
(10.9%);
1 (0.7%)

S. pneumoniae
13 (76%),
H inﬂuenzae
3 (18%),
S viridans
1 (6%)

Not
reported

Diagnosis of severe
bacterial
pneumonia

Not reported

Hospitalized with
CAP and
parapneumonic
effusion

Nosocomial infection

Hospitalized for
CAP

Patient hospitalized 2
weeks prior, referred to
outside hospital

Admitted directly
from community
with CAP

Tuberculosis diagnosis,
sent to pulmonary
hospital for care

Clinical
features,
laboratory
ﬁndings and
positive CXR

Not reported

Lower
respiratory
symptoms and
chest x-ray with
infiltration
Fever ≥37.5°C
and/or
respiratory
symptoms and
positive CXR

96;
2 (2.1%);
2 (2.1%)

152;
6 (4%)

821;
7 (0.9%)

S. pneumoniae
1 (25%),
Stenotrophomonas
maltophilia
1 (25%),
coagulase-negative
Staphylococcus
2 (50%)
streptococcuS.
pneumoniae
2 (33%),
escherichia coli
2 (33%)
S. pneumoniae
7 (100%)

Not
reported

Not
reported

Not
reported

**References marked with an asterisk indicate studies included from previously published SR
++Developed and non-developed countries defined by United Nations World Economic Situation and Prospects (2019)
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Specific Care Question
In pediatric patients with suspected CAP, when should rapid viral testing be used to help distinguish between viral and bacterial pneumonia?
Recommendations from the Community Acquired Pneumonia Team
A strong recommendation is made for viral testing during appropriate seasons, based on expert opinion and review of current literature of the CPG
Team. The Infectious Diseases Society of America/Pediatric Infectious Diseases Society (IDSA/PIDS) recommends rapid testing for influenza and other
respiratory viruses in both inpatient and outpatient settings (Bradley et al., 2011). Testing is typically performed December to March for influenza and
October to March for RSV. Start and end dates of testing are determined by the department of microbiology (Local Expert Consensus).
Literature Summary
Background. Hospital admissions for community-acquired pneumonia is a common reason for pediatric hospitalization in the United States (G. E. Lee,
Lorch, Sheffler-Collins, Kronman, & Shah, 2010). There is not a concrete answer for what percentage of CAP is viral vs. bacterial since a large
percentage of cases never have an organism identified. Williams et al. (2015) reported viruses account for approximately 73% of CAP in childhood, but
when stratified by age, children < 2 years old have a much higher rates of viral pneumonia (> 80%) compared with those > 2 years old (49%). In
order to decrease the need for diagnostic testing and the unnecessary provision of antibiotics, the IDSA/PIDS make a strong recommendation based on
high-quality evidence for rapid testing for influenza and other respiratory viruses in both inpatient and outpatient settings (Bradley et al., 2011). At
Children’s Mercy Kansas City, the turn-around-time for respiratory viral testing decreased from Mdn (IQR) = 27.1 (24.7, 50.3) hours with the Luminex
Rapid Viral Panel to Mdn (IQR) = 1.4 (1.2, 1.7) hours with the Biofire Respiratory Panel (Lee, Hassan, Jackson, & Selvarangan, 2019).
Study characteristics. The search for suitable studies was completed on September 10, 2018. K. Johansen, MD and J. Markham, MD reviewed the 93
titles and abstracts found in the search and identified two guidelines and three single studies believed to answer the question using the Rayyanb tool
The IDSA/PIDS and BTS Guidelines were assessed with the AGREE IIa instrument to assist the team to determine the appropriateness to adopt as the
governing guideline for this CAT. IDSA and BTS were selected with the recommendation to be used without modifications (see Table 1). After an indepth review of the remaining articles, zero answered the question.
Summary by Outcome
No studies were identified.
Identification of Studies
Search Strategy and Results (see Figure 1)
PubMed
("community acquired pneumonia" OR "community-acquired pneumonia" OR ("Community-Acquired Infections"[MeSH] AND "Pneumonia"[MAJR]))
AND ((“Respiratory viral panel” OR “Respiratory virus panel” OR "Respiratory Tract Infections/virology"[Mesh] OR "Pneumonia,
Viral/diagnosis"[Mesh] OR "Pneumonia, Viral/virology"[Mesh] OR "Virus Diseases/diagnosis"[Mesh] OR "rapid respiratory viral" OR (rapid[tiab] AND
viral[tiab]) OR "rapid virus" OR "viral test" OR "viral testing") OR (("Polymerase Chain Reaction"[Mesh] OR “Respiratory viral panel” OR “Respiratory
virus panel” OR "rapid respiratory viral" OR (rapid[tiab] AND viral[tiab]) OR "rapid virus" OR "viral test" OR "viral testing") AND ( "Influenza,
Human/diagnosis"[Mesh] OR "Influenza, Human/virology"[Mesh] OR "Respiratory Syncytial Virus Infections/diagnosis"[Mesh] OR "Respiratory
Syncytial Virus Infections/virology"[Mesh] OR "Paramyxoviridae Infections/diagnosis"[Mesh] OR "Paramyxoviridae Infections/virology"[Mesh] OR
"Adenoviridae Infections/diagnosis"[Mesh] OR "Adenoviridae Infections/virology"[Mesh] OR "Metapneumovirus"[Mesh] OR "Coronavirus"[Mesh] OR
"Rhinovirus"[Mesh] OR "Enterovirus"[Mesh] OR "Bordetella pertussis"[Mesh] OR "Chlamydophila pneumoniae"[Mesh] OR "Pneumonia,
* These guidelines do not establish a standard of care to be followed in every case. It is recognized that each case is different, and those individuals involved
in providing health care are expected to use their judgment in determining what is in the best interests of the patient based on the circumstances existing at
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Mycoplasma/diagnosis"[Mesh] OR "Pneumonia, Mycoplasma/virology"[Mesh] OR "Chlamydia Infections/diagnosis"[Mesh] OR "Chlamydia
Infections/virology"[Mesh]))) AND (child OR children OR infant OR adolescence OR pediatr* OR paediatr*) AND ("last 5 years"[PDat])
Records identified through database searching n = 93
Additional records identified through other sources n =
Studies Included in this Review
Citation
No studies identified

Study Type

Studies Not Included in this Review with Exclusion Rationale
Citation
Reason for exclusion
Alcoba et al. (2017)
Does not answer the question – Bacterial pneumonia
Aydemir, Aydemir, Pekcan, and Ozdemir (2017)
Does not answer the question – Multiplex PCR for
diagnosis, not when to test
Rhedin et al. (2015)
Case-control study that does not answer the question
Methods Used for Appraisal and Synthesis
aThe Appraisal of Guidelines Research and Evaluation II (AGREE II) is an international instrument used to assess the quality and reporting of clinical practice
guidelines for this analysis (Brouwers et al. 2010).
bRayyan is a web-based software used for the initial screening of titles and / or abstracts for this analysis (Ouzzani, Hammady, Fedorowicz & Elmagarmid,
2017).
cReview Manager (Higgins & Green, 2011) is a Cochrane Collaborative computer program used to assess the study characteristics as well as the risk of bias
and create the forest plots found in this analysis.
dThe GRADEpro Guideline Development Tool (GDT) is the tool used to create the Summary of Findings table(s) for this analysis
eThe Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) flow diagram depicts the process in which literature is searched,
screened, and eligibility criteria is applied (Moher, Liberati, Tetzlaff, & Altman, 2009).
aBrouwers,

M.C. et al. for the AGREE Next Steps Consortium. (2010) AGREE II: Advancing guideline development, reporting and evaluation in
healthcare. Canadian Medical Association Journal, 182, E839-842. Retrieved from https://www.agreetrust.org/wp-content/uploads/2017/12/AGREEII-Users-Manual-and-23-item-Instrument-2009-Update-2017.pdf
bOuzzani, M., Hammady, H., Fedorowicz, Z., & Elmagarmid, A. (2016). Rayyan-a web and mobile app for systematic reviews. Systematic Reviews, 5(1),
210. doi:10.1186/s13643-016-0384-4
cHiggins, J. P. T., & Green, S. e. (2011). Cochrane Handbook for Systematic Reviews of Interventions [updated March 2011] (Version 5.1.0 ed.): The
Cochrane Collaboration, 2011.
dGRADEpro GDT: GRADEpro Guideline Development Tool (2015). McMaster University, (developed by Evidence Prime, Inc.). [Software]. Available
from gradepro.org.
eMoher D, Liberati A, Tetzlaff J, Altman DG, The PRISMA Group (2009). Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA
Statement. PLoS Med 6(7): e1000097. doi:10.1371/journal.pmed1000097 For more information, visit www.prisma-statement.org.
Question Originator
Community Acquired Pneumonia CPG Team
* These guidelines do not establish a standard of care to be followed in every case. It is recognized that each case is different, and those individuals involved
in providing health care are expected to use their judgment in determining what is in the best interests of the patient based on the circumstances existing at
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Medical Librarian Responsible for the Search Strategy
Kari Swaggart, MLIS, ACIP
EBP Scholar’s Responsible for Analyzing the Literature
Rebecca Frederick, PharmD
EBP Team Member Responsible for Reviewing, Synthesizing, and Developing this Document
Nancy H. Allen, MS, MLS, RD, LD. CPHQ
Acronyms Used in this Document
Acronym
Explanation
EBP
Evidence Based Practice
IDSA
Infectious Diseases Society of America
IQR
Interquartile rage
Mdn
Median
PIDS
Pediatric Infectious Diseases Society
Date Developed/Updated
August 2019
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Figure 1. Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRIMSA)e
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Specific Care Question In pediatric patients with uncomplicated community-acquired pneumonia (CAP), what treatment regimen is more effective in cure
rate, failure rate, and side-effects.
Recommendations from the CAP Clinical Practice Guideline (CPG) Team
A strong recommendation is made for amoxicillin to be used for ambulatory patient and ampicillin for inpatient treatment of uncomplicated CAP, based
on the GRADE evidence to decision instrumentd (see Appendix A). The overall certainty in the evidence is very lowd.
Antibiotics for ambulatory management for uncomplicated CAP.
• Treatment with high dose amoxicillin 80-100 mg/kg/day divided into two or three doses per day for 5-7 days.
Antibiotics for inpatient treatment of uncomplicated CAP.
• Treatment with ampicillin 50-75 mg/kg/dose IV every 6 hours (max 2 g/dose) is recommended when pneumonia is suspected, and
hospitalization is required.
An overview of the results can be found in Table 1. A majority of the antibiotic comparisons found similar cure rates, failure rates, or side effects. The
exceptions to this finding was the cure rate of co-amoxiclavulanic acid was better than amoxicillin (Jibril, Ifere, & Odumah, 1989) and there were fewer
side-effects with azithromycin than co-amoxiclavulanic acid (Lodha, Kabra, & Pandey, 2013).
The evidence was of very low certainty based on serious risk of bias (see Figure 2), serious indirectness, and serious impression. Most of the outcomes
and comparisons are based off one or two small studies. Also, there was a large amount of heterogeneity among studies. Dosage was not analyzed due
to the heterogeneity of the studies.
Literature Summary
Background. Globally, community-acquired pneumonia (CAP) accounts for 15% of deaths in children under 5 years old (WHO, 2015). CAP is defined
as a clinical diagnosis of pneumonia caused by a community-acquired infection in a previously healthy child. Uncomplicated pneumonia is the absence
of significant effusion, empyema, severe or impending respiratory failure, and/or signs and symptoms of sepsis or shock.
Streptococcus pneumoniae is the most common bacterial cause of pneumonia in children of all ages (Barnson, 2018). Other bacterial pathogens that
may be included for hospitalized children include Staphylococcus. aureus (including Methicillin-resistant staphylococcus aureus), Streptococcus
pyogenes (group A Streptococcus), Haemophilus influenzae type b (if unimmunized), non-typeable H. influenzae, and Moraxella catarrhalis (Branson,
2018).
The Pediatric Infectious Disease Society and the Infectious Disease Society of America (PIDS/IDSA) and the British Thoracic Society (BTS) are the
governing guidelines used for this question (Bradley et al., 2011; Harris et al., 2011). The PIDS/IDSA and the BTS recommended amoxicillin as the first
choice for oral antibiotic therapy in all children because it is effective against most pathogens that cause CAP, is well tolerated, and inexpensive
(Bradley et al., 2011; Harris et al., 2011). In fiscal year 2018, Children’s Mercy Hospital providers in the emergency department or urgent care
prescribed amoxicillin 75% of the time for patients seen with the diagnosis of CAP.
The PIDS/IDSA guideline discusses that a shorter course of therapy may be as effective as longer courses, especially in patients with milder disease.
The authors comment that 10-day course of antibiotics for CAP are best studied, but no cited studies are identified in their evidence review. The
guideline also recommends treating for the shortest effective duration to minimize resistance to antimicrobials (Bradley et al., 2011).
* These guidelines do not establish a standard of care to be followed in every case. It is recognized that each case is different, and those individuals involved
in providing health care are expected to use their judgment in determining what is in the best interests of the patient based on the circumstances existing at
the time. It is impossible to anticipate all possible situations that may exist and to prepare guidelines for each. Accordingly, these guidelines should guide
care with the understanding that departures from them may be required at times.
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Children’s Mercy’s previous CPG iteration (2014) for uncomplicated CAP recommended.
Antibiotics for ambulatory management for uncomplicated CAP.
• Treatment with high dose amoxicillin 80-100 mg/kg/day divided twice a day for 5-7 days.
Antibiotics for inpatient treatment of uncomplicated CAP.
• Treatment with ampicillin 75 mg/kg/dose IV every 6 hours (max 2 g/dose) is recommended when pneumonia is suspected, and hospitalization
is required (Bradley, Byington et al., 2011).
• A 3rd generation cephalosporin (ceftriaxone 100mg/kg/day or cefotaxime 200 mg/kg/day) IV may be considered an alternative treatment
(Kaplan, Mason et al., 2001).
• If intravenous calcium or calcium-containing fluids (i.e., Ringer's lactate) is or will be prescribed cefotaxime is the recommended 3rd generation
cephalosporin due to concerns of calcium deposition with the use of ceftriaxone and calcium products (FDA, 2007).
Study characteristics. The search for suitable studies was completed on August 20, 2018. J. Michael, DO and J Markham, MD reviewed the 82 titles
and abstracts and identified seventeen articles that were believed to answer the question. After an in-depth review, 11 randomized control trials (RCT)
answered the question (see Figure 1).
Summary by Outcome Based on antibiotics available in the United States and/or Children’s Mercy Hospital, nine antibiotics comparisons measured cure
rate, failure rate, and/or side-effects.
Cure rate. Nine studies compared cure rate (Aurangzeb & Hameed, 2003; Bradley et al., 2007; Cannavino et al., 2016; ISCAP, 2004; Jibril et al.,
1989; Klein et al., 1995; Kogan et al., 2003; MASCOT, 2002; Wubbel et al., 1999). The odds ratios (see Table 1), for eight of the studies, indicated that
the intervention medication was not different to the comparator medication for (a) azithromycin versus co-amoxiclavulanic acid (Wubbel et al., 1999),
(b) azithromycin versus amoxicillin (Kogan et al., 2003), (c) cefpodoxime versus co-amoxiclavulanic acid (Klein et al., 1995), (d) amoxicillin versus
cefuroxime (Aurangzeb & Hameed, 2003), (e) levoﬂoxacin versus ceftriaxone or co-amoxiclavulanic acid (Bradley et al., 2007), (f) ceftaroline versus
ceftriaxone(Cannavino et al., 2016), and (g) amoxicillin 3-day treatment versus amoxicillin 5-days (ISCAP Study Group, 2004; MASCOT 2002).
One study (Jibril et al.,1989) measured cure rate of amoxicillin versus co-amoxyclavulanic acid in children between two and 12-years of age (N = 100).
The odds ratio indicated co-amoxiclavulanic acid was favorable to amoxicillin, OR = 5.52, 95% CI [1.86, 16.34]. There is uncertainty in the effect size
due to low number of events and high risk of bias based on an unblinded physician’s assessment.
For this outcome, the evidence was of very low certainty based on serious risk of bias (see Figure 2), serious indirectness, and serious imprecision.
Indirectness was serious due to studies performed on patients in developing countries may not apply to children in developed countries. Imprecision
was serious due to the low number of patients
Failure rates. Seven studies compared failure rates (Aurangzeb & Hameed, 2003; Cannavino et al., 2016; Greenberg et al., 2014; Harris, Kolokathis,
Campbell, Cassell, & Hammerschlag, 1998; ISCAP, 2004; MASCOT, 2002; Wubbel et al., 1999). The odds ratio (see Table 1) indicated that the
intervention medication was not different to the comparator medication for (a) azithromycin versus co-amoxyclavulanic acid (Harris et al., 1998;
Wubbel et al., 1999), (b) amoxicillin versus cefuroxime (Aurangzeb & Hameed, 2003), (c) ceftaroline versus ceftriaxone (Cannavino et al., 2016), (d)
amoxicillin 5-day treatment versus amoxicillin 10-day treatment (Greenberg et al., 2014), and (e) amoxicillin 3-day treatment versus amoxicillin 5-day
treatment (ISCAP Study Group, 2004; MASCOT 2002).
* These guidelines do not establish a standard of care to be followed in every case. It is recognized that each case is different, and those individuals involved
in providing health care are expected to use their judgment in determining what is in the best interests of the patient based on the circumstances existing at
the time. It is impossible to anticipate all possible situations that may exist and to prepare guidelines for each. Accordingly, these guidelines should guide
care with the understanding that departures from them may be required at times.
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One randomized control trial (Greenberg et al., 2014) measured failure rate for amoxicillin 10-day treatment versus amoxicillin 3-day treatment in
children 6 months to 59 months old. (N = 115). The trial was stopped early when four of 12 patients in the 3-day treatment group experienced
treatment failure. The 3-day treatment group was changed to receive 5 days of amoxicillin. There were no treatment failures for the 5-day treatment
group (n = 56) or the 10 day treatment group (n = 59).
For this outcome, the evidence was of very low certainty based on serious risk of bias (see Figure 2), serious indirectness, and serious imprecision.
Indirectness was serious due to studies performed on patients in developing countries may not apply to children in developed countries. Imprecision
was serious due to the low number of patients.
Side-effects. Five studies compared side-effects (Harris et al., 1998; Jibril et al., 1989; Klein et al., 1995; Kogan et al., 2003; Wubbel et al., 1999).
The odds ratios (see Table 1), for three of the studies, indicated that the intervention was not different to the comparator for (a) amoxicillin versus coamoxiclavulanic (Jibril et al., 1989) (b) azithromycin versus amoxicillin (Kogan et al., 2003), (c) cefpodoxime versus co-amoxiclavulanic acid (Klein et
al., 1995).
Two studies (Harris et al., 1998; Wubbel et al., 1999) were found which measured side-effects of azithromycin versus co-amoxiclavulanic in children
below ﬁve years of age (N = 283). The odds ratio indicated that the azithromycin group had fewer side-effects, OR = 0.15, 95% [CI 0.04, 0.61].
For this outcome the evidence was of very low certainty based on serious risk of bias (see Figure 2), serious indirectness, and serious imprecision.
Indirectness was serious due to studies performed on patients in developing countries may not apply to children in developed countries. Imprecision
was serious due to the low number of patients.
Identification of Studies
Search Strategy and Results (see Figure 1)
("community-acquired pneumonia" OR "community-acquired pneumonia" OR ("Community-Acquired Infections"[MeSH] AND "Pneumonia"[MAJR])) AND
(antibiotic* OR "Anti-Bacterial Agents"[Pharmacological Action] OR "Anti-Bacterial Agents"[Mesh]) AND (child OR children OR infant OR adolescence OR
pediatr* OR paediatr*) AND ("last 5 years"[PDat]) Filters: Clinical Study, Clinical Trial, Comparative Study, Controlled Clinical Trial, Guideline, MetaAnalysis, Multicenter Study, Practice Guideline, Systematic Reviews (SR).
Records identified through database searching n = 79
Previously published systematic reviews n = 3
Studies Included in this Review
Citation
Cannavino et al. (2016)
Greenberg et al. (2014)
Lodha et al. (2013)
*Harris et al. (1998)
*Wubbel et al. (1999
*Jibril et al. (1989)
*Kogan et al. (2003)
*Klein et al. (1995)

Study Type
RCT
RCT
SR
RCT
RCT
RCT
RCT
RCT
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*Aurangzeb et al. (2003)
RCT
*Bradley et al. (2007)
RCT
Hairder et al. (2011)
SR
*ISCAP Study Group (2004)
RCT
*MASCOT (2002)
RCT
*References marked with an asterisk indicate studies included from previously published SR
Studies Not Included in this Review with Exclusion Rationale
Citation
Gardiner, Gavranich, and Chang (2015)
In-iw, Winijkul, Sonjaipanich, and Manaboriboon (2015)
Kaplan et al. (2001)
López Alcalde et al. (2018)
Williams et al. (2013)
Lassi et al. (2014)

Reason for exclusion
No RCT found looking at lower respiratory tract infection secondary to M pneumoniae
Study on transition of oral medication from IV
Not RCT
No studies were comparing short versus long term treatment
Not RCT
Duplicate studies from another SR

Methods Used for Appraisal and Synthesis
aRayyan is a web-based software used for the initial screening of titles and / or abstracts for this analysis (Ouzzani, Hammady, Fedorowicz & Elmagarmid,
2017).
bReview Manager (Higgins & Green, 2011) is a Cochrane Collaborative computer program used to assess the study characteristics as well as the risk of bias
and create the forest plots found in this analysis.
cThe Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) flow diagram depicts the process in which literature is searched,
screened, and eligibility criteria is applied (Moher, Liberati, Tetzlaff, & Altman, 2009).
dThe GRADEpro Guideline Development Tool (GDT) is the tool used for the Evidence to Decision (EtD) for this analysis.
aOuzzani,

M., Hammady, H., Fedorowicz, Z., & Elmagarmid, A. (2016). Rayyan-a web and mobile app for systematic reviews. Systematic Reviews, 5(1),
210. doi:10.1186/s13643-016-0384-4
bHiggins, J. P. T., & Green, S. e. (2011). Cochrane Handbook for Systematic Reviews of Interventions [updated March 2011] (Version 5.1.0 ed.): The
Cochrane Collaboration, 2011.
cMoher D, Liberati A, Tetzlaff J, Altman DG, The PRISMA Group (2009). Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA
Statement. PLoS Med 6(7): e1000097. doi:10.1371/journal.pmed1000097 For more information, visit www.prisma-statement.org.
dGRADEpro GDT: GRADEpro Guideline Development Tool (2015). McMaster University, (developed by Evidence Prime, Inc.). [Software]. Available
from gradepro.org.
Question Originator
CAP Clinical Practice Guideline (CPG) Team
Medical Librarian Responsible for the Search Strategy
Keri Swaggart, MLIS, AHIP
EBP Scholar’s Responsible for Analyzing the Literature
Helen Murphy, BHS, RRT, AE-C
Britney Snodgrass, MSN, RN, CPN
EBP Team Member Responsible for Reviewing, Synthesizing, and Developing this Document
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Jarrod Dusin, MS, RD, LD, CPHQ
Acronyms Used in this Document
Acronym
Explanation
BTS
The British Thoracic Society
CABP
Community-acquired bacterial pneumonia
CAP
Community-acquired pneumonia
CI
Confidence interval
CPG
EBP
EOIV
EOT
EtD
IDSA
LFU
MASCOT
MRSA
OR
PIDS
PRISMA
RCT
SR
TOC
WHO

Clinical Practice Guideline
Evidence Based Practice
End of IV treatment
End of treatment
Evidence to decision
Infectious Disease Society of America
Late follow-up
Multicenter Amoxicillin Short Course Therapy
Methicillin-resistant Staphylococcus aureus
Odds ratio
The Pediatric Infectious Disease Society
Preferred reporting items for systematic reviews and meta-analyses
Randomized control trial
Systematic review
Test of cure
World Health Organization

Date Developed/Updated
January 2019
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Figure 1. Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRIMSA)e
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Figure 2. Risk of Bias Summary
*Risk of bias from previously published systematic reviews
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Table 1
Overview of Studies
Intervention and
comparator

Participants

Azithromycin versus Coamoxiclavulanic

6 months to 16
years;
Harris et al.
(1998) N = 456,
Wubbel et al.
(1999) N = 174

Amoxicillin versus Coamoxiclavulanic

2 years to 12
years, N = 100

Azithromycin versus
Amoxicillin

1 month to 14
years, N = 110

Dose and Length of Treatment
Wubbel et al. (1999) Azithromycin for 5-days
versus co-amoxiclavulanic for 10-day course
Harris et al. (1998) Azithromycin 10mg/kg
versus co-amoxiclavulanic 40mg/kg/day

Cure Rate

Failure Rate

Adverse effects

Reference

OR = 1.02, 95% CI
[0.54, 1.95]

OR = 1.21, 95%
CI [0.42, 3.53]

OR = 0.15,
95% CI [0.04,
0.61]

*Harris et al.
(1998),
*Wubbel et al.
(1999)

OR = 5.21,
95% CI [0.24,
111.24]

*Jibril et al.
(1989)

Amoxicillin 250 or 500mg versus Amoxicillin
250 or 500mg with clavulanic acid 62.5 or 12.5
mg. dosage and duration determined by
severity of condition

++
OR =
5.52, 95% CI
[1.86, 16.34]

Oral azithromycin 10 mg/kg for 3 days versus
oral Amoxicillin 75 mg/kg/d for 7 days

OR = 2.85, 95% CI
[0.73, 11.09]

Cefpodoxime versus Coamoxiclavulanic

3 months to
11.5 years, N =
348

Oral Cefpodoxime 5 to 12mg/kg/day for 10
days versus co-amoxiclavulanate 6 to 13
mg/kg/day for 10 days

OR = 0.69, 95% CI
[0.18, 2.60]

Amoxicillin versus
Cefuroxime

2 months to 72
months, N =
171

Amoxicillin 75mg/kg/day versus Cefuroxime
75mg/kg/day

OR = 2.05, 95% CI
[0.18, 23.51]

6 months to 16
years, N = 709

Levofloxacin 10mg/kg/dose

OR = 1.05, 95% CI
[0.46, 2.42]

Ceftaroline 12 mg/kg <33 kg or 400mg is >33
kg versus Ceftriaxone 75mg/kg/day

OR = 1.36, 95% CI
[0.39, 4.72]

Levofloxacin versus Coamoxiclavulanic acid or
Ceftriaxone
Ceftaroline versus
Ceftriaxone
Amoxicillin 10-day
Treatment versus 5-day
Treatment

2 months to <18
years, N = 160
6 months to 59
months, N =
115

Amoxicillin 5-day
Treatment versus 3-day
Treatment

2 months to 59
months, N =
4012

Oral Amoxicillin first
48hours in hospital
versus Amoxicillin at
home

3 months to 59
months, N =
1118

++Significant

Amoxicillin 80mg/kg/day x 10 days versus
Amoxicillin 80mg/kg/d x 5 days
ISCAP Study Group (2004) Amoxicillin 3154mg/kg/day for 3 days versus 5 days
MASCOT (2002) Amoxicillin 45mg/kg/day for 3
days versus 5 days
Oral Amoxicillin 50mg/kg/day, first 48 hours
administered in the hospital followed by 5 days
at home versus Oral Amoxicillin 50mg/kg/day
administered at home x 7 days

OR = 0.88, 95% CI
[0.72, 1.08]

++

OR = 8.37 95%
CI [0.41,
171.55]
OR = 0.46,
95% CI [0.16,
1.35]
OR = 0.49, 95%
CI [0.04, 5.59]

*Kogan et al.
(2003)
*Klein et al.
(1995)
*Aurangzeb et
al. (2003)
*Bradley et al.
(2007)

OR = 1.32, 95%
CI [0.35, 4.95]
Not estimable
(no treatment
failures)
OR = 1.13, 95%
CI [0.93, 1.39]
++
OR = 0.55,
95% CI [0.39,
0.78]

Cannavino et al.
(2016)
Greenberg et al.
(2014)
*ISCAP Study
Group (2004)
*MASCOT (2002)
Patel et al.
(2015)

difference; *Study from previously published SR
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Specific Care Question In pediatric patients with complicated community-acquired pneumonia (CAP), what treatment regimen is more effective in cure
rate, failure rate, and side-effects?
Recommendation from the CAP Clinical Practice Guideline (CPG) Team
A strong recommendation is made for ampicillin/sulbactam to be used for patients with complicated CAP, based on the GRADE evidence to decision
instrumentd (see Appendix A). The overall certainty in the evidence is lowd.
Antibiotics for inpatient treatment of complicated CAP.
• Treatment with ampicillin/sulbactam 50 mg of ampicillin component/kg/dose IV every 6 hours (max 2 g of ampicillin component/dose) is
recommended when pneumonia is complicated.
• If concerns for methicillin-resistant Staphylococcus aureus or severe disease, addition of vancomycin 15 mg/kg/dose IV every 6 – 8 hours is
recommended.
An overview of the results can be found in Table 1. A majority of the antibiotic comparisons found similar cure rates, failure rates, or side effects. The
exceptions to this finding was the cure rate of co-amoxiclavulanic acid was higher than amoxicillin (Jibril, Ifere, & Odumah, 1989), fewer side-effects
with azithromycin than co-amoxiclavulanic acid (Lodha, Kabra, & Pandey, 2013), and fewer side-effects with ceftaroline fosmil than ceftriaxone (Blumer
et al., 2016).
The evidence was of low certainty based on serious risk of bias (see Figure 2) and serious indirectness. Most of the outcomes and comparisons are
based off one or two small studies. Also, there was a large amount of heterogeneity among studies. Dosage and length of treatment was not analyzed
due to the heterogeneity of the studies. These issues will be discussed in the literature summary.
Literature Summary
Background. Community-acquired pneumonia (CAP) is the leading cause of mortality in children under five years of age globally (WHO, 2015).
Community-acquired pneumonia is a clinical diagnosis caused by a community-acquired infection in a previously healthy child. Complicated pneumonia
is a pulmonary parenchymal infection with parapneumonic effusions, multilobar disease, abscess, or cavities; necrotizing pneumonia, empyema,
pneumothorax, or bronchopleural fistula; or pneumonia that is a complication of bacteremic disease that includes other sites of infection (Bradley et al.,
2011).
Streptococcus pneumoniae is the most common bacterial cause of pneumonia in children of all ages (Barnson, 2018). Other bacterial pathogens that
may be found for hospitalized children include Staphylococcus aureus (including Methicillin-resistant staphylococcus aureus), Streptococcus pyogenes
(group A Streptococcus), Haemophilus influenzae type b (if unimmunized), non-typeable H. influenzae, and Moraxella catarrhalis (Branson, 2018).
The Pediatric Infectious Disease Society and the Infectious Disease Society of America (PIDS/IDSA) and the British Thoracic Society (BTS) are the
governing guidelines used for this review (Bradley et al., 2011; Harris et al., 2011). For complicated infections, the PIDS/IDSA guideline recommends
therapy should be individualized based on the clinical, laboratory, and imaging response to antimicrobial treatment (Bradley et al., 2011). Complicated
infections that result in parapneumonic effusions, empyema, or lung abscess may require therapy for 10-days, but prospective, randomized trials that
deﬁne length of antibiotic treatment based on attributes of the pathogen or characteristics of pneumonia have not been performed (Bradley et al.,
2011).
* These guidelines do not establish a standard of care to be followed in every case. It is recognized that each case is different, and those individuals involved
in providing health care are expected to use their judgment in determining what is in the best interests of the patient based on the circumstances existing at
the time. It is impossible to anticipate all possible situations that may exist and to prepare guidelines for each. Accordingly, these guidelines should guide
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The BTS recommends antibiotics administered orally are effective for children presenting with even severe CAP (Harris et al., 2011). Intravenous
antibiotics should be used in the treatment of pneumonia when the patient is unable to tolerate oral ﬂuids, absorb oral antibiotics, or presents with
signs of septicemia (Harris et al., 2011). Harris et al. (2011) recommended the antibiotics of amoxicillin, co-amoxiclavulanic acid, cefuroxime, or
ceftriaxone for complicated pneumonia.
Children’s Mercy microbiology data from January 1, 2017, to June 4, 2019, was reviewed and included polymerase chain reaction (PCR) results as well
as pleural fluid cultures. Growth of an organism occurred in 33 of the 163 pleural fluid cultures (20%) obtained during this time period. Organisms
identified by positive culture in more than one patient included Streptococcus pyogenes (n = 9), viridians group Streptococcus (n = 6), Streptococcus
pneumoniae (n = 3), methicillin-resistant Staphylococcus aureus (n = 3), methicillin susceptible Staphylococcus aureus (n = 2), and coagulasenegative Staphylococcus species (n = 5). Streptococcus pneumoniae and Staphylococcus aureus PCR testing on pleural fluid was completed in 66 and
67 patients respectively. S. pneumoniae PCR results were positive in 36% of the cases (n = 24). S. aureus PCR results were positive in 3% of cases (n
= 2) and indeterminant in 3% of cases (n = 2). Children’s Mercy 2018 antibiogram data was also considered. For S. pneumoniae isolated (n = 101),
high rates of susceptibility to penicillin (97%) and ceftriaxone (97%) are observed. For S. aureus isolates (n = 1657), observed susceptibility rates
were 68% for oxacillin and 78% for clindamycin.
Study characteristics. The search for suitable studies was completed on August 20, 2018. F. Turcotte Benedict, MD and A. Burns, PharmD reviewed
the 82 titles and abstracts and identified 10 articles that were believed to answer the question. A second search was completed on March 28, 2019. J.
Michael DO reviewed the 38 titles and abstracts and identified 13 articles that were believed to answer the question. After an in-depth review of the two
searches, seven articles were found to answer the question. The studies included three systematic reviews (SR) (Lassi et al., 2014; Lodha, Kabra, &
Pandey, 2013; Lodha, Randev, & Kabra, 2016), two randomized control trials (RCT) (Blumer et al., 2016; Cannavino et al., 2016), and two cohort
studies (Shah et al., 2016; Stockmann et al., 2015) (see Figure 1). The three SRs included 14 RCTs.
Selection of the studies were based on antibiotics available in the United States and/or Children’s Mercy Hospital. The outcomes reviewed were “cure
rate”, “failure rate”, and “side-effects”. The studies used different definitions for each of these outcomes resulting in uncertainty of the results. The
interventions included comparisons of different antibiotics and the comparison of oral antibiotics versus parental antibiotics. Length of treatment was
not compared in most of the studies.
Summary by Outcome
Cure rate. Nine RCTs examined cure rate (Aurangzeb & Hameed, 2003; Blumer et al., 2016; Bradley et al., 2007; Cannavino et al., 2016; Harris et al.,
1998, Jibril et al., 1989; Klein et al., 1995; Kogan et al., 2003; Wubbel et al., 1999). The odds ratios (see Table 1), for eight of the studies, indicated
that the intervention medication was not different to the comparator medication for (a) azithromycin versus co-amoxiclavulanic acid (Harris et al. &
Wubbel et al., 1999), (b) azithromycin versus amoxicillin (Kogan et al., 2003), (c) cefpodoxime versus co-amoxiclavulanic acid (Klein et al., 1995), (d)
amoxicillin versus cefuroxime (Aurangzeb & Hameed, 2003), (e) levoﬂoxacin versus ceftriaxone or co-amoxiclavulanic acid (Bradley et al., 2007), (f)
ceftaroline versus ceftriaxone (Cannavino et al., 2016), and (g) ceftaroline fosmil versus ceftriaxone (Blumer et al., 2016). One RCT (Jibril et al.,1989)
measured cure rate of amoxicillin versus co-amoxyclavulanic acid in children between two and 12-years of age (N = 100). The odds ratio indicated coamoxiclavulanic acid was favorable over amoxicillin, OR = 5.52, 95% CI [1.86, 16.34]. There is uncertainty in the effect size due to low number of
events and high risk of bias based on an unblinded physician’s assessment.
For this outcome, the evidence was of low certainty based on serious risk of bias (see Figure 2) and serious indirectness. Risk of bias was serious due to
six of the nine studies had a lack of blinding for participants and/or personnel (Aurangzeb et al., 2003; Blumer et al., 2016; Bradley et al., 2007; Jibril
* These guidelines do not establish a standard of care to be followed in every case. It is recognized that each case is different, and those individuals involved
in providing health care are expected to use their judgment in determining what is in the best interests of the patient based on the circumstances existing at
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et al., 1989; Klein et al., 1995; Wubbel et al., 1999). Indirectness was serious due to four of the nine studies were performed on patients in developing
countries may not apply to children in developed countries.
Failure rates. Eleven RCTs and two cohort studies examined failure rates (Addo-Yobo et al., 2004; Agweyu et al., 2015; Aurangzeb & Hameed, 2003;
Bansal, Singhi, & Jayashree, 2006; Blumer et al., 2016; Campbell et al., 1988; Cannavino et al., 2016; Harris et al., 1998; Hazir et al., 2008; Peltola et
al., 2001; Shah et al., 2016; Stockman et al., 2015; Wubbel et al., 1999).
The odds ratios (see Table 1) indicated that the intervention medication was not different to the comparator medication for (a) azithromycin versus coamoxyclavulanic acid (Harris et al., 1998; Wubbel et al., 1999), (b) amoxicillin versus cefuroxime (Aurangzeb & Hameed, 2003), (c) ceftaroline versus
ceftriaxone (Cannavino et al., 2016), (d) ampicillin 48-hours plus 3-day amoxicillin versus 5-days Amoxicillin (Hazir et al., 2008), (e) procaine penicillin
or Cefuroxime 4-days versus 7 days (Peltola et al., 2001), (f) ceftaroline fosmil versus ceftriaxone (Blumer et al., 2016), (g) Oral antibiotics versus
parenteral antibiotics (Addo-Yobo et al., 2004; Agweyu et al., 2015; Campbell et al., 1988; Hazir et al., 2008; Shah et al., 2016; Stockman et al.,
2015), and (h) penicillin and gentamicin versus amoxicillin/clavulante (Bansal et al., 2006).
For this outcome, the evidence was of low certainty based on serious risk of bias (see Figure 2) and serious indirectness. Risk of bias was serious due
to seven of the eleven RCTs had a lack of blinding for participants and/or personnel (Addo-Yobo et al., 2004; Aurangzeb et al., 2003; Bansal et al.,
2006; Blumer et al., 2016; Campbell et al., 1988; Haziz et al., 2008; Wubbel et al., 1999). Indirectness was serious due to six of the thirteen studies
were performed on patients in developing countries may not apply to children in developed countries.
Side-effects. Six RCTs and one cohort study examined side-effects (Blumer et al., 2016; Harris et al., 1998; Jibril et al., 1989; Klein et al., 1995;
Kogan et al., 2003; Stockman et al., 2015; Wubbel et al., 1999). The odds ratios (see Table 1), for four of the studies, indicated that the intervention
was not different to the comparator for (a) amoxicillin versus co-amoxiclavulanic (Jibril et al., 1989) (b) azithromycin versus amoxicillin (Kogan et al.,
2003), (c) cefpodoxime versus co-amoxiclavulanic acid (Klein et al., 1995), and (d) oral versus parenteral antibiotics (Stockman et al., 2015). Two
RCTs (Harris et al., 1998; Wubbel et al., 1999) were found which measured side-effects of azithromycin versus co-amoxiclavulanic in children below
ﬁve years of age (N = 283). The odds ratio indicated that the azithromycin group had fewer side-effects, OR = 0.15, 95% [CI 0.04, 0.61]. One RCT
(Blumer et al., 2016) was found which measured side-effects of ceftaroline fosmil versus ceftriaxone plus vancomycin (N = 35). The odds ratio
indicated that the ceftaroline fosmil has fewer side-effects, OR = 0.17, 95% CI [0.03, 0.92].
For this outcome the evidence was of low certainty based on serious risk of bias (see Figure 2) and serious indirectness. Risk of bias was serious due to
four of the six RCTs had a lack of blinding for participants and/or personnel (Blumer et al., 2016, Jibril et al., 1989; Klein et al., 1995; Wubbel et al.,
1999). Indirectness was serious due to three of seven were studies performed on patients in developing countries may not apply to children in
developed countries.
Identification of Studies
Search Strategy and Results (see Figure 1)
(“community-acquired pneumonia” OR “community-acquired pneumonia” OR (“Community-Acquired Infections”[MeSH] AND “Pneumonia”[MAJR]))
AND (antibiotic* OR “Anti-Bacterial Agents”[Pharmacological Action] OR “Anti-Bacterial Agents”[Mesh]) AND (child OR children OR infant OR
adolescence OR pediatr* OR paediatr*) AND (“last 5 years”[PDat]) Filters: Clinical Study, Clinical Trial, Comparative Study, Controlled Clinical Trial,
Guideline, Meta-Analysis, Multicenter Study, Practice Guideline, Systematic Reviews (SR).
Records identified through database searching n = 79
Previously published systematic reviews n = 2
* These guidelines do not establish a standard of care to be followed in every case. It is recognized that each case is different, and those individuals involved
in providing health care are expected to use their judgment in determining what is in the best interests of the patient based on the circumstances existing at
the time. It is impossible to anticipate all possible situations that may exist and to prepare guidelines for each. Accordingly, these guidelines should guide
care with the understanding that departures from them may be required at times.

Department of Evidence Based Practice
Service and Performance Excellence
Date Finalized/Revised: 10/2018; 03/2020

51

Search: (“complicated pneumonia” OR “severe pneumonia” OR “complicated community acquired pneumonia” OR “severe community acquired
pneumonia” OR “complicated community-acquired pneumonia” OR “severe community-acquired pneumonia” OR (“Pneumonia”[Mesh] AND (“Lung
Abscess” OR “necrotizing pneumonia” OR “Empyema” OR “Pneumothorax” OR “Pleural Effusion” OR “parapneumonic effusions” OR “bronchopleural
fistula” OR “multilobar disease” OR “cavitary lesions”))) AND (antibiotic* OR “Anti-Bacterial Agents”[Pharmacological Action] OR “Anti-Bacterial
Agents”[Mesh]) AND (child OR children OR infant OR adolescence OR pediatr* OR paediatr*) AND (“last 5 years”[Pdat]) Filters: Clinical Study, Clinical
Trial, Comparative Study, Controlled Clinical Trial, Guideline, Multicenter Study, Practice Guideline, Systematic Reviews, Meta-Analysis
Records identified through database searching n = 38
Previously published systematic reviews n = 1
Studies Included in this Review
Citation
Study Type
Blumer et al. (2016)
RCT
Cannavino et al. (2016)
RCT
Lassi et al. (2013)
SR
*Hazir et al. (2008)
RCT
*Peltola et al. (2001)
RCT
*Bansal et al., (2006)
RCT
Lodha et al. (2016)
SR
*Addo-Yobo et al. (2004)
RCT
*Agweyu et al. (2015)
RCT
*Campbell et al. (1988)
RCT
Lodha et al. (2013)
SR
*Harris et al. (1998)
RCT
*Wubbel et al. (1999
RCT
*Jibril et al. (1989)
RCT
*Kogan et al. (2003)
RCT
*Klein et al. (1995) 1
RCT
*Aurangzeb et al. (2003)
RCT
*Bradley et al. (2007)
RCT
Shah et al. (2016)
Cohort
Stockman et al. (2015)
Cohort
*References marked with an asterisk indicate studies included from previously published SR
Studies Not Included in this Review with Exclusion Rationale
Citation
Breuer et al. (2015)
Gardiner, Gavranich, and Chang (2015)

Reason for exclusion
Uncomplicated CAP patients
Systematic review found no studies that answered the question

1
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Greenberg et al. (2014)
Haas et al. (2016)
Hairder et al. (2011)
In-iw, Winijkul, Sonjaipanich, and Manaboriboon (2015)
Kaplan et al. (2001)
Krenke et al. (2014)
Lassi et al. (2017)
López Alcalde et al. (2018)
Patel et al. (2017)
Queen et al. (2014)
Wang et al. (2016)
Williams et al. (2013)
Williams et al. (2017)
Atkinson et al. (2007)

Uncomplicated CAP patients
Non-English study
Uncomplicated CAP patients
Study on transition to oral medication from IV
Uncomplicated CAP patients
No antibiotics comparisons
Systematic review found no studies that answered the question
No studies found
Uncomplicated CAP patients
Uncomplicated CAP patients
Uncomplicated CAP patients
Uncomplicated CAP patients
Only measured antibiotic use
Data on cure rate, failure rate, and side-effects not provided

Methods Used for Appraisal and Synthesis
aRayyan is a web-based software used for the initial screening of titles and / or abstracts for this analysis (Ouzzani, Hammady, Fedorowicz & Elmagarmid,
2017).
bReview Manager (Higgins & Green, 2011) is a Cochrane Collaborative computer program used to assess the study characteristics as well as the risk of bias
and create the forest plots found in this analysis.
cThe Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) flow diagram depicts the process in which literature is searched,
screened, and eligibility criteria is applied (Moher, Liberati, Tetzlaff, & Altman, 2009).
dThe GRADEpro Guideline Development Tool (GDT) is the tool used for the Evidence to Decision (EtD) for this analysis.
aOuzzani,

M., Hammady, H., Fedorowicz, Z., & Elmagarmid, A. (2016). Rayyan-a web and mobile app for systematic reviews. Systematic Reviews, 5(1),
210. doi:10.1186/s13643-016-0384-4
bHiggins, J. P. T., & Green, S. e. (2011). Cochrane Handbook for Systematic Reviews of Interventions [updated March 2011] (Version 5.1.0 ed.): The
Cochrane Collaboration, 2011.
cMoher D, Liberati A, Tetzlaff J, Altman DG, The PRISMA Group (2009). Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA
Statement. PLoS Med 6(7): e1000097. doi:10.1371/journal.pmed1000097 For more information, visit www.prisma-statement.org.
dGRADEpro GDT: GRADEpro Guideline Development Tool (2015). McMaster University, (developed by Evidence Prime, Inc.). [Software]. Available
from gradepro.org.
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Acronyms Used in this Document
Acronym
Explanation
BTS
The British Thoracic Society
CABP
Community-acquired bacterial pneumonia
CAP
Community-acquired pneumonia
cCABP
Complicated community acquired bacterial pneumonia
CI
Confidence interval
CPG
EBP
EOIV
EOT
EtD
IDSA
IQR
LFU
MASCOT

MSSA

MRSA
OPAT
OR
PHIS
PIDS
PRISMA
RCT
SAE
SR
TOC
WHO

Clinical Practice Guideline
Evidence Based Practice
End of IV treatment
End of treatment
Evidence to decision
Infectious Disease Society of America
Interquartile range
Late follow-up
Multicenter Amoxicillin Short Course Therapy
Methicillin-susceptible Staphylococcus aureus
Methicillin-resistant Staphylococcus aureus
Outpatient antibiotic therapy
Odds ratio
Pediatric Health Information System
The Pediatric Infectious Disease Society
Preferred Reporting Items for Systematic Reviews and Meta-Analyses
Randomized control trial
Serious adverse events
Systemic review
Test of cure
World Health Organization
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Figure 1. Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRIMSA)c
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Figure 2. Risk of Bias Summary
*Risk of bias from previously published systematic reviews
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Cure Rate

Failure Rate

Side-effects

Reference

Study
Type

OR = 1.02,
95% CI [0.54,
1.95]

OR = 1.21,
95% CI [0.42,
3.53]

++OR =
0.15, 95%
CI [0.04,
0.61]

*Harris et al.
(1998),
*Wubbel et al.
(1999)

SR

=
5.52, 95% CI
[1.86, 16.34]

OR = 5.21,
95% CI
[0.24,
111.24]

*Jibril et al.
(1989)

RCT

Oral Azithromycin 10 mg/kg for 3days versus oral Amoxicillin 75
mg/kg/d for 7-days

OR = 2.85,
95% CI [0.73,
11.09]

*Kogan et al.
(2003)

3 months to 11.5
years, N = 348

Oral Cefpodoxime 5 to 12mg/kg/day
for 10-days versus
Co-amoxyclavulanate 6 to 13
mg/kg/day for 10-days

OR = 8.37
95% CI
[0.41,
171.55]

OR = 0.69,
95% CI [0.18,
2.60]

OR = 0.46,
95% CI
[0.16, 1.35]

*Klein et al.
(1995)

RCT

Amoxicillin versus
Cefuroxime

2 months to 72
months, N = 171

Amoxicillin 75mg/kg/day versus
Cefuroxime 75mg/kg/day

OR = 2.05,
95% CI [0.18,
23.51]

*Aurangzeb et
al. (2003)

RCT

Levofloxacin versus
Co-amoxiclavulanic
acid or Ceftriaxone

6 months to 16
years, N = 709

Levofloxacin 10mg/kg/dose

*Bradley et al.
(2007)

RCT

Ceftaroline versus
Ceftriaxone

2 months to <18
years, N = 160

Cannavino et
al. (2016)

RCT

Ampicillin 48-hours
plus 3-day
Amoxicillin versus 5days Amoxicillin

3 months to 59
months, N =
2100

*Hazir et al
(2008)

RCT

Participants

Dose and Length of Treatment

Azithromycin versus
Co-amoxiclavulanic

6 months to 16
years; Harris et
al. (1998) N =
456,
Wubbel et al.
(1999) N = 174

Amoxicillin versus
Co-amoxiclavulanic

2 years to 12
years, N = 100

Wubbel et al. (1999) Azithromycin for
5-days versus Co-amoxiclavulanic for
10-day course
Harris et al. (1998) Azithromycin
10mg/kg versus Co-amoxiclavulanic
40mg/kg/day
Amoxicillin 250 or 500mg versus
Amoxicillin 250 or 500mg with
Clavulanic acid 62.5 or 12.5 mg.
dosage and duration determined by
severity of condition

Azithromycin versus
Amoxicillin

1 month to 14
years, N = 110

Cefpodoxime versus
Co-amoxiclavulanic

Ceftaroline 12 mg/kg <33 kg or
400mg is >33 kg versus Ceftriaxone
75mg/kg/day
Ampicillin 100mg/kg/day for 48 hours,
followed by 3-days of oral Amoxicillin
80-90 mg/kg per day versus 5-days
oral Amoxicillin 80-90 mg/kg per day

++OR

OR = 1.05,
95% CI [0.46,
2.42]
OR = 1.36,
95% CI [0.39,
4.72]

OR = 0.49,
95% CI [0.04,
5.59]

OR = 1.32,
95% CI [0.35,
4.95]
OR = 1.20
[0.71, 2.04]

RCT

* These guidelines do not establish a standard of care to be followed in every case. It is recognized that each case is different, and those individuals involved
in providing health care are expected to use their judgment in determining what is in the best interests of the patient based on the circumstances existing at
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Participants
3 months to 15
years, N = 154

Ceftaroline fosmil
versus Ceftriaxone
plus Vancomycin ≥3
days

3 months to 17
years, N = 35

Penicillin and
Gentamicin Therapy
versus
Amoxicillin/Clavulana
te

2 months to 59
months, N = 71

Oral antibiotics
(Amoxicillin or Cotrimoxazole) versus
parental antibiotics
(Penicillin/Ampicillin
or IM Procaine
Penicillin)
Oral antibiotics
versus parenteral
antibiotics

Dose and Length of Treatment
Procaine penicillin (50,000 IU/kg once
daily intramuscular) versus
Cefuroxime (100 mg/kg per day in 3
divided doses intravenous), 4-days
versus 7-days
Ceftaroline < 6 months old, 10mg/kg
or > 6 months old 15mg/kg versus IV
Ceftriaxone, 75 mg/kg/day and IV
Vancomycin, 15 mg/kg. Both groups
could switch from IV study drug to
open-label oral study drug (Amoxicillin
Clavulanate, Clindamycin, or
Linezolid) on or after study day 3.
Injectable Crystalline Penicillin 50,000
IU/kg and Gentamicin 2.5 mg/kg IV
for at least 3-days combination
followed by oral Amoxicillin 15 gm/kg
versus IV and oral AmoxicillinClavulanate 30mg/kg IV for at least 3days

Cure Rate

Failure Rate

Side-effects

OR = 3.37
[0.14, 84.09]

OR = 0.40,
95% CI [0.02,
8.45]

OR = 2.51,
95% CI [0.12,
53.23]

OR = 0.86,
95% CI [0.05,
14.39]

++OR

=
0.17 95%
CI [0.03,
0.92]

Reference

Study
Type

*Peltola et al
(2001)

RCT

Blumer et al.
(2016)

RCT

*Bansal et al.
(2006)

RCT

SR

Below 5 years of
age, N = 4391

Oral antibiotics (Amoxicillin or Cotrimoxazole) versus parental
antibiotics (Penicillin/Ampicillin or IM
Procaine Penicillin)

OR = 0.93,
95% CI [0.78,
1.12]

Below 5 years of
age, N = 2123

Oral antibiotics: anti-MSSA , antiMRSA, anti-MRSA + anti-MSSA,
Amoxicillin versus Parenteral
antibiotics: anti-MSSA , anti-MRSA,
and anti-MRSA + anti-MSSA

*Addo-Yobo
et al. (2004),
*Agweyu et
al. (2015),
*Campbell et
al. (1988)
*Hazir et al.
(2008)

OR = 1.26,
95% CI [0.54,
2.94]

Shah et al.
(2016)

Cohort

* These guidelines do not establish a standard of care to be followed in every case. It is recognized that each case is different, and those individuals involved
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Participants

Dose and Length of Treatment

Oral antibiotic therapy (Amoxicillin
alone, Clindamycin alone, Clindamycin
and rifampin, Amoxicillin/clavulanate
alone, Lefloxacin alone, and others
(5.6% of total) versus Outpatient
Oral antibiotics
2 years to 9
antibiotic therapy (OPAT) (Ceftriaxone
versus parenteral
years, N = 391
or cefotaxime alone, Ceftriaxone or
antibiotics
cefotaxime and clindamycin,
Ceftriaxone or cefotaxime,
Clindamycin alone Clindamycin and
others, and others (4.5% of total).
++Significant difference; *Study from previously published SR

Cure Rate

Failure Rate

Side-effects

Reference

OR = 1.23,
95% CI [0.06,
25.99]

OR = 1.23,
95% CI
[0.06,
25.99]

Stockman et
al. (2015

Study
Type

Cohort

* These guidelines do not establish a standard of care to be followed in every case. It is recognized that each case is different, and those individuals involved
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Specific Care Question
In pediatric patients with CAP and a penicillin allergy, what treatment regimen is recommended:
• Non-serious/Non-type I hypersensitivity
• Serious/Type I hypersensitivity
Recommendation from the CAP Clinical Practice Guideline (CPG) Team
A strong recommendation is made for clindamycin or anti-pneumococcal cephalosporin antibiotics for treatment of CAP patients with a penicillin allergy.
• Antimicrobial recommendations for patients that have had a non-serious/non-type I hypersensitivity to penicillin (rash and itching) include oral
clindamycin 30-40 mg/kg/day divided every 8 hours (max 1800 mg/day) or an anti-pneumococcal cephalosporin.
• Anti-pneumococcal cephalosporins are cefuroxime, cefpodoxime, and cefprozil.
Cefuroxime 250 – 500 mg PO q12h (available in tablet form only)
Cefpodoxime 5 mg/kg/dose PO q12h (max 200 mg/dose)
Cefprozil 15 mg/kg/dose PO q12h (max 500 mg/dose)
• Patients with a serious hypersensitivity (hives and anaphylaxis) should be treated with clindamycin 30-40 mg/kg/day divided every 8 hours (max
1800 mg/day).
• Cefdinir is not recommended for oral therapy.
An overview of the results can be found in Table 1. A majority of the antibiotic comparisons found similar cure rates, failure rates, side effects, and
length of stay (LOS). Queen et al. (2014) found patients treated with narrow-spectrum antibiotics had a shorter LOS than patients treated with broadspectrum antibiotics while Breuer et al. (2015) reported patients treated with broad-spectrum antibiotics had a shorter LOS than those treated with
narrow-spectrum antibiotics.
The evidence was of very low certainty based on serious risk of bias (see Figure 2), serious indirectness, and serious imprecision. Most outcomes and
comparisons were based off one or two small studies. There was a large amount of heterogeneity among the studies, which lead to the inability to
analyze dosage and length of stay. These issues will be discussed, in more detail, within the literature summary.
Literature Summary
Background. Globally, CAP accounts for 15% of deaths in children under 5-years-old (WHO, 2015). CAP is a clinical diagnosis caused by a communityacquired infection in a previously healthy child. Streptococcus pneumoniae is the most common bacterial cause of pneumonia in children of all ages
(Barnson, 2018). Other bacterial pathogens in hospitalized children include Staphylococcus aureus (including Methicillin-resistant staphylococcus
aureus), Streptococcus pyogenes (group A Streptococcus), Haemophilus influenzae type b (if unimmunized), non-typeable Haemophius influenzae, and
Moraxella catarrhalis (Branson, 2018).
The Pediatric Infectious Disease Society and the Infectious Disease Society of America (PIDS/IDSA) and the British Thoracic Society (BTS) are the
governing guidelines for this review (Bradley et al., 2011; Harris et al., 2011). The PIDS/IDSA and the BTS recommends amoxicillin as the first choice
for oral antibiotic therapy in all children because it is effective against most pathogens that cause CAP, is well tolerated, and inexpensive (Bradley et al.,
2011; Harris et al., 2011). For non-serious/non-type I hypersensitivity (rash and itching) to penicillin, options include oral cefpodoxime, cefprozil, or
cefuroxime; levoﬂoxacin; linezolid; clindamycin; or macrolide. Patients with a history of serious/type I hypersensitivity (hives or anaphylaxis) should be
treated with clindamycin (Bradley et al., 2011).
* These guidelines do not establish a standard of care to be followed in every case. It is recognized that each case is different, and those individuals involved
in providing health care are expected to use their judgment in determining what is in the best interests of the patient based on the circumstances existing at
the time. It is impossible to anticipate all possible situations that may exist and to prepare guidelines for each. Accordingly, these guidelines should guide
care with the understanding that departures from them may be required at times.
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Children’s Mercy’s previous CAP CPG (2014) recommended empiric antibiotic alternatives to penicillin for patients with a history of
serious/type I and non-serious/non-type I hypersensitivity.
•
Antimicrobial recommendations for patients that have had a non-serious/non-type I hypersensitivity to penicillin (rash and itching) include
oral clindamycin or an anti-pneumococcal cephalosporin.
•
Anti-pneumococcal cephalosporins are cefuroxime, cefpodoxime, and cefprozil.
•
Cefdinir is not recommended for oral therapy.
•
Patients with a serious hypersensitivity (hives and anaphylaxis) should be treated with clindamycin.
Study characteristics. The search for suitable studies was completed on August 20, 2018. S. Chan MD, PhD and J. Goldman MD, MS-CR reviewed the
79 titles and abstracts and identified 11 articles that were believed to answer the question. A second search was completed on April 11, 2019. J.
Michael DO reviewed five titles and abstracts and identified two articles that were believed to answer the question. After an in-depth review of the two
searches, nine articles were believed to answer the question. The studies included two systematic reviews (SR) (Lassi et al., 2014; Lodha, Kabra, &
Pandey, 2013), three randomized control trials (Amarilyo et al., 2014; Blumer et al., 2016; Cannavino et al., 2016), and four cohort studies (Breuer et
al., 2015; Leyenaar, Shieh, Lagu, Pekow, & Lindenauer, 2014; Queen et al., 2014; Williams et al., 2013) (see Figure 1). The two SRs included four
RCTs (Aurangzeb & Hameed, 2003; Bradley et al., 2007; Klein, 1995; Peltola, Vuori-Holopainen, Kallio, & Group, 2001) that answered the question.
Selection of the studies was based on antibiotics available in the United States and/or Children’s Mercy Hospital. The outcomes reviewed were (a) cure
rate, (b) failure rate, (c) side-effects, and (d) LOS. The interventions included comparisons of different antibiotics. The studies used different definitions
for all the outcomes resulting in uncertainty of the results. Length of treatment was not compared in most of the studies. Three cohorts reviewed broadspectrum versus narrow-spectrum antibiotics (Breuer et al., 2015; Queen et al., 2014; Williams et al., 2013). Narrow-spectrum antibiotics included (a)
amoxicillin, (b) ampicillin, (c) penicillin, and (d) amoxicillin/clavulanic acid. Broad-spectrum antibiotics included (a) second and third-generation
cephalosporins (ceftriaxone & cefotaxime) and (b) fluoroquinolones.
Summary by Outcome
Cure rate. Five RCTs examined cure rate (Aurangzeb & Hameed, 2003; Blumer et al., 2016; Bradley et al., 2007; Cannavino et al., 2016; Klein, 1995).
The odds ratios (see Table 1) indicated that the intervention medication was not different to the comparator medication for (a) amoxicillin versus
cefuroxime (Aurangzeb & Hameed, 2003), (b) ceftaroline fosmil versus ceftriaxone (Blumer et al., 2016), (c) levoﬂoxacin versus ceftriaxone or coamoxiclavulanic acid (Bradley et al., 2007), (d) ceftaroline versus ceftriaxone (Cannavino et al., 2016), or (e) cefpodoxime versus co-amoxiclavulanic
acid (Klein, 1995).
For this outcome, the evidence was of low certainty based on serious risk of bias (see Figure 2) and serious indirectness. Risk of bias was serious due to
four of the five studies had a lack of blinding for participants and/or personnel (Aurangzeb & Hameed, 2003; Blumer et al., 2016; Bradley et al., 2007;
Klein et al., 1995). Indirectness was serious due to two of the five studies (Aurangzeb & Hameed, 2003; Klein, 1995) occurred in developing countries
which may not apply to children in developed countries.
Failure rates. Four RCTs and three cohort studies examined failure rates (Aurangzeb & Hameed, 2003; Blumer et al., 2016; Cannavino et al., 2016;
Leyenaar et al., 2014; Peltola et al., 2001; Queen et al., 2014; Willams et al., 2013). The odds ratios or p-values (see Table 1) indicated that the
intervention medication was not different to the comparator medication for (a) amoxicillin versus cefuroxime (Aurangzeb & Hameed, 2003), (b)
ceftaroline fosmil versus ceftriaxone (Blumer et al., 2016), (c) ceftaroline versus ceftriaxone (Cannavino et al., 2016), (d) ceftriaxone versus
ceftriaxone plus macrolide (Leyenaar et al., 2014), (e) procaine penicillin or cefuroxime 4-days versus 7 days (Peltola et al., 2001), (f) broad-spectrum
versus narrow-spectrum antibiotics (Queen et al., 2014; Willams et al., 2013).
* These guidelines do not establish a standard of care to be followed in every case. It is recognized that each case is different, and those individuals involved
in providing health care are expected to use their judgment in determining what is in the best interests of the patient based on the circumstances existing at
the time. It is impossible to anticipate all possible situations that may exist and to prepare guidelines for each. Accordingly, these guidelines should guide
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For this outcome, the evidence was of very low certainty based on serious risk of bias of the RCTs (see Figure 2) and three of the studies were cohort
studies that did not report a large effect size (Leynaar et al., 2014; Willams et al., 2013; Queen et al., 2014). Risk of bias was serious due to three of
the four RCTs had a lack of blinding for participants and/or personnel (Aurangzeb & Hameed, 2003; Blumer et al., 2016; Peltola et al., 2001).
Side-effects. Two RCTs examined side-effects (Blumer et al., 2016; Klein, 1995). The odds ratios (see Table 1), indicated that the intervention was
not different to the comparator for cefpodoxime versus co-amoxiclavulanic acid (Klein, 1995). One RCT (Blumer et al., 2016) was found which
measured the side-effects of ceftaroline fosmil versus ceftriaxone plus vancomycin (N = 35). The odds ratio indicated that the ceftaroline fosmil has
fewer side-effects, OR = 0.17, 95% CI [0.03, 0.92].
For this outcome the evidence was of low certainty based on serious risk of bias (see Figure 2) and serious imprecision. Risk of bias was serious due to
both RCTs had a lack of blinding for participants and/or personnel (Blumer et al., 2016, Klein, 1995). Imprecision was serious due to the low number of
participants (N = 383) in the two studies.
LOS. One RCT (Amarilyo et al., 2014) and four cohorts (Breuer et al., 2015; Leyenaar et al., 2014; Queen et al., 2014; Williams et al., 2013) reported
LOS. Based on either the reported MD or p-values (see Table 1) the intervention medication was not different to the comparator medication for (a) IV
penicillin G versus cefuroxime (Amarilyo et al., 20140), (b) ceftriaxone versus ceftriaxone plus macrolide (Leyenaar et al., 2014), and (c) broadspectrum versus narrow-spectrum antibiotics (Williams et al., 2013). The MD of two cohorts (Breuer et al., 2015; Queen et al., 2014) where in direct
opposition to each other for broad-spectrum versus narrow-spectrum antibiotics. Breuer et al. (2015) found LOS was shorter for broad-spectrum
antibiotics than for narrow-spectrum antibiotics MD = 0.70 days, 95% CI [0.26, 1.14]. Queen et al. (2014) found LOS was shorter for narrow-spectrum
antibiotics than for broad-spectrum antibiotics MD = 9.3 hours, 95% CI [3.46, 15.14].
For this outcome, the evidence was of very low certainty based on serious risk of bias (see Figure 2) (Amarilyo et al., 2014) and four studies were
cohort studies that did not report a large effect size (Breuer et al., 2015; Leyenaar et al., 2014; Queen et al., 2014; Williams et al., 2013). Risk of bias
was serious due to lack of blinding for participants and/or personnel.
Identification of Studies
Search Strategy and Results (see Figure 1)
(“community-acquired pneumonia” OR “community-acquired pneumonia” OR (“Community-Acquired Infections”[MeSH] AND “Pneumonia”[MAJR])) AND
(antibiotic* OR “Anti-Bacterial Agents”[Pharmacological Action] OR “Anti-Bacterial Agents”[Mesh]) AND (child OR children OR infant OR adolescence OR
pediatr* OR paediatr*) AND (“last 5 years”[PDat]) Filters: Clinical Study, Clinical Trial, Comparative Study, Controlled Clinical Trial, Guideline, MetaAnalysis, Multicenter Study, Practice Guideline, Systematic Reviews (SR).
Records identified through database searching n = 79
Previously published systematic reviews n = 3
Search: ("community acquired pneumonia" OR "community-acquired pneumonia" OR ("Community-Acquired Infections"[MeSH] AND
"Pneumonia"[Mesh])) AND ("Penicillin Allergy" OR "penicillin hypersensitivity" OR (("Penicillins"[Mesh] OR penicillin[tiab]) AND ("Type 1 hypersensitivity"
OR Non-type 1 hypersensitivity OR "Drug Hypersensitivity"[Mesh] OR hypersensitivity[tiab] OR allergy[tiab]))) AND (child OR children OR infant OR
adolescence OR pediatr* OR paediatr*)
Records identified through database searching n = 5
* These guidelines do not establish a standard of care to be followed in every case. It is recognized that each case is different, and those individuals involved
in providing health care are expected to use their judgment in determining what is in the best interests of the patient based on the circumstances existing at
the time. It is impossible to anticipate all possible situations that may exist and to prepare guidelines for each. Accordingly, these guidelines should guide
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Studies Included in this Review
Citation
Study Type
Amarilyo et al. (2014)
RCT
Blumer et al. (2016)
RCT
Breuer et al. (2015)
Cohort
Cannavino et al. (2016)
RCT
Lassi et al. (2014)
SR
*Peltola et al. (2001)
RCT
Leyenaar et al. (2014)
Cohort
Lodha et al. (2013)
SR
*Klein (1995)
RCT
*Aurangzeb and Hameed (2003)
RCT
*Bradley et al. (2007)
RCT
Queen et al. (2014)
Cohort
Williams et al. (2013)
Cohort
*References marked with an asterisk indicate studies included from previously published SR
Studies Not Included in this Review with Exclusion Rationale
Citation
Atkinson et al. (2007)
Bao, Qu, Liu, Qin, and Cao (2013)
Gardiner, Gavranich, and Chang (2015)
Lassi, Imdad, and Bhutta (2017)
Leung, Wong, and Hon (2018)
Lopez et al. (2018)
Nascimento-Carvalho, Andrade, and Vilas-Boas (2016)
Parikh et al. (2017)
Williams et al. (2017)

Reason for exclusion
Data on cure rate or failure not provided
Non-English journal
No RCT found looking at lower respiratory tract infection secondary to M pneumoniae
No RCT found to answer question for this SR
Review article
No RCT found to answer question for this SR
Review article
Only measured antibiotic use
Only measured antibiotic use

Methods Used for Appraisal and Synthesis
aRayyan is a web-based software used for the initial screening of titles and / or abstracts for this analysis (Ouzzani, Hammady, Fedorowicz & Elmagarmid,
2017).
bReview Manager (Higgins & Green, 2011) is a Cochrane Collaborative computer program used to assess the study characteristics as well as the risk of bias
and create the forest plots found in this analysis.
cThe Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) flow diagram depicts the process in which literature is searched,
screened, and eligibility criteria is applied (Moher, Liberati, Tetzlaff, & Altman, 2009).
dThe GRADEpro Guideline Development Tool (GDT) is the tool used for the Evidence to Decision (EtD) for this analysis.
aOuzzani,

M., Hammady, H., Fedorowicz, Z., & Elmagarmid, A. (2016). Rayyan-a web and mobile app for systematic reviews. Systematic Reviews, 5(1),
210. doi:10.1186/s13643-016-0384-4
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bHiggins,

J. P. T., & Green, S. e. (2011). Cochrane Handbook for Systematic Reviews of Interventions [updated March 2011] (Version 5.1.0 ed.): The
Cochrane Collaboration, 2011.
cMoher D, Liberati A, Tetzlaff J, Altman DG, The PRISMA Group (2009). Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA
Statement. PLoS Med 6(7): e1000097. doi:10.1371/journal.pmed1000097 For more information, visit www.prisma-statement.org.
dGRADEpro GDT: GRADEpro Guideline Development Tool (2015). McMaster University, (developed by Evidence Prime, Inc.). [Software]. Available
from gradepro.org.
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EBP Scholar’s Responsible for Analyzing the Literature
Teresa Bontrager, MSN, RN, CPEN
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Acronyms Used in this Document
Acronym
Explanation
BTS
The British Thoracic Society
CABP
Community-acquired bacterial pneumonia
CAP
Community-acquired pneumonia
cCABP
Complicated community acquired bacterial pneumonia
CI
Confidence interval
CPG
EBP
EOIV
EOT
EtD
IDSA
LFU
LOS

Clinical Practice Guideline
Evidence Based Practice
End of IV treatment
End of treatment
Evidence to decision
Infectious Disease Society of America
Late follow-up
Length of stay
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MRSA
OR
PIDS
PRISMA
RCT
SR
TOC
WHO

Methicillin-resistant Staphylococcus aureus
Odds ratio
The Pediatric Infectious Disease Society
Preferred reporting items for systematic reviews and meta-analyses
Randomized control trial
Systemic review
Test of cure
World Health Organization

Date Developed/Updated
April 2019
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Figure 1. Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRIMSA)c
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Figure 2. Risk of Bias Summary
*Risk of bias from previously published systematic reviews
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Table 1
Overview of Studies
Intervention and
comparator
Cefpodoxime
versus Coamoxiclavulanic
Amoxicillin
versus
Cefuroxime
Levofloxacin
versus Coamoxiclavulanic
acid or
Ceftriaxone
Ceftaroline
versus
Ceftriaxone

67

Dose and Length of Treatment

Cure Rate

3 months to
11.5 years, N =
348

Oral Cefpodoxime 5 to 12mg/kg/day
for 10 days versus
Co-amoxyclavulanate 6 to 13
mg/kg/day for 10 days

OR = 0.69,
95% CI
[0.18, 2.60]

2 months to 72
months, N =
171

Amoxicillin 75mg/kg/day versus
Cefuroxime 75mg/kg/day

OR = 2.05,
95% CI
[0.18,
23.51]

6 months to 16
years, N = 709

Levofloxacin 10mg/kg/dose

OR = 1.05,
95% CI
[0.46, 2.42]

Participants

2 months to
<18 years, N =
160

Ceftaroline 12 mg/kg <33 kg or
400mg is >33 kg versus Ceftriaxone
75mg/kg/day
Low dose Penicillin G (200,000
IV Penicillin G
3 months to 15
U/Kg/d) versus High dose Penicillin G
versus
years, N = 58
(400,00 U/Kg/d) versus Cefuroxime
Cefuroxime
(100 mg/kg/d).
Procaine penicillin (50,000 IU/kg once
Procaine penicillin
daily intramuscular) versus
or Cefuroxime 43 months to 15
Cefuroxime (100 mg/kg per day in 3
days versus 7
years, N = 154
divided doses intravenous), 4 days
days
versus 7 days
Ceftaroline < 6 months old, 10mg/kg
or > 6 months old 15mg/kg versus IV
Ceftaroline fosmil
Ceftriaxone, 75 mg/kg/day and IV
versus
3 months to 17
Vancomycin, 15 mg/kg. Both groups
Ceftriaxone plus
years, N = 35
could switch from IV study drug to
Vancomycin ≥3
open-label oral study drug (Amoxicillin
days
Clavulanate, Clindamycin, or Linezolid)
on or after study day 3.
Note. ++Significant difference; *Study from previously published SR

OR = 1.36,
95% CI
[0.39, 4.72]

Failure Rate

Sideeffects

Length of
stay

OR = 0.46,
95% CI
[0.16,
1.35]
OR = 0.49,
95% CI [0.04,
5.59]

OR = 1.32,
95% CI [0.35,
4.95]
LOS, p = .29

OR = 3.37,
95% CI [0.14,
84.09]

OR = 0.40,
95% CI
[0.02, 8.45]

OR = 2.51,
95% CI [0.12,
53.23]

++OR =
0.17 95%
CI [0.03,
0.92]

Reference

Study
Type

*Klein et al.
(1995)

RCT

*Aurangzeb
et al.
(2003)

RCT

*Bradley et
al. (2007)

RCT

Cannavino
et al.
(2016)

RCT

Amarilyo et
al. (2014)

RCT

*Peltola et
al. (2001)

RCT

Blumer et
al. (2016)

RCT
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Table 1 (cont.)
Intervention and
comparator
Ceftriaxone
versus
Ceftriaxone plus
Macrolide
Broad-spectrum
versus Narrowspectrum
Antibiotics
Broad-spectrum
versus Narrowspectrum
Antibiotics
Broad-spectrum
versus Narrowspectrum
Antibiotics
Note.
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Participants

Dose and Length of Treatment

1 to 17 years, N
= 13593

Ceftriaxone versus Ceftriaxone with
Macrolide, no dose given

6 months to 10
years, N =
15,564

Ceftriaxone or Cefotaxime versus
Penicillin or Ampicillin, no dose given

2 months to 18
years, N = 492

Second and third generation
cephalosporins with and without
Macrolide or Fluoroquinolones alone
versus Amoxicillin or Ampicillin or
Penicillin or Amoxicillin/Clavulanic acid,
no doses given

3months to 18
years, N = 337

Cefuroxime or Ceftriaxone or Cefazolin
versus Penicillin or Ampicillin or
Amoxicillin, no doses given

++Significant

Cure Rate

Failure Rate
OR = 1.18,
95% CI [0.75,
1.86]
OR = 0.85,
95% CI [0.45,
1.63]

Sideeffects

Other
LOS, MD = 0.01, 95% CI [
-0.07, 0.04]
LOS, MD =
0.01, 95% CI [–
0.22 to 0.24]
++LOS,

p = .25

MD =
9.3 hours,
95% CI [3.46,
15.14]
++LOS

MD =
0.70 days,
95% CI [0.26,
1.14]

Referenc
e
Leyenaar
et al.
(2014)

Study
Type
Cohort

Willams
et al.
(2013)

Cohort

Queen et
al.
(2014)

Cohort

Breuer et
al.
(2015)

difference; *Study from previously published SR
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Specific Care Question
In pediatric patients with suspected CAP, what clinical features suggest atypical pneumonia?
Recommendations from the CAP Clinical Practice Guideline (CPG) Team
There are no strong clinical features to differentiate atypical pneumonia from other organisms. The overall certainty in the evidence is moderated (see
Summary by Symptom for substantiation of recommendations).
Overall there is moderate certainty in the evidence reported by Wang et al. (2012) who stated M. pneumoniae cannot be diagnosed based on signs and
symptoms. Wang et al. (2012) reported the prevalence of M. pneumoniae at 10% to 36%. Although absence of wheeze is 12% more likely in patients
with M. pneumoniae, if treatment was based on lack of this symptom, 61% to 89% would not have M. pneumoniae, and 25% of children infected with
M. pneumoniae would not be properly treated (Wang et al., 2012). The more recent trials do not have the rigor of Wang (2012) and do not change the
certainty that signs and symptoms can predict atypical pneumonia.
Literature Summary
Background Symptoms and clinical features of community acquired pneumonias overlap, and are not reliable in characterizing viral, bacterial, and
atypical pneumonias (Kavanagh, 2018). Approximately 80% of pneumonias are of viral origin (Bradley et al., 2011, p e38). Of the remaining cases of
bacterial origin, 3-23% were atypical pneumonias (Bradley et al., 2011, p. e38). Some pneumonias are classified as atypical because (a) they present
with milder symptoms, (b) the symptoms have a longer duration, (c) chest radiographs may have a different appearance, and (d) the usual antibiotic
used to treat typical pathogens are not effective (CDC, 2018).
The most common bacteria responsible for atypical pneumonias are Chlamydophila pneumoniae (C. pneumoniae) in infants and Mycoplasma
pneumoniae (M. pneumoniae) in older children, (Bradley et al., 2011, p. e39). The Infectious Diseases Society of America (IDSA) makes a strong
recommendation based on high-quality evidence that diagnostic testing for C. pneumoniae should not be performed because laboratory tests to confirm
this diagnosis do not exist (Bradley et al, 2001, p. e28).
In a sample of 2,638 children in the United States, M. pneumoniae was more common in children greater than 5-years of age (Jain et al., 2015). The
(IDSA) makes a weak recommendation, based on moderate quality evidence, that children with signs and symptoms suspicious for M. pneumoniae
should be tested to help guide antibiotic selection (Bradley et al., 2011, p. e28). IDSA delineates the signs and symptoms of atypical pneumonias as:
(a) slowly progressing symptoms, (b) malaise, (c) sore throat, (d) low grade fever, and (e) cough that develops over 3 to 5 days. This review will
summarize identified literature to determine if any of these symptoms are valid or reliable symptoms to guide the clinician to tests for M. pneumoniae
to guide antibiotic selection.
Study characteristics. The search for suitable studies was completed on October 16, 2018. F. Turcotte Benedict, MD, MPH, FAAP and S. Brackett,
APRN reviewed the 124 titles and/or abstracts found in the search and identified 11 articles believed to answer the question. Two additional articles
were identified by an ancestry search. After an in-depth review three articles answered the question (Guo, Wang, Zhu, & Hao, 2015; Medjo et al.,
2014; Wang et al., 2012) The studies included one systematic review of seven diagnostic test accuracy studies (Wang et al., 2012) and two cohorts
(Guo et al., 2015; Medjo et al., 2014).
Wang et al. (2012) was a well-done SR/MA (Higgins & Green, 2011), but the included studies exhibited inconsistency, indirectness, and imprecision. An
example of inconsistency was various methods were used to confirm the diagnosis of M. pneumoniae, since there is no gold standard. Tests employed
for diagnosis included (a) IgM serology on a single blood sample, (b) antigen detection in a nasopharyngeal aspirate, (c) single antibody titer, or (d)
* These guidelines do not establish a standard of care to be followed in every case. It is recognized that each case is different, and those individuals involved
in providing health care are expected to use their judgment in determining what is in the best interests of the patient based on the circumstances existing at
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PCR analysis of respiratory secretions. An example of indirectness was that baseline study populations were different, some studies tested for M.
pneumoniae to be included in the sample, while others did not. Finally, imprecision was exhibited by 20-50-fold differences in specificity values from
individual studies. The range of specificities for the symptom fever ranged from 0.02 to 0.43. The evidence from Wang et al. (2012) was reported as
moderate certainty.
The other studies are of low certainty. Since Guo, Wang, Zhu, and Hao (2015) was retrospective cohort study, and Medjo et al. (2014) was prospective
cohort study and neither had. Both were designed to determine if clinical, radiological, or laboratory tests could guide the accuracy of the diagnosis of
M. pneumoniae. Neither study had findings that could be added to the sensitivity and specificity 2X2 tables reported in Wang et al. (2012).
Summary by Symptom
Wheeze. Three studies (Guo et al., 2015; Medjo et al., 2014; Wang et al., 2012) measured wheeze (N =1952). Wang et al. (2012) is a systematic
review/meta-analysis (SR/MA) of diagnostic tests accuracy. It included seven trials (Agarwal, Awasthi, Rajput, Tiwari, & Jain, 2009; Chan, Lum,
Ngeow, & Yasim, 2001; Kumar, Saigal, & Sethi, 2011; Maheshwari, Kumar, Sethi, & Bhalla, 2011; Prapphal et al., 2006; Principi, Esposito, Blasi,
Allegra, & Mowgli study, 2001; Somer, Salman, Yalcin, & Agacfidan, 2006) for this symptom. The findings were presented as pooled sensitivities and
specificities (n = 1698). Table 1 contains the pooled data, along with positive and negative likelihood ratios. Although the symptom “absence of
wheeze” was a statistically significant diagnostic factor for atypical pneumonia, it was not clinically significant (Wang, et al., 2012). If CAP patients
without wheeze were treated with antibiotic for M. pneumoniae, the range of patients who would be treated who did not have CAP would be 61-89%.
Furthermore, appropriate antibiotic treatment would have been missed in 25% of patients with CAP who did wheeze and were M. pneumoniae positive
by serology or culture (Wang, et al., 2012).
The other included studies could not be added to the pooled results for sensitivity and specificity symptoms for the diagnosis of atypical CAP (see Table
2). Guo et al. (2015) and Medjo et al. (2014) included a total of 254 subjects. Guo et al. (2015) reported 4.3% (3/70) of patients with atypical CAP
wheezed, while 44% (8/18) of those with viral pneumonia wheezed (p < .0001). Medjo et al. (2014) reported 33% (8/24) of those with
M. pneumoniae CAP had a wheeze and 15% (22/142) of those with non-M. pneumoniae CAP wheezed.
Cough. Three studies (Guo et al., 2015; Medjo et al., 2014; Wang et al., 2012) are included for the symptom of cough (n = 1695). Wang et al. (2012)
reported the pooled sensitivity, specificity, positive and negative likelihood ratios from five studies (Agarwal et al., 2009; Kumar et al., 2011; Prapphal
et al., 2006; Principi et al., 2001; Somer et al., 2006) for this symptom. Wang et al. (2012) reported the symptom of cough had a sensitivity of 89%
but the specificity for indicating M. pneumoniae was poor (15%). (see Table 1). Guo et al., (2015) reported subjects with and without M. pneumoniae
had a cough 60% of the time, while (Medjo et al., 2014) reported cough symptoms were present 83% of the time in those with M. pneumoniae versus
39% of the time in those without M. pneumoniae (see Table 2).
Other symptoms. Coryza, crepitations/rales were other symptoms studied. Wang et al. (2012) included four trials (Kumar et al., 2011; Maheshwari et
al., 2011; Principi et al., 2001; Somer et al., 2006) for coryza and five studies for crepitations (Agarwal et al., 2009; Maheshwari et al., 2011; Prapphal
et al., 2006; Principi et al., 2001; Somer et al., 2006). Coryza was not a useful indicator, noted by the pooled LR+ and LR- in Table 1. Crepitations were
sensitive, but not a specific indicator of M. pneumoniae. From Guo et al. (2015) and Medjo et al. (2014) coryza was present in 99% or 100% of those
with M. pneumoniae and 99% or 89% in those without M. pneumoniae, respectively. Medjo et al. (2014) reported on rales (not crepitations) and found
17% of subjects with M. pneumoniae and 33% of subjects without M. pneumoniae had rales. Guo et al. (2015) did not report on this symptom (see
Table 2).
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Identification of Studies
Search Strategy and Results (see Figure 1)

PubMed

(("community acquired pneumonia"[All Fields] OR "community-acquired pneumonia"[All Fields] OR ("Community-Acquired Infections"[MeSH] AND
"Pneumonia"[MAJR])) AND ("Signs and Symptoms"[Mesh] OR "clinical prediction"[All Fields] OR "clinical features"[All Fields] OR "atypical
pneumonia"[All Fields] OR "Pneumonia, Mycoplasma"[Mesh])) AND (child OR children OR infant OR adolescence OR pediatr* OR paediatr*) AND ("last 5
years"[PDat])
Records identified through database searching n = 124
Records identified through other sources n = 2
Studies Included in this Review
Citation
*Agarwal, Awasthi, Rajput, Tiwari, and Jain (2009)
*Chan, Lum, Ngeow, and Yasim (2001)
Guo et al. (2015)
*Kumar, Saigal, and Sethi (2011)
*Maheshwari, Kumar, Sethi, and Bhalla (2011)
Medjo et al. (2014)
*Prapphal et al. (2006)
*Principi, Esposito, Blasi, Allegra, and Mowgli study (2001)
*Somer, Salman, Yalcin, and Agacfidan (2006)
Wang et al. (2012)
Note: * Included in SR/MA

Study Type
Cohort
Cohort
Cohort
Cohort
Cohort
Cohort
Cohort
Cohort
Cohort
SR/MA

Studies Not Included in this Review with Exclusion Rationale
Citation
Reason for exclusion
Arfaatabar et al. (2018)
Does not answer the question
Jain et al. (2015)
Epidemiologic information
Rodriquez de Ita et al. (2014)
Does not answer the question
Saraya et al. (2018)
Includes the wrong population
Shu et al. (2015)
Article is not in English
Sondergaard, Friis, Hansen, and Jorgensen (2018)
Does not answer the question
Sun et al. (2015)
Does not answer the question
Zhao, Chen, Yang, and Deng (2016)
Article is not in English
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Methods Used for Appraisal and Synthesis
aRayyan is a web-based software used for the initial screening of titles and / or abstracts for this analysis (Ouzzani, Hammady, Fedorowicz & Elmagarmid,
2017).
bReview Manager (Higgins & Green, 2011) is a Cochrane Collaborative computer program used to assess the study characteristics as well as the risk of bias
and create the forest plots found in this analysis.
cThe Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) flow diagram depicts the process in which literature is searched,
screened, and eligibility criteria is applied (Moher, Liberati, Tetzlaff, & Altman, 2009).
aOuzzani, M., Hammady, H., Fedorowicz, Z., & Elmagarmid, A. (2016). Rayyan-a web and mobile app for systematic reviews. Systematic Reviews, 5(1),
210. doi:10.1186/s13643-016-0384-4
bHiggins, J. P. T., & Green, S. e. (2011). Cochrane Handbook for Systematic Reviews of Interventions [updated March 2011] (Version 5.1.0 ed.): The
Cochrane Collaboration, 2011.
cMoher D, Liberati A, Tetzlaff J, Altman DG, The PRISMA Group (2009). Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA
Statement. PLoS Med 6(7): e1000097. doi:10.1371/journal.pmed1000097 For more information, visit www.prisma-statement.org.
Question Originator CAP Clinical Practice Guideline (CPG) Team
Medical Librarian Responsible for the Search Strategy
Keri Swaggart, MLIS, AHIP
EBP Scholar’s Responsible for Analyzing the Literature
Rebecca Frederick, PharmD
Kori Hess, PharmD
Erin Lindhorst, MS, RD, LD
Hope Scott, RN, BSN, CPEN
Rhonda Sullivan, MS, RD, CSP, LD
EBP Team Member Responsible for Reviewing, Synthesizing, and Developing this Document
Nancy H. Allen, MS, MLS, RD, LD, CPHQ
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Acronyms Used in this Document
Acronym
Explanation
APRN
Advanced Practice Nurse
CAP
Community Acquired Pneumonia
CDC
Centers for Disease Control
CI
Confidence Intervals
CRP
C-reactive Protein
FAAP
Fellow of the American Academy of Pediatrics
GRADE
Grading of Recommendations, Assessment, Development and Evaluation
IgG
Immunoglobulin G
IgM
Immunoglobulin M
IDSA
Infectious Diseases Society of America
MPH
Master of Public Health
OR
Odds Ratio
QAUDUS-2
Quality Assessment of Diagnostic Accuracy Studies-2
RT-PCR
Reverse Transcription Polymerase Chain Reaction
SD
Standard Deviation
SR/MA
Systematic Review/Meta-analysis
WBC
White Blood Cell
Date Developed/Updated
June 2019
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Figure 1. Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRIMSA)e
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Table 1

Pooled Sensitivity, Specificity, Positive Likelihood Ratio, and Negative Likelihood Ratio of CAP Symptom for the
Diagnosis of M. pneumoniae
Symptom, n = number of
studies
Cough, n= 5
Wheeze n = 6
Coryza n= 4
Crepitations n = 5
(Wang et al., 2012)

Sensitivity, [95% CI]

Specificity, [95% CI]

.89, [.67, .97]
.25, [.17, .36]
.32, [.08, 072]
.84, [078, .88]

.15,
.67,
.66,
.22,

[.05,
[.56,
[.28,
[.14,

.37]
.76]
.91]
.32]

Positive likelihood ratio,
[95% CI]
1.04, [0.95, 1.13]
.76, [.67, .97]
0.95, [0.71, 1.26]
1.06, [0.96, 1.18]

Negative likelihood ratio,
[95% CI]
0.78, [0.44, 1.39]
1.12, [1.02, 1.23]
1.03, [0.9, 1.17]
0.77, [0.52, 1.12]

Table 2

Clinical Signs and Symptoms of Subjects With and Without M. pneumoniae Pneumonia
Study

Guo 2015

Subjects (N =)
88
Number with M. pneumoniae
70
With M. pneumoniae (%)
Wheeze
4.3
Cough
60
Coryza
99%
Rales
Did not report
Without M. pneumoniae (%)
Wheeze
44
Cough
60
Coryza
99
Rales
Did not report
(Guo et al., 2015; Medjo et al., 2014)

Medjo 2014
166
24
33
83
100
17
8
39
89
33

* These guidelines do not establish a standard of care to be followed in every case. It is recognized that each case is different, and those individuals involved
in providing health care are expected to use their judgment in determining what is in the best interests of the patient based on the circumstances existing at
the time. It is impossible to anticipate all possible situations that may exist and to prepare guidelines for each. Accordingly, these guidelines should guide
care with the understanding that departures from them may be required at times.
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Appendix I
Table 3
Summary of Findings Tabled: Should CRP >0.74mg/dL be used to diagnose bacterial CAP
Sensitivity

0.51 to 0.64

Specificity

0.69 to 0.81

Outcome

True positives
(patients with CAP)
False negatives
(patients incorrectly
classified as not having
CAP)
True negatives
(patients without CAP)
False-positives
(patients incorrectly
classified as having
CAP)

№ of
studies (№
of patients)

Prevalences 25% 50%

Factors that may decrease certainty of evidence
Study
design

Effect per 100 patients
tested

Risk of
bias

Indirectness Inconsistency Imprecision

Publication
bias

pre-test
pre-test
probability of probability of
25%
50%

not serious

none

13 to 16

26 to 32

9 to 12

18 to 24

52 to 61

35 to 41

14 to 23

9 to 15

2 studies
307
patients

cohort &
casecontrol
type
studies

serious

2 studies
227
patients

cohort &
casecontrol
type
studies

serious

a

a

not serious

serious

serious

b

b

serious

serious

c

c

none

Test
accuracy
CoE

⨁◯◯◯
VERY
LOW

⨁◯◯◯
VERY
LOW

Explanations
a. No gold standard reference test to determine bacterial pneumonia
b. Studies used different reference standards
c. Too few participants

* These guidelines do not establish a standard of care to be followed in every case. It is recognized that each case is different, and those individuals involved
in providing health care are expected to use their judgment in determining what is in the best interests of the patient based on the circumstances existing at
the time. It is impossible to anticipate all possible situations that may exist and to prepare guidelines for each. Accordingly, these guidelines should guide
care with the understanding that departures from them may be required at times.
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Table 4
Should CRP >4mg/dL be used to diagnose bacterial CAP
Sensitivity

0.77 to 0.95

Specificity

0.32 to 0.77

Outcome

True positives
(patients with
CAP)

№ of studies
(№ of
patients)
3 studies
206 patients

Prevalences

25%

Factors that may decrease certainty of evidence
Study
design

cohort &
case-control
type studies

Risk of
bias
serious
a

False-positives
(patients
incorrectly
classified as
having CAP)

3 studies
731 patients

cohort &
case-control
type studies

serious
a

Effect per 100 patients
tested

Indirectness Inconsistency Imprecision

Publication
bias

pre-test
probability of
25%

pre-test
probability of
50%

serious

none

19 to 24

39 to 48

1 to 6

2 to 11

24 to 58

16 to 39

17 to 51

11 to 34

b,c

serious

d

not serious

False negatives
(patients
incorrectly
classified as not
having CAP)
True negatives
(patients without
CAP)

50%

serious

b,c

serious

d

serious

e

none

Test
accuracy
CoE

⨁◯◯◯
VERY LOW

⨁◯◯◯
VERY LOW

Explanations
a. No gold standard reference test to determine bacterial pneumonia
b. Higdon et al. (2017) included human immunodeficiency virus (HIV) patients
c. Hidgon et al. (2017) and Gialetto-Lacour et al. (2013) included patients <5years of age and Alcoba et al. (2017) included patient 3 months-15 years of
age.
d. Studies used different reference standards
e. Specificity range is wide

* These guidelines do not establish a standard of care to be followed in every case. It is recognized that each case is different, and those individuals involved
in providing health care are expected to use their judgment in determining what is in the best interests of the patient based on the circumstances existing at
the time. It is impossible to anticipate all possible situations that may exist and to prepare guidelines for each. Accordingly, these guidelines should guide
care with the understanding that departures from them may be required at times.
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Table 5
Should CRP >8mg/dL be used to diagnose bacterial CAP?
Sensitivity

0.74 to 0.92

Specificity

0.61 to 0.70

Outcome

True positives
(patients with
CAP)

№ of studies
(№ of
patients)
2 studies
87 patients

Prevalences 25%
Factors that may decrease certainty of evidence

Study
design

cohort &
case-control
type studies

Risk of
bias
serious
a

2 studies
130 patients

cohort &
case-control
type studies

serious
a

Effect per 100 patients
tested

Indirectness Inconsistency Imprecision

Publication
bias

pre-test
probability of
25%

pre-test
probability of
50%

Not serious

none

19 to 23

37 to 46

2 to 6

4 to 13

46 to 52

31 to 35

23 to 29

15 to 19

serious

b

serious

c

False negatives
(patients
incorrectly
classified as not
having CAP)
True negatives
(patients without
CAP)

50%

Not serious

False-positives
(patients
incorrectly
classified as
having CAP)

serious

b

serious

c

none

Test
accuracy
CoE

⨁◯◯◯
VERY LOW

⨁◯◯◯
VERY LOW

Explanations
a. No gold standard reference test to determine bacterial pneumonia
b. Studies used different reference standards
c. Too few participants

* These guidelines do not establish a standard of care to be followed in every case. It is recognized that each case is different, and those individuals involved
in providing health care are expected to use their judgment in determining what is in the best interests of the patient based on the circumstances existing at
the time. It is impossible to anticipate all possible situations that may exist and to prepare guidelines for each. Accordingly, these guidelines should guide
care with the understanding that departures from them may be required at times.
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Table 6
Should WBC >10.10 103/uL be used to diagnose bacterial CAP?
Sensitivity

0.62 to 0.80

Specificity

0.38 to 0.50

Outcome

True positives
(patients with
CAP)

№ of studies
(№ of
patients)
3 studies
143 patients

Prevalences 25%
Factors that may decrease certainty of evidence

Study
design

cohort &
case-control
type studies

Risk of
bias
serious
a

3 studies
67 patients

cohort &
case-control
type studies

serious
a

Effect per 100 patients
tested

Indirectness Inconsistency Imprecision

Publication
bias

pre-test
probability of
25%

pre-test
probability of
50%

not serious

none

16 to 20

31 to 40

5 to 9

10 to 19

29 to 38

19 to 25

37 to 46

25 to 31

serious

b

serious

c

False negatives
(patients
incorrectly
classified as not
having CAP)
True negatives
(patients without
CAP)

50%

not serious

False-positives
(patients
incorrectly
classified as
having CAP)

serious

b

serious

c

none

Test
accuracy
CoE

⨁◯◯◯
VERY LOW

⨁◯◯◯
VERY LOW

Explanations
a. No gold standard reference test to determine bacterial pneumonia
b. Studies used different reference standards
c. Too few participants

* These guidelines do not establish a standard of care to be followed in every case. It is recognized that each case is different, and those individuals involved
in providing health care are expected to use their judgment in determining what is in the best interests of the patient based on the circumstances existing at
the time. It is impossible to anticipate all possible situations that may exist and to prepare guidelines for each. Accordingly, these guidelines should guide
care with the understanding that departures from them may be required at times.
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Table 7
Should WBC >15 103/uL be used to diagnose bacterial CAP?
Sensitivity

0.57 to 0.65

Specificity

0.67 to 0.68

Outcome

True positives
(patients with
CAP)

№ of studies
(№ of
patients)
2 studies
83 patients

Prevalences 25%
Factors that may decrease certainty of evidence

Study
design

cohort &
case-control
type studies

Risk of
bias
serious
a

2 studies
59 patients

cohort &
case-control
type studies

serious
a

Effect per 100 patients
tested

Indirectness Inconsistency Imprecision

Publication
bias

pre-test
probability of
25%

pre-test
probability of
50%

not serious

none

14 to 16

28 to 33

9 to 11

17 to 22

50 to 51

34 to 34

24 to 25

16 to 16

serious

b

serious

c

False negatives
(patients
incorrectly
classified as not
having CAP)
True negatives
(patients without
CAP)

50%

not serious

False-positives
(patients
incorrectly
classified as
having CAP)

serious

b

serious

c

none

Test
accuracy
CoE

⨁◯◯◯
VERY LOW

⨁◯◯◯
VERY LOW

Explanations
a. No gold standard reference test to determine bacterial pneumonia
b. Studies used different reference tests
c. Too few participants

* These guidelines do not establish a standard of care to be followed in every case. It is recognized that each case is different, and those individuals involved
in providing health care are expected to use their judgment in determining what is in the best interests of the patient based on the circumstances existing at
the time. It is impossible to anticipate all possible situations that may exist and to prepare guidelines for each. Accordingly, these guidelines should guide
care with the understanding that departures from them may be required at times.
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Table 8
Should WBC >25 103/uL be used to diagnose bacterial CAP?
Sensitivity

0.11 to 0.60

Specificity

0.72 to 1.00

Outcome

True positives
(patients with
CAP)

№ of studies
(№ of
patients)
2 studies
114 patients

Prevalences 25%
Factors that may decrease certainty of evidence

Study
design

cohort &
case-control
type studies

Risk of
bias
serious
a

Publication
bias

Indirectness Inconsistency

Imprecision

not serious

very serious none

serious

b, c

d,e

False negatives
(patients
incorrectly
classified as not
having CAP)
True negatives
(patients without
CAP)

2 studies
391 patients

50%

cohort &
case-control
type studies

serious
a

not serious

False-positives
(patients
incorrectly
classified as
having CAP)

serious

b, c

very serious none
d,f

Effect per 100 patients
tested
pre-test
probability of
25%

pre-test
probability of
50%

3 to 15

6 to 30

10 to 22

20 to 44

54 to 75

36 to 50

0 to 21

0 to 14

Test
accuracy
CoE

⨁◯◯◯
VERY LOW

⨁◯◯◯
VERY LOW

Explanations
a. No gold standard reference test to determine bacterial pneumonia
b. Studies use different reference test
c. Brauner et al. (2010) included severe patient populations
d. Too few participants
e. Wide sensitivity
f. Wide specificity
Table 9
* These guidelines do not establish a standard of care to be followed in every case. It is recognized that each case is different, and those individuals involved
in providing health care are expected to use their judgment in determining what is in the best interests of the patient based on the circumstances existing at
the time. It is impossible to anticipate all possible situations that may exist and to prepare guidelines for each. Accordingly, these guidelines should guide
care with the understanding that departures from them may be required at times.
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Should ESR >40mm/h be used to diagnose bacterial CAP?
Sensitivity

0.74 (95% CI: 0.59 to 0.86)

Specificity

0.35 (95% CI: 0.15 to 0.59)

Outcome

True positives
(patients with
CAP)

№ of
studies (№
of patients)
1 study
46 patients

False negatives
(patients
incorrectly
classified as not
having CAP)
True negatives
(patients without
CAP)
False-positives
(patients
incorrectly
classified as
having CAP)

1 study
20 patients

Prevalences

25%

50%

Factors that may decrease certainty of evidence
Study design

Effect per 100 patients
tested

Risk of
bias

Indirectness Inconsistency Imprecision

Publication
bias

pre-test
probability of
25%

cross-sectional
(cohort type
accuracy
study)

serious

not serious

none

19 (15 to 22) 37 (30 to 43)

cross-sectional
(cohort type
accuracy
study)

serious

a

not serious

very
serious

b

6 (3 to 10)

a

not serious

not serious

very
serious

b

none

pre-test
probability of
50%

Test
accuracy
CoE

⨁◯◯◯
VERY
LOW

13 (7 to 20)

26 (11 to 44) 18 (8 to 30)

⨁◯◯◯
VERY
LOW

49 (31 to 64) 32 (20 to 42)

Explanations
a. No gold standard reference test to determine bacterial pneumonia
b. Too few participants

* These guidelines do not establish a standard of care to be followed in every case. It is recognized that each case is different, and those individuals involved
in providing health care are expected to use their judgment in determining what is in the best interests of the patient based on the circumstances existing at
the time. It is impossible to anticipate all possible situations that may exist and to prepare guidelines for each. Accordingly, these guidelines should guide
care with the understanding that departures from them may be required at times.
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Table 10
Should ESR >65mm/h be used to diagnose bacterial CAP?
Sensitivity

0.59 (95% CI: 0.43 to 0.73)

Specificity

0.70 (95% CI: 0.46 to 0.88)

Outcome

True positives
(patients with
CAP)

№ of
studies (№
of patients)
1 study
46 patients

False negatives
(patients
incorrectly
classified as not
having CAP)
True negatives
(patients without
CAP)
False-positives
(patients
incorrectly
classified as
having CAP)

1 study
20 patients

Prevalences

25%

50%

Factors that may decrease certainty of evidence
Study design

Effect per 100 patients
tested

Risk of
bias

Indirectness Inconsistency Imprecision

Publication
bias

pre-test
probability of
25%

cross-sectional
(cohort type
accuracy
study)

serious

not serious

none

15 (11 to 18) 30 (22 to 37)

cross-sectional
(cohort type
accuracy
study)

serious

a

not serious

very
serious

b

10 (7 to 14)

a

not serious

not serious

very
serious

b

none

pre-test
probability of
50%

⨁◯◯◯
VERY
LOW

20 (13 to 28)

52 (35 to 66) 35 (23 to 44)

23 (9 to 40)

Test
accuracy
CoE

⨁◯◯◯
VERY
LOW

15 (6 to 27)

Explanations
a. No gold standard reference test to determine bacterial pneumonia
b. Too few participants

* These guidelines do not establish a standard of care to be followed in every case. It is recognized that each case is different, and those individuals involved
in providing health care are expected to use their judgment in determining what is in the best interests of the patient based on the circumstances existing at
the time. It is impossible to anticipate all possible situations that may exist and to prepare guidelines for each. Accordingly, these guidelines should guide
care with the understanding that departures from them may be required at times.
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Table 11
Should ESR >90mm/h be used to diagnose diagnosis CAP?
Sensitivity

0.33 (95% CI: 0.20 to 0.49)

Specificity

0.95 (95% CI: 0.76 to 1.00)

Outcome

True positives
(patients with
CAP)

№ of
studies (№
of patients)
1 study
45 patients

False negatives
(patients
incorrectly
classified as not
having CAP)
True negatives
(patients without
CAP)
False-positives
(patients
incorrectly
classified as
having CAP)

1 study
21 patients

Prevalences

25%

50%

Factors that may decrease certainty of evidence
Study design

Effect per 100 patients
tested

Risk of
bias

Indirectness Inconsistency Imprecision

Publication
bias

pre-test
probability of
25%

pre-test
probability of
50%

cross-sectional
(cohort type
accuracy
study)

serious

not serious

none

8 (5 to 12)

17 (10 to 25)

cross-sectional
(cohort type
accuracy
study)

serious

a

not serious

very
serious

b

Test
accuracy
CoE

⨁◯◯◯
VERY
LOW

17 (13 to 20) 33 (25 to 40)

a

not serious

not serious

very
serious

b

none

71 (57 to 75) 48 (38 to 50)

4 (0 to 18)

⨁◯◯◯
VERY
LOW

2 (0 to 12)

Explanations
a. No gold standard reference test to determine bacterial pneumonia
b. Too few participants

Table 12
* These guidelines do not establish a standard of care to be followed in every case. It is recognized that each case is different, and those individuals involved
in providing health care are expected to use their judgment in determining what is in the best interests of the patient based on the circumstances existing at
the time. It is impossible to anticipate all possible situations that may exist and to prepare guidelines for each. Accordingly, these guidelines should guide
care with the understanding that departures from them may be required at times.
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Should ESR >115mm/h be used to diagnose bacterial CAP?
Sensitivity

0.11 (95% CI: 0.04 to 0.24)

Specificity

0.95 (95% CI: 0.75 to 1.00)

Outcome

True positives
(patients with
CAP)

№ of
studies (№
of patients)
1 study
46 patients

False negatives
(patients
incorrectly
classified as not
having CAP)
True negatives
(patients without
CAP)
False-positives
(patients
incorrectly
classified as
having CAP)

1 study
20 patients

Prevalences 25%

50%

Factors that may decrease certainty of evidence
Study design

Effect per 100 patients
tested

Risk of
bias

Indirectness Inconsistency Imprecision

Publication
bias

pre-test
probability of
25%

pre-test
probability of
50%

cross-sectional
(cohort type
accuracy
study)

serious

not serious

none

3 (1 to 6)

6 (2 to 12)

cross-sectional
(cohort type
accuracy
study)

serious

a

not serious

very
serious

b

Test
accuracy
CoE

⨁◯◯◯
VERY
LOW

22 (19 to 24) 44 (38 to 48)

a

not serious

not serious

very
serious

b

none

71 (56 to 75) 48 (38 to 50)

4 (0 to 19)

⨁◯◯◯
VERY
LOW

2 (0 to 12)

Explanations
a. No gold standard reference test to determine bacterial pneumonia
b. Too few participants

* These guidelines do not establish a standard of care to be followed in every case. It is recognized that each case is different, and those individuals involved
in providing health care are expected to use their judgment in determining what is in the best interests of the patient based on the circumstances existing at
the time. It is impossible to anticipate all possible situations that may exist and to prepare guidelines for each. Accordingly, these guidelines should guide
care with the understanding that departures from them may be required at times.
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Table 13
Should PCT >0.188ng/mL be used to diagnose bacterial CAP?
Sensitivity

0.67 to 0.86

Specificity

0.65 to 0.82

Outcome

True positives
(patients with
CAP)

№ of studies
(№ of
patients)
2 studies
170 patients

Prevalences 25% 50%

Factors that may decrease certainty of evidence
Study
design

cohort &
case-control
type studies

Risk of
bias
serious
a

Indirectness Inconsistency Imprecision

Publication
bias

pre-test
probability of
25%

pre-test
probability of
50%

not serious

none

17 to 22

34 to 43

3 to 8

7 to 16

49 to 62

33 to 41

13 to 26

9 to 17

serious

b

serious

c

False negatives
(patients
incorrectly
classified as not
having CAP)
True negatives
(patients without
CAP)

2 studies
148 patients

cohort &
case-control
type studies

serious
a

Effect per 100 patients
tested

not serious

False-positives
(patients
incorrectly
classified as
having CAP)

serious

b

serious

c

none

Test
accuracy
CoE

⨁◯◯◯
VERY LOW

⨁◯◯◯
VERY LOW

Explanations
a. No gold standard reference test to determine bacterial pneumonia
b. Studies used different reference test
c. Too few participants

* These guidelines do not establish a standard of care to be followed in every case. It is recognized that each case is different, and those individuals involved
in providing health care are expected to use their judgment in determining what is in the best interests of the patient based on the circumstances existing at
the time. It is impossible to anticipate all possible situations that may exist and to prepare guidelines for each. Accordingly, these guidelines should guide
care with the understanding that departures from them may be required at times.
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Table 14
Should PCT >0.4ng/mL be used to diagnose bacterial CAP?
Sensitivity

0.76 to 0.97

Specificity

0.29 to 0.47

Outcome

True positives
(patients with
CAP)

№ of studies
(№ of
patients)
3 studies
133 patients

Prevalences 25%
Factors that may decrease certainty of evidence

Study
design

cohort &
case-control
type studies

Risk of
bias
serious
a

3 studies
151 patients

cohort &
case-control
type studies

serious
a

Effect per 100 patients
tested

Indirectness Inconsistency Imprecision

Publication
bias

pre-test
probability of
25%

pre-test
probability of
50%

not serious

none

19 to 24

38 to 49

1 to 6

1 to 12

22 to 35

14 to 24

40 to 53

26 to 36

serious

b

serious

c

False negatives
(patients
incorrectly
classified as not
having CAP)
True negatives
(patients without
CAP)

50%

not serious

False-positives
(patients
incorrectly
classified as
having CAP)

serious

b

serious

c

none

Test
accuracy
CoE

⨁◯◯◯
VERY LOW

⨁◯◯◯
VERY LOW

Explanations
a. No gold standard reference test to determine bacterial pneumonia
b. Studies used different reference tests
c. Too few participants

* These guidelines do not establish a standard of care to be followed in every case. It is recognized that each case is different, and those individuals involved
in providing health care are expected to use their judgment in determining what is in the best interests of the patient based on the circumstances existing at
the time. It is impossible to anticipate all possible situations that may exist and to prepare guidelines for each. Accordingly, these guidelines should guide
care with the understanding that departures from them may be required at times.
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Figure 3. CRP >0.74mg/dL

Figure 4. CRP >4mg/dL

Figure 5. CRP >8mg/dL

Figure 6. WBC >10.10 103/uL

Figure 7. WBC >15.10 103/uL
* These guidelines do not establish a standard of care to be followed in every case. It is recognized that each case is different, and those individuals involved
in providing health care are expected to use their judgment in determining what is in the best interests of the patient based on the circumstances existing at
the time. It is impossible to anticipate all possible situations that may exist and to prepare guidelines for each. Accordingly, these guidelines should guide
care with the understanding that departures from them may be required at times.
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Figure 8. WBC >25.10 103/uL

Figure 9. ESR >40mm/h

Figure 10. ESR >65mm/h

Figure 11. ESR >90mm/h

Figure 12. ESR >115mm/h

Figure 13. PCT >0.188ng/mL
* These guidelines do not establish a standard of care to be followed in every case. It is recognized that each case is different, and those individuals involved
in providing health care are expected to use their judgment in determining what is in the best interests of the patient based on the circumstances existing at
the time. It is impossible to anticipate all possible situations that may exist and to prepare guidelines for each. Accordingly, these guidelines should guide
care with the understanding that departures from them may be required at times.
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Figure 14. PCT >0.4ng/mL

* These guidelines do not establish a standard of care to be followed in every case. It is recognized that each case is different, and those individuals involved
in providing health care are expected to use their judgment in determining what is in the best interests of the patient based on the circumstances existing at
the time. It is impossible to anticipate all possible situations that may exist and to prepare guidelines for each. Accordingly, these guidelines should guide
care with the understanding that departures from them may be required at times.
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Appendix K
Question 2 Characteristics of Studies
Alcoba et al., 2017
Patient Selection
Risk of Bias
Patient Sampling

Prospective Cohort Consecutive Sample

Was a consecutive or random sample of patients enrolled?

Yes

Was a case-control design avoided?

Yes

Did the study avoid inappropriate exclusions?

Unclear

Could the selection of patients have introduced bias?

Low risk

Concerns regarding applicability
Patient characteristics and setting

Pediatric Emergency Department
Patients presented with pneumonia: N =
142
Age: >2months old to <16 years old

Are there concerns that the included patients and setting do not match the review question?

Low concern

Index Test
Index tests

PCT
CRP

•
•

Cut-off >2ng/mL
Cut-off >0.5ng/mL

•
•

Cut-off >80mg/L
Cutoff >40mg/L

All tests
Risk of Bias
Were the index test results interpreted without knowledge of the results of the reference standard?

Unclear

If a threshold was used, was it pre-specified?

Yes

Could the conduct or interpretation of the index test have introduced bias?

Low risk

Concerns regarding applicability
Are there concerns that the index test, its conduct, or interpretation differ from the review question?

Unclear concern

Reference Standard
Risk of Bias
* These guidelines do not establish a standard of care to be followed in every case. It is recognized that each case is different, and those individuals involved
in providing health care are expected to use their judgment in determining what is in the best interests of the patient based on the circumstances existing at
the time. It is impossible to anticipate all possible situations that may exist and to prepare guidelines for each. Accordingly, these guidelines should guide
care with the understanding that departures from them may be required at times.
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Target condition and reference standard(s)

Blinded Chest X-ray
CAP with consolidation was considered a
proxy for bacterial pneumonia

Is the reference standards likely to correctly classify the target condition?

Unclear

Were the reference standard results interpreted without knowledge of the results of the index tests?

Yes

Could the reference standard, its conduct, or its interpretation have introduced bias?

Unclear risk

Concerns regarding applicability
Are there concerns that the target condition as defined by the reference standard does not match the
question?

Unclear concern

Flow and Timing
Risk of Bias
Flow and timing

Tests done at the same time

Was there an appropriate interval between index test and reference standard?

Unclear

Did all patients receive the same reference standard?

Yes

Were all patients included in the analysis?

Yes

Could the patient flow have introduced bias?

Low risk

Notes

•
•
•
•
•

Inclusion criteria were ≥ 2 months old and ≤16 years old, fever (>38 °C), cough, increased respiratory rate or respiratory distress
and infiltrates on chest radiographs
Exclusion criteria were immunodeficiency, chronic lung or heart diseases, and hospital-acquired pneumonia.
Three clinical signs (unilateral hypoventilation, grunting, and absence of wheezing), elevated PCT, CRP, negative nasopharyngeal viral
PCR, or positive blood pneumococcal PCR (P-PCR) were significantly associated with both pneumonia with consolidation and
complicated pneumonia.
Children with negative clinical signs and low CRP values had a low probability of having pneumonia with consolidation (13%) or
complicated pneumonia (6%).
Associating the three clinical signs, CRP >80 mg/L and a positive P-PCR ruled in the diagnosis of complicated pneumonia with a
positive predictive value of 75%.

* These guidelines do not establish a standard of care to be followed in every case. It is recognized that each case is different, and those individuals involved
in providing health care are expected to use their judgment in determining what is in the best interests of the patient based on the circumstances existing at
the time. It is impossible to anticipate all possible situations that may exist and to prepare guidelines for each. Accordingly, these guidelines should guide
care with the understanding that departures from them may be required at times.
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Brauner et al., 2011
Patient Selection
A. Risk of Bias
Patient Sampling

Retrospective Case-control

Was a consecutive or random sample of patients enrolled?

Yes

Was a case-control design avoided?

No

Did the study avoid inappropriate exclusions?

Unclear

Could the selection of patients have introduced bias?

High risk

B. Concerns regarding applicability
Patient characteristics and setting

Total: N = 438 Children aged 3 months to 36 months admitted to the
Emergency Department with fever (>38°C)
Group 1, Extreme Leukocytosis >25,000/mm3: n = 146
Group 2, Moderate Leukocytosis 15,000-24,999/mm3: n = 292

Are there concerns that the included patients and setting do not match the
review question?

High concern

Index Test
Index tests

Extreme Leukocytosis >25,000/mm3

All tests
Risk of Bias
Were the index test results interpreted without knowledge of the results of the reference standard?

Yes

If a threshold was used, was it pre-specified?

Yes

Could the conduct or interpretation of the index test have introduced bias?

Low risk

Concerns regarding applicability
Are there concerns that the index test, its conduct, or interpretation differ from the review question?

High concern

* These guidelines do not establish a standard of care to be followed in every case. It is recognized that each case is different, and those individuals involved
in providing health care are expected to use their judgment in determining what is in the best interests of the patient based on the circumstances existing at
the time. It is impossible to anticipate all possible situations that may exist and to prepare guidelines for each. Accordingly, these guidelines should guide
care with the understanding that departures from them may be required at times.
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Reference Standard
Risk of Bias
Target condition and reference standard(s)

Pneumonia was defined as the presence of
a lobar or segmental infiltrate. Reviewed
by two pediatricians

Is the reference standards likely to correctly classify the target condition?

Yes

Were the reference standard results interpreted without knowledge of the results of the index tests?

Yes

Could the reference standard, its conduct, or its interpretation have introduced bias?

High risk

Concerns regarding applicability
Are there concerns that the target condition as defined by the reference standard does not match the question? Unclear concern
Flow and Timing
A. Risk of Bias
Flow and timing

Retrospective Chart Review

Was there an appropriate interval between index test and reference standard?

Yes

Did all patients receive the same reference standard?

Yes

Were all patients included in the analysis?

No

Could the patient flow have introduced bias?

Low risk

Notes

Study included other diagnosis besides pneumonia

* These guidelines do not establish a standard of care to be followed in every case. It is recognized that each case is different, and those individuals involved
in providing health care are expected to use their judgment in determining what is in the best interests of the patient based on the circumstances existing at
the time. It is impossible to anticipate all possible situations that may exist and to prepare guidelines for each. Accordingly, these guidelines should guide
care with the understanding that departures from them may be required at times.
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Don et al., 2008
Patient Selection
A. Risk of Bias
Patient Sampling

Prospective Consecutive Cohort

Was a consecutive or random sample of patients enrolled?

Yes

Was a case-control design avoided?

Yes

Did the study avoid inappropriate exclusions?

Unclear

Could the selection of patients have introduced bias?

Low risk

B. Concerns regarding applicability
Patient characteristics and setting

Previously healthy children with clinically
suspected CAP: N = 68
<5 years old: n = 43
>5 years old: n = 25

Are there concerns that the included patients and setting do not match the review question?

Low concern

Index Test
Index tests

CRP
Erythrocyte Sedimentation Rate
PCT
WBC
WBC count, ESR, CRP, and PCT were studied in blood and serum samples
obtained on admission.

All tests
Risk of Bias
Were the index test results interpreted without knowledge of the results of the reference standard?

Unclear

If a threshold was used, was it pre-specified?

Yes

Could the conduct or interpretation of the index test have introduced bias?

Low risk

Concerns regarding applicability
Are there concerns that the index test, its conduct, or interpretation differ from the review question?

Unclear concern

Reference Standard
Risk of Bias
Target condition and reference standard(s)

Bacterial Pneumonia
Streptococcus pneumoniae infection was diagnosed by significant increases
of IgG antibodies to pneumococcal pneumolysin and/or to pneumococcal

* These guidelines do not establish a standard of care to be followed in every case. It is recognized that each case is different, and those individuals involved
in providing health care are expected to use their judgment in determining what is in the best interests of the patient based on the circumstances existing at
the time. It is impossible to anticipate all possible situations that may exist and to prepare guidelines for each. Accordingly, these guidelines should guide
care with the understanding that departures from them may be required at times.
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capsular C-polysaccharide using enzyme immunoassay (EIA) in paired sera.
Non-capsulated Haemophilus influenzae and Moraxella catarrhalis infections
were diagnosed by significant increases of IgG antibodies to whole-cell
antigens on EIA; all cases were mixed infections with viruses or other
bacteria. Mycoplasma pneumoniae infection was diagnosed by complement
fixation (CF) and EIA. Chlamydophila pneumoniae etiology was confirmed on
EIA and micro immunofluorescence (MIF).
Is the reference standards likely to correctly classify the target condition?

Unclear

Were the reference standard results interpreted without knowledge of the
results of the index tests?

Unclear

Could the reference standard, its conduct, or its interpretation have
introduced bias?

Unclear risk

B. Concerns regarding applicability
Are there concerns that the target condition as defined by the reference standard does not match the
question?

Unclear concern

Flow and Timing
Risk of Bias
Flow and timing

Tests at the time of admission.

Was there an appropriate interval between index test and reference standard?

Unclear

Did all patients receive the same reference standard?

No

Were all patients included in the analysis?

No

Could the patient flow have introduced bias?

Low risk

Notes

•
•
•

For the combination of CRP > 100 mg/L, WBC count > 15 × 10 9 /L, PCT > 1.0 ng/mL and ESR > 65 mm/h, the likelihood ratio for
a positive test result (LR+) was 2.7 in the distinction between pneumococcal and viral CAP and 3.9 between atypical and viral CAP.
If there was a higher value in one of these four parameters (CRP > 200 mg/L, WBC count > 22 × 10 9 /L, PCT > 18 ng/mL or ESR
> 90 mm/h) LR+ changed to 3 .4, which means a significant increase from pre-test to post-test disease probability.
An alveolar radiological infiltration was associated with higher values in non-specific inflammatory markers when compared with
interstitial infiltrates, but there were no significant associations between radiological and etiological findings.

* These guidelines do not establish a standard of care to be followed in every case. It is recognized that each case is different, and those individuals involved
in providing health care are expected to use their judgment in determining what is in the best interests of the patient based on the circumstances existing at
the time. It is impossible to anticipate all possible situations that may exist and to prepare guidelines for each. Accordingly, these guidelines should guide
care with the understanding that departures from them may be required at times.
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Elemraid et al., 2014
Patient Selection
Risk of Bias
Patient Sampling

Retrospective Cohort

Was a consecutive or random sample of patients enrolled?

Unclear

Was a case-control design avoided?

Yes

Did the study avoid inappropriate exclusions?

No

Could the selection of patients have introduced bias?

Unclear risk

Concerns regarding applicability
Patient characteristics and setting

Children Diagnoses with CAP: N = 401
Age: 0-16 years
73% <5 years

Are there concerns that the included patients and setting do not match the review question?

High concern

Index Test
Index tests

C-reactive Protein
White cell count
Neutrophil count

All tests
Risk of Bias
Were the index test results interpreted without knowledge of the results of the reference standard?

Unclear

If a threshold was used, was it pre-specified?

Yes

Could the conduct or interpretation of the index test have introduced bias?

Unclear risk

Concerns regarding applicability
Are there concerns that the index test, its conduct, or interpretation differ from the review question?

Unclear concern

Reference Standard
Risk of Bias
Target condition and reference standard(s)

Microbiological and virologic testing.
Undetermined diagnosis was not included

Is the reference standards likely to correctly classify the target condition?

No

Were the reference standard results interpreted without knowledge of the results of the index tests?

No

Could the reference standard, its conduct, or its interpretation have introduced bias?

High risk

* These guidelines do not establish a standard of care to be followed in every case. It is recognized that each case is different, and those individuals involved
in providing health care are expected to use their judgment in determining what is in the best interests of the patient based on the circumstances existing at
the time. It is impossible to anticipate all possible situations that may exist and to prepare guidelines for each. Accordingly, these guidelines should guide
care with the understanding that departures from them may be required at times.
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Concerns regarding applicability
Are there concerns that the target condition as defined by the reference standard does not match the
question?

High concern

Flow and Timing
Risk of Bias
Flow and timing

Test done on admission

Was there an appropriate interval between index test and reference standard?

Yes

Did all patients receive the same reference standard?

No

Were all patients included in the analysis?

No

Could the patient flow have introduced bias?

High risk

Notes

•
•
•
•

Patients with bacterial pneumonia were older than those with viral pneumonia (p < .001).
Compared to viral, bacterial infections had a higher median CRP level (p < .001), whereas WBC and neutrophil count were not
different.
Bacterial infections were associated with higher CRP >80 mg/L than viral infections (p = .001), but levels <20 mg/L were not
discriminatory (p = .254).
Receiver operating characteristic curve of the model for differentiating bacterial from viral pneumonia based on age, CRP, and
neutrophil count produced area under the curve of 0.894 with 75.7% sensitivity and 89.4% specificity.

Esposito et al., 2016
Patient Selection
Risk of Bias
Patient Sampling

Prospective Cohort

Was a consecutive or random sample of patients enrolled?

Yes

Was a case-control design avoided?

Yes

Did the study avoid inappropriate exclusions?

Unclear

Could the selection of patients have introduced bias?

Unclear risk

Concerns regarding applicability
Patient characteristics and setting

Children hospitalized for clinical signs
suggestive of CAP: N = 432
4 months-14 years old: Mean age 4.2 ± 3.5
years

Are there concerns that the included patients and setting do not match the review question?

Low concern

* These guidelines do not establish a standard of care to be followed in every case. It is recognized that each case is different, and those individuals involved
in providing health care are expected to use their judgment in determining what is in the best interests of the patient based on the circumstances existing at
the time. It is impossible to anticipate all possible situations that may exist and to prepare guidelines for each. Accordingly, these guidelines should guide
care with the understanding that departures from them may be required at times.
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Index Test
Index tests

WBC
CRP
PCT

All tests
Risk of Bias
Were the index test results interpreted without knowledge of the results of the reference standard?

Unclear

If a threshold was used, was it pre-specified?

Unclear

Could the conduct or interpretation of the index test have introduced bias?

Low risk

Concerns regarding applicability
Are there concerns that the index test, its conduct, or interpretation differ from the review question?

Unclear concern

Reference Standard
Risk of Bias
Target condition and reference standard(s)

Two different persons in the laboratory of the Pediatric High Intensity Care
Unit of the University of Milan performed the determination of the new
biomarkers and the viral and bacterial analyses on nasopharyngeal samples
without exchanging information and in absence of any clinical and
radiographic information.

Is the reference standards likely to correctly classify the target condition?

Unclear

Were the reference standard results interpreted without knowledge of the
results of the index tests?

Yes

Could the reference standard, its conduct, or its interpretation have
introduced bias?

Unclear risk

Concerns regarding applicability
Are there concerns that the target condition as defined by the reference standard does not match the
question?

Unclear concern

Flow and Timing
Risk of Bias
Flow and timing

Unclear flow and timing

Was there an appropriate interval between index test and reference standard?

Unclear

Did all patients receive the same reference standard?

Yes

* These guidelines do not establish a standard of care to be followed in every case. It is recognized that each case is different, and those individuals involved
in providing health care are expected to use their judgment in determining what is in the best interests of the patient based on the circumstances existing at
the time. It is impossible to anticipate all possible situations that may exist and to prepare guidelines for each. Accordingly, these guidelines should guide
care with the understanding that departures from them may be required at times.
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Were all patients included in the analysis?

No

Could the patient flow have introduced bias?

High risk

Notes

•
•
•
•
•
•

CRP and PCT had the best performances for both bacterial and viral CAP identification.
The cut-off values with the highest combined sensitivity and specificity for the identification of bacterial and viral infections using CRP
were 7.98 mg/L and 7.5 mg/L, respectively.
When PCT was considered, the cut-off values with the highest combined sensitivity and specificity were 0.188 ng/mL for bacterial CAP
and 0.07 ng/mL for viral CAP.
WBC cut-off >7.98 and <15,740 cells/uL
CRP cut-off >7.98 and <7.5mg/L
PCT cut-off >0.188 and <0.07ng/mL

Esposito et al., 2016
Patient Selection
Risk of Bias
Patient Sampling

Prospective Cohort

Was a consecutive or random sample of patients enrolled?

Yes

Was a case-control design avoided?

Yes

Did the study avoid inappropriate exclusions?

Unclear

Could the selection of patients have introduced bias?

Low risk

Concerns regarding applicability
Patient characteristics and setting

Children hospitalized with clinical signs of
CAP: N = 110
<14 years old: mean age 4.8 ± 3.4 years

Are there concerns that the included patients and setting do not match the review question?

Unclear concern

Index Test
Index tests

CRP
Wbc count

* These guidelines do not establish a standard of care to be followed in every case. It is recognized that each case is different, and those individuals involved
in providing health care are expected to use their judgment in determining what is in the best interests of the patient based on the circumstances existing at
the time. It is impossible to anticipate all possible situations that may exist and to prepare guidelines for each. Accordingly, these guidelines should guide
care with the understanding that departures from them may be required at times.
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All tests
Risk of Bias
Were the index test results interpreted without knowledge of the results of the reference standard?

Unclear

If a threshold was used, was it pre-specified?

No

Could the conduct or interpretation of the index test have introduced bias?

Unclear risk

Concerns regarding applicability
Are there concerns that the index test, its conduct, or interpretation differ from the review question?

Unclear concern

Reference Standard
Risk of Bias
Target condition and reference standard(s)

The CAP diagnoses were confirmed by chest radiography, as evaluated by an
independent expert radiologist, who classified the findings as alveolar
pneumonia, non-alveolar pneumonia, or no pneumonia in accordance with
the World Health Organization criteria for the standardized interpretation of
pediatric chest radiographs for a diagnosis of pneumonia

Is the reference standards likely to correctly classify the target condition?

Unclear

Were the reference standard results interpreted without knowledge of the
results of the index tests?

Unclear

Could the reference standard, its conduct, or its interpretation have
introduced bias?

Unclear risk

Concerns regarding applicability
Are there concerns that the target condition as defined by the reference standard does not match the
question?

Unclear concern

Flow and Timing
Risk of Bias
Flow and timing

Biomarkers measured on admission and day 5

Was there an appropriate interval between index test and reference standard?

Yes

Did all patients receive the same reference standard?

Yes

Were all patients included in the analysis?

Yes

Could the patient flow have introduced bias?

Low risk

* These guidelines do not establish a standard of care to be followed in every case. It is recognized that each case is different, and those individuals involved
in providing health care are expected to use their judgment in determining what is in the best interests of the patient based on the circumstances existing at
the time. It is impossible to anticipate all possible situations that may exist and to prepare guidelines for each. Accordingly, these guidelines should guide
care with the understanding that departures from them may be required at times.
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Notes

CAP was considered to be due to a probable bacterial infection in 74 children (67.3 %) and due to a probable viral infection in 16 children
(14.5 %).
Overall, 84 children (76.4 %) were diagnosed with severe CAP.
CRP serum concentrations were significantly higher in children with probable bacterial CAP than in those with probable viral disease
(32.2±55.5 mg/L vs 9.4±17.0 mg/L, p <0.05).
The WBC count was the best predictor of severe CAP, but the differences among the studied variables were marginal.
The WBC count was significantly lower on day 5 in children with probable bacterial CAP (p < .01) and in those with an undetermined
etiology (p < .01).

Galetto-Lacour et al., 2013
Patient Selection
Risk of Bias
Patient Sampling

Prospective Cohort

Was a consecutive or random sample of patients enrolled?

Yes

Was a case-control design avoided?

Yes

Did the study avoid inappropriate exclusions?

Unclear

Could the selection of patients have introduced bias?

Unclear risk

Concerns regarding applicability
Patient characteristics and setting

Children requiring hospitalization for CAP N
= 75
Presumed CAP: 35.1 months (18-46.9)
Without presumed CAP: 37.2 months (16.255.4)

Are there concerns that the included patients and setting do not match the review question?

Low concern

Index Test
Index tests

CRP >100mg/L, >40mg/L
PCT >1.5, >0.5ng/mL
WBC >15,000

All tests
Risk of Bias
Were the index test results interpreted without knowledge of the results of the reference standard?

Unclear

If a threshold was used, was it pre-specified?

Yes

Could the conduct or interpretation of the index test have introduced bias?

Unclear risk

* These guidelines do not establish a standard of care to be followed in every case. It is recognized that each case is different, and those individuals involved
in providing health care are expected to use their judgment in determining what is in the best interests of the patient based on the circumstances existing at
the time. It is impossible to anticipate all possible situations that may exist and to prepare guidelines for each. Accordingly, these guidelines should guide
care with the understanding that departures from them may be required at times.
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Concerns regarding applicability
Are there concerns that the index test, its conduct, or interpretation differ from the review question?

Unclear concern

Reference Standard
Risk of Bias
Target condition and reference standard(s)

Positive blood culture or pleural culture, a
positive PLY-PCR and/or significant anti-PSP
response to any PSP (>2-fold increase
between acute-phase and convalescentphase samples)

Is the reference standards likely to correctly classify the target condition?

Unclear

Were the reference standard results interpreted without knowledge of the results of the index tests?

Unclear

Could the reference standard, its conduct, or its interpretation have introduced bias?

Unclear risk

Concerns regarding applicability
Are there concerns that the target condition as defined by the reference standard does not match the
question?

Unclear concern

Flow and Timing
A. Risk of Bias
Flow and timing

Test done on admission

Was there an appropriate interval between index test and reference standard?

Unclear

Did all patients receive the same reference standard?

Yes

Were all patients included in the analysis?

Yes

Could the patient flow have introduced bias?

Low risk

Notes

•
•
•
•
•

Seventy-five patients were included from which 37 (49%) met the criteria of P-CAP.
Elevated PCT and CRP values were strongly associated with P-CAP with OR = 23, 95% CI [5, 117] for PCT and OR = 19, 95% CI [5,
75) for CRP in multivariate analysis.
The sensitivity was 94.4% for PCT (cutoff: 1.5 ng/mL) and 91.9% for CRP (cutoff: 100mg/L).
A value of ≤0.5 ng/mL of PCT ruled out P-CAP in >90% of cases (negative likelihood ratio: 0.08).
Conversely, a PCT value ≥1.5 ng/mL associated with a positive pneumococcal urinary antigen had a diagnostic probability for P-CAP of
almost 80% (positive likelihood ratio: 4.59).

* These guidelines do not establish a standard of care to be followed in every case. It is recognized that each case is different, and those individuals involved
in providing health care are expected to use their judgment in determining what is in the best interests of the patient based on the circumstances existing at
the time. It is impossible to anticipate all possible situations that may exist and to prepare guidelines for each. Accordingly, these guidelines should guide
care with the understanding that departures from them may be required at times.
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Guo et al., 2015
Patient Selection
Risk of Bias
Patient Sampling

Retrospective Chart Review

Was a consecutive or random sample of patients enrolled?

No

Was a case-control design avoided?

Yes

Did the study avoid inappropriate exclusions?

Unclear

Could the selection of patients have introduced bias?

Unclear risk

Concerns regarding applicability
Patient characteristics and setting

Pediatric CAP cases, with lobe or multi foci
infiltration: N = 126
Age: 0-23 months, n = 34
2-4 years, n = 39
>5 years, n = 53
Mycoplasma versus virus patients

Are there concerns that the included patients and setting do not match the review question?

Unclear concern

Index Test
Index tests

CRP

All tests
Risk of Bias
Were the index test results interpreted without knowledge of the results of the reference standard?

Unclear

If a threshold was used, was it pre-specified?

No

Could the conduct or interpretation of the index test have introduced bias?

Low risk

Concerns regarding applicability
Are there concerns that the index test, its conduct, or interpretation differ from the review question?

High concern

Reference Standard
Risk of Bias
Target condition and reference standard(s)

The diagnosis of mycoplasma pneumonia was based on the results from
real-time PCR targeting the P1 cyto adhesion type 1 and 2 genes of the
Mycoplasma pneumoniae genome, using DNA extracted from
nasopharyngeal swab specimens. Mycoplasma pneumonia was defined as
acute respiratory disease with abnormal chest radiograph findings and
positive laboratory tests combined with real-time PCR

* These guidelines do not establish a standard of care to be followed in every case. It is recognized that each case is different, and those individuals involved
in providing health care are expected to use their judgment in determining what is in the best interests of the patient based on the circumstances existing at
the time. It is impossible to anticipate all possible situations that may exist and to prepare guidelines for each. Accordingly, these guidelines should guide
care with the understanding that departures from them may be required at times.
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Is the reference standards likely to correctly classify the target condition?

Yes

Were the reference standard results interpreted without knowledge of the
results of the index tests?

Unclear

Could the reference standard, its conduct, or its interpretation have
introduced bias?

Low risk

Concerns regarding applicability
Are there concerns that the target condition as defined by the reference standard does not match the
question?

Low concern

Flow and Timing
Risk of Bias
Flow and timing

Obtained within 24 hours

Was there an appropriate interval between index test and reference standard?

Yes

Did all patients receive the same reference standard?

Yes

Were all patients included in the analysis?

No

Could the patient flow have introduced bias?

Unclear risk

Notes

•
•
•
•

71 (56%) male and 55 (44%) female CAP cases with lobar or multi foci infiltration.
70 pneumonia cases were caused by Mycoplasma pneumoniae and 18 by viruses.
Univariate analysis of the mycoplasma and viral causes of the CAP revealed that increased respiratory rate, wheeze, male gender and
lymphocyte percentage were the factors associated with the differentiation of mycoplasma and viral etiologies of pneumonia (p <
.05).
A stepwise logistic regression analysis was performed to assess independent factors which allow the differential diagnosis of viral and
mycoplasma pneumonia. Increased respiratory rate, wheeze, and lymphocyte percentage were reliable independent factors which
allow the differential diagnosis of viral and mycoplasma CAP with lobar or multi foci infiltration

Higdon et al., 2017
Patient Selection
Risk of Bias
Patient Sampling

Retrospective Case Control
Case: Patients with Severe and Very Severe
CAP

Was a consecutive or random sample of patients enrolled?

No

Was a case-control design avoided?

No

Did the study avoid inappropriate exclusions?

Unclear

* These guidelines do not establish a standard of care to be followed in every case. It is recognized that each case is different, and those individuals involved
in providing health care are expected to use their judgment in determining what is in the best interests of the patient based on the circumstances existing at
the time. It is impossible to anticipate all possible situations that may exist and to prepare guidelines for each. Accordingly, these guidelines should guide
care with the understanding that departures from them may be required at times.
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Could the selection of patients have introduced bias?

High risk

Concerns regarding applicability
Patient characteristics and setting

Children <5years of age HIV-Negative
Patients only N = 720
Seven countries across Africa

Are there concerns that the included patients and setting do not match the review question?

High concern

Index Test
Index tests

CRP

All tests
Risk of Bias
Were the index test results interpreted without knowledge of the results of the reference standard?

Unclear

If a threshold was used, was it pre-specified?

No

Could the conduct or interpretation of the index test have introduced bias?

Unclear risk

Concerns regarding applicability
Are there concerns that the index test, its conduct, or interpretation differ from the review question?

Unclear concern

Reference Standard
Risk of Bias
Target condition and reference standard(s)

World Health Organization–defined severe or very severe pneumonia
Unclear how bacterial CAP was identified

Is the reference standards likely to correctly classify the target condition?

Unclear

Were the reference standard results interpreted without knowledge of the
results of the index tests?

Unclear

Could the reference standard, its conduct, or its interpretation have
introduced bias?

Unclear risk

Concerns regarding applicability
Are there concerns that the target condition as defined by the reference standard does not match the
question?

Unclear concern

Flow and Timing
A. Risk of Bias
Flow and timing

Flow and timing of tests were unclear

Was there an appropriate interval between index test and reference standard?

Unclear

* These guidelines do not establish a standard of care to be followed in every case. It is recognized that each case is different, and those individuals involved
in providing health care are expected to use their judgment in determining what is in the best interests of the patient based on the circumstances existing at
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Did all patients receive the same reference standard?

No

Were all patients included in the analysis?

No

Could the patient flow have introduced bias?

High risk

Notes

•
•
•

Among 601 human immunodeficiency virus (HIV)–negative tested controls, 3% had CRP ≥40 mg/L.
Among 119 HIV-negative cases with confirmed bacterial pneumonia, 77% had CRP ≥40 mg/L compared with 17% of 556 RSV
pneumonia cases.
The ROC analysis produced an area under the curve of 0.87, indicating very good discrimination; a cut-point of 37.1 mg/L best
discriminated confirmed bacterial pneumonia (sensitivity 77%) from RSV pneumonia (specificity 82%). CRP ≥100 mg/L substantially
improved specificity over CRP ≥40 mg/L, though at a loss to sensitivity.

Hoshina et al., 2014
Patient Selection
Risk of Bias
Patient Sampling

Retrospective Cohort

Was a consecutive or random sample of patients enrolled?

Yes

Was a case-control design avoided?

Yes

Did the study avoid inappropriate exclusions?

Unclear

Could the selection of patients have introduced bias?

High risk

Concerns regarding applicability
Patient characteristics and setting

Children admitted with community acquired
lower respiratory tract infection: N = 108
Less than 15 years of age

Are there concerns that the included patients and setting do not match the review question?

Low concern

Index Test
Index tests

WBC
Neutrophil
CRP
PCT

All tests
Risk of Bias
Were the index test results interpreted without knowledge of the results of the reference standard?

Unclear

If a threshold was used, was it pre-specified?

Yes

* These guidelines do not establish a standard of care to be followed in every case. It is recognized that each case is different, and those individuals involved
in providing health care are expected to use their judgment in determining what is in the best interests of the patient based on the circumstances existing at
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Could the conduct or interpretation of the index test have introduced bias?

Unclear risk

Concerns regarding applicability
Are there concerns that the index test, its conduct, or interpretation differ from the review question?

Unclear concern

Reference Standard
Risk of Bias
Target condition and reference standard(s)

CAP based on both clinical history such as
fever, cough, and dyspnea, and
auscultatory findings of abnormal breath
sounds, wheezes or crackles. In addition,
the patients with consolidation on the chest
X-ray were diagnosed as having pneumonia.
Diagnosis with bacteriological findings of
sputum samples, and biological,
nasopharyngeal aspirate or throat swabs.

Is the reference standards likely to correctly classify the target condition?

Unclear

Were the reference standard results interpreted without knowledge of the results of the index tests?

Unclear

Could the reference standard, its conduct, or its interpretation have introduced bias?

High risk

Concerns regarding applicability
Are there concerns that the target condition as defined by the reference standard does not match the question?

High concern

Flow and Timing
Risk of Bias
Flow and timing

Labs tests done on admission

Was there an appropriate interval between index test and reference standard?

Yes

Did all patients receive the same reference standard?

No

Were all patients included in the analysis?

Unclear

Could the patient flow have introduced bias?

Unclear risk

* These guidelines do not establish a standard of care to be followed in every case. It is recognized that each case is different, and those individuals involved
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Notes

CRP (p = .02) and PCT (p = .0008) were significant. Neutrophil count was best to differentiate bacterial bronchitis.
Cut-offs:
WBC 10,500/ul
Neutrophil 7665/ul
CRP 5.73mg/dl
PCT 0.2ng/ml
Prevalence

Stockman et al., 2018
Patient Selection
Risk of Bias
Patient Sampling

Retrospective Cohort

Was a consecutive or random sample of patients enrolled?

Unclear

Was a case-control design avoided?

Yes

Did the study avoid inappropriate exclusions?

Unclear

Could the selection of patients have introduced bias?

Unclear risk

Concerns regarding applicability
Patient characteristics and setting

Children with Etiology of Pneumonia from a
previous study: N = 532
Age: median, 2.4 years; interquartile range
[IQR], 1.0–6.3

Are there concerns that the included patients and setting do not match the review question?

Low concern

Index Test
Index tests

PCT

All tests
Risk of Bias
Were the index test results interpreted without knowledge of the results of the reference standard?

Unclear

If a threshold was used, was it pre-specified?

Yes

Could the conduct or interpretation of the index test have introduced bias?

Low risk

Concerns regarding applicability
Are there concerns that the index test, its conduct, or interpretation differ from the review question?

Low concern

* These guidelines do not establish a standard of care to be followed in every case. It is recognized that each case is different, and those individuals involved
in providing health care are expected to use their judgment in determining what is in the best interests of the patient based on the circumstances existing at
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Reference Standard
Risk of Bias
Target condition and reference standard(s)

Radiographically confirmed CAP

Is the reference standards likely to correctly classify the target condition?

Unclear

Were the reference standard results interpreted without knowledge of the results of the index tests?

Unclear

Could the reference standard, its conduct, or its interpretation have introduced bias?

Unclear risk

Concerns regarding applicability
Are there concerns that the target condition as defined by the reference standard does not match the
question?

Unclear concern

Flow and Timing
A. Risk of Bias
Flow and timing

Not clear on flow and timing

Was there an appropriate interval between index test and reference standard?

Unclear

Did all patients receive the same reference standard?

Yes

Were all patients included in the analysis?

Yes

Could the patient flow have introduced bias?

Low risk

Notes

•

•
•
•
•

Among 532 children (median age, 2.4 years; [IQR], 1.0–6.3), patients with typical bacteria had higher PCT concentrations (±viruses;
n = 54; median, 6.10; IQR, 0.84–22.79 ng/mL) than those with atypical bacteria (±viruses; n = 82; median, 0.10; IQR, 0.06–0.39
ng/mL), viral pathogens only (n = 349; median, 0.33; IQR, 0.12–1.35 ng/mL), or no pathogen detected (n = 47; median, 0.44; IQR,
0.10–1.83 ng/mL) (p < .001 for all).
No child with PCT <0.1 ng/mL had typical bacteria detected.
PV = 96%, 95% CI [93,99%]
Sensitivity = 85%, 95% CI [76, 95%]
Specificity = 45%, 95% CI [40, 50]

* These guidelines do not establish a standard of care to be followed in every case. It is recognized that each case is different, and those individuals involved
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Andrews et al., 2015
Methods
Participants

Interventions

Decision analysis model to determine universal versus targeted approach to obtaining blood cultures in children hospitalized
with CAP
Participants:
•
Hospitalized children with (CAP)
Setting:
•
Six studies referenced in the model included data from 12 United States hospitals that care for children from the
years 2010 - 2013.
Number enrolled: N = 6 studies containing over 4900 patients.
Number completed: N = Not applicable
Gender, males:
•
Not applicable
Race / ethnicity or nationality (as defined by researchers):
•
Not reported
Age, years/month (mean):
•
Not applicable
Inclusion Criteria:
•
Not reported
Exclusion Criteria:
•
Not reported
Covariates identified:
•
Not reported

•
•
•

The authors used six studies to identify key assumptions to be applied to the decision tree.
Infectious Diseases Society of America (IDSA) CAP management guidelines were applied to the model
Consistent with IDSA guidelines, the authors assumed that all children hospitalized with CAP were started on
ampicillin or another narrow-spectrum penicillin
• The authors assumed that the guidelines for identifying children who are at high risk for bacteremia would be 90%
sensitive
• Using the assigned sensitivity and the known number of cases of true bacteremia per 100 patients, the authors
assigned a proportion of positive cultures, true positive cultures, contaminants, and cases of missed bacteremia in
the targeted arm of the decision model.
Group 1: Apply a universal approach to obtaining blood cultures in children hospitalized with CAP
Group 2: Apply a targeted (pneumonia with effusion or empyema or patients admitted to the intensive care unit or
immunosuppressed) approach to obtaining blood cultures in children hospitalized with CAP

* These guidelines do not establish a standard of care to be followed in every case. It is recognized that each case is different, and those individuals involved
in providing health care are expected to use their judgment in determining what is in the best interests of the patient based on the circumstances existing at
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Outcomes

Results

Primary outcomes:
• The number of patients identified with true bacteremia that would lead to meaningful antibiotic change per 100
hypothetical patients entered each arm of the model
• The number of patients with missed bacteremia with associated treatment failure (bacteria not susceptible to
ampicillin) per 100 hypothetical patients in the targeted arm
• Difference in blood culture cost per 100 patients between the targeted arm (assuming 90% guideline sensitivity)
and the universal arm
• Difference in two-day hospital readmission for patients with missed bacteremia and associated treatment failure per
100 patients between the targeted arm and the universal arm
Secondary outcomes:
• Number of blood cultures drawn to identify one case of bacteremia that leads to a meaningful antibiotic change in
each arm
• The difference in laboratory-related costs between the arms on an annual population level
• The difference in overall direct costs (laboratory costs plus hospital costs, assuming a 0.8-day length of stay
differential between arms) (assuming 90% guideline sensitivity) per 100 patients
• The difference in overall direct costs (laboratory costs plus hospital costs, assuming a 0.8-day length of stay
differential between arms) on an annual population level
Results:
• Difference in blood culture cost per 100 patients between the targeted arm (assuming 90% guideline sensitivity)
and the universal arm
o $3186 (Universal $5178 - Targeted approach, 90% sensitivity $1992)
• The difference in overall direct costs (laboratory costs plus hospital costs, assuming a 0.8-day length of stay
differential between arms, assuming 90% guideline sensitivity) per 100 patients
o $105,458 (Universal $381,178 - Targeted approach $275,720)
Notes:
• The authors do not provide specific patient demographics. "To arrive at our final model inputs as listed above, we
averaged the data from all contributing studies and weighted to account for sample size."
• The authors did not receive institutional review board review or approval for the decision analysis model

* These guidelines do not establish a standard of care to be followed in every case. It is recognized that each case is different, and those individuals involved
in providing health care are expected to use their judgment in determining what is in the best interests of the patient based on the circumstances existing at
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Davis et al., 2016
Methods
Participants

Interventions

Retrospective data analysis
Participants:
•
Children admitted to Gosford Hospital during the 2-year period from July 2013 to June 2015 with a diagnosis of
pneumonia
Setting:
•
Gosford Hospital, Gosford, New South Wales, Australia
Number enrolled: N = 215
Number completed: N = 177
Gender, males: N = 139 (64.65%)
Race / ethnicity or nationality (as defined by researchers):
•
Not reported
Age [range]:
•
10 months - 17 years
Inclusion Criteria:
• Admission to hospital
• Diagnosis-related group code of pneumonia
• Patients under 16 years old
Exclusion Criteria:
•
Not reported
Covariates identified: none

•
•

Outcomes

Results

Blood cultures were collected on children with moderate to severe community-acquired pneumonia (CAP), children
with CAP requiring hospital admission and any child presenting with sepsis
Patient's electronic medical record (EMR) were accessed and data collected on details of admission, including
demographics, treatment, X-ray findings, blood results and length of stay

Primary outcome(s):
• Number of positive blood cultures *
Secondary outcome(s):
• Effect of positive blood culture results on management *
• Identification of other clinical/biochemical variables that could predict blood culture results or course of illness
*Outcomes of interest to the CMH CPG or CAT development team
Results:
•
Seven out of the 177 blood culture collected were positive; only two were determined to be true positives on final
reports. No treatment changes were made based on positive blood culture results.

* These guidelines do not establish a standard of care to be followed in every case. It is recognized that each case is different, and those individuals involved
in providing health care are expected to use their judgment in determining what is in the best interests of the patient based on the circumstances existing at
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Kwon et al., 2017
Methods
Participants

Retrospective cohort study to investigate the utility of BC in children with CAP who were admitted to ED of a tertiary
hospital.
Participants:
•
Previously healthy children with CAP aged 6 months to 18 years as a primary diagnosis who were admitted to the
ED and underwent a BC for the diagnosis of Bacteremia from January 2009 through September 2016
Setting:
•
Tertiary hospital ED in Seoul, Korea
Number enrolled: N = 2705
Number completed: N = 2705
Gender, males (%):
• Group 1 BC Justified: n = 469 (56.3)
• Group 2 BC Unjustified: n = 950 (50.7)
Race / ethnicity or nationality (as defined by researchers):
•
Not reported
Age, years/month (mean):
• Group 1 BC Justified: n = 5.0 (2.0-7.0)
• Group 2 BC Unjustified: n = 2.0 (1.0-4.0)
Inclusion Criteria:
• Previously healthy children 6 months- 18 years
• CAP as the primary diagnosis
• underwent a BC from the diagnosis of bacteremia from January 2009- September 2016
Exclusion Criteria:
• Cardiopulmonary diseases
• Presumed viral or noninfectious pneumonia
• Non-ambulatory status
• Known immunocompromised status
• Indwelling devices
• Healthcare-associated pneumonia
Covariates identified:
• M pneumoniae (1044 of the 2705 children)
• Viruses, rhinovirus, and RSV (710 of the 2705 children)

Interventions

•

Blood culture was performed in the ED by physician or nurse. BC was retrospectively justified if it had been
performed on children with respiratory distress, admission to the intensive care unit, or complicated pneumonia.

Outcomes

•
•

Utility of BC in children with CAP who were admitted to the ED
Comparison of the utilization of BC in children with and without a BC justified by the current guideline

* These guidelines do not establish a standard of care to be followed in every case. It is recognized that each case is different, and those individuals involved
in providing health care are expected to use their judgment in determining what is in the best interests of the patient based on the circumstances existing at
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Results:

•
•
•
•
•

12 out of 2705 children (0.4%; 95% CI: 0.2-0.8) had positive BC results
Out of the 12 positive BC results seven (0.8) were justified and five (0.3) were unjustified
Isolated organisms identified in BC: StreptococcuS. pneumoniae, Staphylococcus hominis; VGS, Corynebacterium
spp., Propionibacterium acnes, Pepto streptococcus magnus, Staphylococcus epidermidis
The rate of bacteremia (0.11%) indicates that the number needed to test was 909 out of 2705.
Study results recommend judicious use of BC can decrease unnecessary venipuncture, antibiotic treatment, and
healthcare costs.

Notes:
Study limitations - single center study and retrospective design
Lai et al., 2015
Methods

Prospective cohort study to evaluate the yield of blood cultures in children hospitalized with CAP, and the impact of blood
cultures on the adjustment of empiric antibiotic treatment.

Participants

Participants:
•
Children aged between one month and 12 years who were admitted for CAP and had blood cultures performed
before starting intravenous antibiotics.
Setting:
•
A tertiary hospital in Malaysia
Number enrolled: N = 171
Number completed: N = 171
Gender, males:
• 59%, male
Age, years (Median, [range]):
• 1 year & 1 month [38 days, 10 years & 3 months]
Race / ethnicity or nationality (as defined by researchers):
•
Not reported
Inclusion Criteria:
• Fever (> 38 oC)
• Age adjusted tachypnea
• Any of the listed clinical features of pulmonary infection: cough, audible wheeze, rhonchi, nasal flaring, grunting,
chest retraction, crepitations, decreased breath sounds or bronchial breathing.
• Other causes of fever were ruled out.
Exclusion Criteria:
• Congenital pneumonia
• Bronchiolitis
• Immunodeficiency, primary or secondary
• Chronic cardiac disorders
• Chronic respiratory disorders

* These guidelines do not establish a standard of care to be followed in every case. It is recognized that each case is different, and those individuals involved
in providing health care are expected to use their judgment in determining what is in the best interests of the patient based on the circumstances existing at
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•
•

Nosocomial pneumonia
Systemic corticosteroid therapy for more than six weeks
Covariates identified: Not reported
Interventions

•
•
•

Outcomes

Results

Attending physicians performed blood cultures using a sterile technique according to standard procedures including
wearing a face mask, standard hand washing, use of sterile gloves, use of povidone iodine for sterilization of the
skin, use of sterile blood culture set with sterile needles and syringes.
Nasopharyngeal secretions (NPS) were analyzed for common respiratory viruses (respiratory syncytial virus,
parainfluenza 1,2,3, adenovirus, and influenza A&B)
Empirical intravenous antibiotics for community-acquired pneumonia

Primary outcome(s):
• To evaluate the yield of sterile blood cultures in children hospitalized for CAP.
• To evaluate the impact of blood cultures on the adjustment of empiric antibiotic treatment.

•
•
•
•

Two patients had evidence of bacteremia, with a rate of 1.2 %, 95% CI [0.19, 3.81]
The contamination rate was 1.8 %, 95% CI [0.45, 4.70]
o Contamination was two cases of coagulase negative Staphylococcus and one case of Bacillus species. These
contaminants were analyzed as negative blood cultures.
Blood culture results contributed to the adjustment of empiric antibiotic treatment in only one of the two bacteremia
patients.
None of the patients had their antibiotics stopped based on negative blood culture results.

McCulloh et al., 2015
Methods
Participants

Retrospective, cohort study
Participants:
•
Otherwise healthy children aged 3 months to 18 years initially admitted to a general inpatient unit for Community
Acquired Pneumonia (CAP)
Setting:
•
Four pediatric hospitals in the United States; Children’s Hospital at Dartmouth, Lebanon, NH, Hasbro Children’s
Hospital, Providence, RI, the Golisano Children’s Hospital at Rochester Medical Center, Rochester, NY, Children’s
Hospital of San Antonio, San Antonio, TX from January 1, 2011-December 31, 2012.
Number enrolled: N = 614
Number completed: N = 614
Gender, males:
• Group 1: Blood culture drawn, n = 209
• Group 2: No blood culture drawn, n = 115
Race / ethnicity or nationality (as defined by researchers):
•
Not reported
Age, years mean (SD):

* These guidelines do not establish a standard of care to be followed in every case. It is recognized that each case is different, and those individuals involved
in providing health care are expected to use their judgment in determining what is in the best interests of the patient based on the circumstances existing at
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•
•

Group 1: 5.2 (4.8)
Group 2: 5.1 (4.3)
Inclusion Criteria:
• Identified by admitting or discharge diagnosis of pneumonia by international classification of disease, ninth edition
(ICD-9) codes 480–488.1.
• Children aged 3 months to 18 years initially admitted to a general inpatient unit for CAP.
Exclusion Criteria:
• Direct admission to the PICU or the presence of ICD-9 codes indicating medical complexity, including chronic
neuromuscular, cardiovascular, respiratory, renal, gastrointestinal, hematologic, immunologic, metabolic,
congenital/genetic, or malignancy as defined elsewhere.
• Patients initially admitted to an outside hospital or ED did not have available temporal data on blood culture
obtainment, antimicrobial prescriptions, or total length of stay (LOS)
Interventions

•
•

Group 1: 390 children had blood cultures obtained.
Group 2: 224 did not have blood cultures obtained.

Outcomes

•

Primary outcome(s): To identify clinical factors associated with obtaining blood cultures in children hospitalized with
CAP, and to estimate the association between blood culture obtainment and hospital length of stay (LOS).

•
•
•

390 children had blood cultures obtained.
Children with blood cultures, six (1.5%) were positive for a pathogen and nine (2.3%) grew a contaminant.
Blood cultures are more likely to be obtained on patients with higher acuity, which correlates to a higher LOS.

Results

Either increase or decrease the odds of having blood cultures drawn:
Factor
Decreased Odds
Patient age (in years)
Female gender
Received supplemental oxygen at presentation
Duration of preceding illness (in days)
Pleural effusion identified
Insured
Increased Odds
Met SIRS (Sepsis) criteria at presentation
Received antibiotics pre-admit
Received intravenous hydration
Admitted from ED

Adjusted OR [95% CI]
0.98
0.88
0.80
0.99
0.79
0.42

[0.96,
[0.73,
[0.63,
[0.96,
[0.59,
[0.30,

1.01]
1.05]
1.02]
1.02]
1.06]
0.60]

1.78
1.49
3.94
1.65

[1.10,
[1.17,
[3.22,
[1.05,

2.89]
1.89]
4.83]
2.60]

* These guidelines do not establish a standard of care to be followed in every case. It is recognized that each case is different, and those individuals involved
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Neuman et al., 2017
Methods
Participants

Retrospective cohort study
Participants:
•
Children aged 3 months to 18 years, hospitalized with community acquired pneumonia (CAP) between Jan 1, 2007
to Dec 31st, 2011
Setting:
•
Six children’s hospitals in USA
Number enrolled: N = 7,509
• Group 1: No blood culture, n = 4,941
• Group 2: Blood culture, n = 2,568
Number completed: N = 7,509
Gender, males:
• Group 1: n = 2,533 (53.1%)
• Group 2: n = 1,315 (51.2%)
Race / ethnicity or nationality (as defined by researchers):
•
Not reported
Age, Years
• Group 1: n = 4,941
o 1-5 years, n = 3,586 (72.6%)
o 6-12 years; n = 1,083 (21.9%)
o 13-18 years, n = 272 (5.5%)
• Group 2: n = 2568
o 1-5 years, n = 1,857 (72.3%)
o 6-12 years; n = 540 (21.0%)
o 13-18 years, n = 171 (6.7%)
Inclusion Criteria:
• Children aged 3 months to 18 years
• Hospitalized children
• Primary diagnosis of pneumonia (ICD 9 codes 480-483 and 485-487)
• Primary diagnosis of plural effusion (510.0, 510.9, 511.0, 511.1, 511.9)
• Secondary diagnosis of pneumonia
• Participated in the Pediatric Health Information System Plus (PHIS+) database
Exclusion Criteria:
• Children that were transferred to participating hospitals.
• Children with a complex chronic condition recorded among their discharge diagnoses
• Children with a secondary discharge diagnosis consistent with an underlying chronic condition not identified by the
complex chronic condition algorithm

* These guidelines do not establish a standard of care to be followed in every case. It is recognized that each case is different, and those individuals involved
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Interventions
Outcomes

Results

•
•

Group 1: Children with community-acquired pneumonia with blood culture test and penicillin susceptibility results
Group 2: Children with community-acquired pneumonia with no blood culture

Primary outcome(s):
• Rate of bacteremia in children with CAP: Performed blood culture on the first or second hospital day.
Secondary outcome(s)
• Penicillin susceptibility: For each isolated pathogen, susceptibility test was performed for penicillin.

•
•
•

Children hospitalized with CAP had a blood culture 34.2% (n = 2568)
Overall bacteremia was identified in 0.9%, 95% CI [0.7, 1.1] hospitalized children with CAP
The rate of bacteremia among patients with severe or complicated pneumonia on presentation was 4.2%, 95% CI
[2.6%, 6.8%] and was 2.2%, 95% CI [1.6%, 2.9%] among children presenting without severe and complicated
pneumonia
• Children were positive for blood culture 2.5%, 95% CI [2.0, 3.2] (65/2568)
• S. pneumoniae was the most common (78.0%, 51/65) organisms identified
• Contamination was observed 1.0%, 95% CI [.6, 1.4] (25/2568)
• Coagulase-negative staphylococci was accounted for the most contaminants.
• Among the 61 susceptibility results available, 82.0% (50/61) pathogens were susceptible to penicillin
• S pneumonia was susceptible to penicillin 92.0%
• Children were non-susceptible to penicillin, 0.4% (11/2568)
Conclusions: The rate of bacteremia in children without comorbidity hospitalized with CAP was low. When bacteremia
occurred, >80% of isolates were susceptible to ampicillin, the
recommended first-line treatment of children with CAP.

* These guidelines do not establish a standard of care to be followed in every case. It is recognized that each case is different, and those individuals involved
in providing health care are expected to use their judgment in determining what is in the best interests of the patient based on the circumstances existing at
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Neuman et al., 2012
Methods
Participants

Interventions
Outcomes

Cross-sectional retrospective chart review
Participants:
•
Otherwise healthy children hospitalized with uncomplicated CAP.
Setting:
•
Medical records of patients discharged from Children's Mercy Hospital in Kansas City, MO, a tertiary referral hospital,
were reviewed retrospectively. Patients were hospitalized between July 8, 2007 and July 9, 2009.
Number enrolled: N = 1033
• Group 1 (Pre-Guideline): n = 530
• Group 2 (Post-Guideline): n = 503
Gender, males:
• Group 1 (Pre-Guideline): n = 260, 49%
• Group 2 (Post-Guideline): n = 262, 52%
Race / ethnicity or nationality (as defined by researchers):
•
Not reported
Age, years/month (mean): mean not reported
Inclusion Criteria:
• Patients with principal or secondary discharge International Classification of Diseases, Ninth Revision, Clinical
Modification (ICD-9) code of 480 through 486 for pneumonia AND received an antibiotic
Exclusion Criteria:
• Patient age < 2 months
• Patient prematurity < 36 week gestation
• Patient diagnosed with pneumonia three days after admission
• Immunocompromised patients
• Patients with one of the following
o Congenital heart disease
o Chronic lung disease, except asthma
o Sickle cell disease
o Neurologic condition
o Neuromuscular disorder
• Patients admitted with an effusion on CXR requiring a diagnostic or therapeutic procedure including chest tube,
thoracentesis, or video-assisted thoracoscopic surgery (VATS) were excluded for complicated pneumonia
Group 1 (Pre-Guideline): Patients admitted July 8, 2007 until the implementation of the CPG on July 9, 2008.
Group 2 (Post-Guideline): Patients admitted July 10, 2008 through July 9, 2009, after CPG implementation.

•

Determine the impact a CPG had on antibiotic management of children hospitalized with (CAP).

* These guidelines do not establish a standard of care to be followed in every case. It is recognized that each case is different, and those individuals involved
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Results

•
•
•

Increase in ampicillin use was 34% (p < .001).
Significant increase in amoxicillin use (p < .001)
Significant decrease in cefdinir and amoxicillin/clavulanate (p < .001) to 12% (p < 0.001) and 16% (p < .001)
reduction, respectively.
• Overall, treatment failure was infrequent (1.5% vs 1%).
A major goal of the CPG was to increase the use of ampicillin as the empiric antibiotic in healthy children with
uncomplicated CAP
• Group 1 (Pre-Guideline): Percent of patients receiving empiric ampicillin or ceftriaxone for the treatment of
uncomplicated CAP before CPG implementation
o Ampicillin: 13%
o Ceftriaxone: 63%
• Group 2 (Post-Guideline): Percent of patients receiving empiric ampicillin or ceftriaxone for the treatment of
uncomplicated CAP after CPG implementation
o Ampicillin: 72%
o Ceftriaxone: 21%
Blood cultures were recommended by the CPG to be obtained in all hospitalized children
• Number of blood cultures obtained
o Group 1 (Pre-Guideline): 56%
o Group 2 (Post-Guideline): 54%
• Number of blood cultures that grew an organism
o Group 1 (Pre-Guideline): n = 24 (8%)
 n = 10 considered pathogen (9 S. pneumoniae and 1 Streptococcus pyogenes)
o Group 2 (Post-Guideline): n = 17 (6%)
 n = 13 considered pathogen (12 S. pneumoniae and 1 Streptococcus pyogenes)
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Senavonge et al., 2016
Methods
Participants

Interventions

Prospective descriptive study to determine the rate and identify clinical factors associated with bacteremia in children
hospitalized with CAP.
Participants:
•
Pediatric patients aged 60 days to 15 years hospitalized with CAP between June 2014 to April 2015
Setting:
•
King Chulalongkorn Memorial Hospital, Thailand
Number enrolled: N = 152
Number completed: N = 152
Gender, males (%): n = 73 (48%)
Race / ethnicity or nationality (as defined by researchers):
•
Not reported
Age, years (median): 1.9
Inclusion Criteria:
• Aged 60 days to 15 years
• Hospitalized for CAP (diagnosis criteria: lower respiratory symptoms and chest x-ray with infiltration)
Exclusion Criteria:
• Patients hospitalized 2 weeks prior to admission
• Patients referred to hospital from outside hospital

•
•

•
•

Blood cultures were obtained from each study participant on admission using sterile technique. The blood was
inoculated into a pediatric blood culture bottle.
Contaminated blood culture was defined as a patient whose clinical status remained stable or improved without use
of antibiotics, first blood culture result was abnormal, and repeated blood culture taken immediately after first
resulted as negative. Specimens were considered negative if contaminated with Staphylococcus, Corynebacterium,
and Micrococcus.
Specimens were considered positive for following pathogens: S. pneumonia, Escherichia coli, and Salmonella group
B.
Severe sepsis was defined as sepsis-induced hypoperfusion or organ dysfunction.

* These guidelines do not establish a standard of care to be followed in every case. It is recognized that each case is different, and those individuals involved
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Outcomes

Results

Primary outcomes:
• Clinical factors
o History of underlying disease
o History of vaccines (pneumococcal, Haemophilus influenza type B, influenza)
o Median duration of fever (days)
o Median duration of upper respiratory infection symptoms (days)
o Body temperature
o Severe sepsis
o Mechanical ventilation
o Respiratory distress
• Lab factors
o White blood count (WBC)
o Median absolute neutrophil count
o Median hemoglobin
o Median platelet count
o Chest radiograph findings (perihilar/interstitial infiltration, patchy infiltration)
o Pleural effusion
Secondary outcome:
• Percentage of contaminants in blood culture collection
Rate: The rate of bacteremia in study participants with CAP was 3.9% (n = 6).
Clinical and Lab Factors: The authors concluded five factors were significantly associated with bacteremia in the study
participants: body temperature >38.5 degrees Celsius, severe sepsis, mechanical ventilation, white blood count >17,000
per µ/l, and patchy infiltration on chest x-ray. Forty percent of participants had at least one of the five factors associated
with bacteremia. The likelihood of bacteremia increased with the number of associated clinical factors.
• Clinical Factors:
o Body temperature >38.5 degrees Celsius, OR = 9.2, p = 0.03, 95% CI [1.6-53.2]: 66.7% (n = 4) of
participants with positive blood culture results and 17.8% (n = 26) of participants with negative blood
culture results had an elevated body temperature greater than 38.5 degrees Celsius.
o Severe sepsis, OR = 27.2, p < 0.001, 95% CI [4.1, 167]: 50% (n = 3) of participants with bacteremia had
severe sepsis versus 0.7% (n = 1) of participants with a negative blood culture.
o Mechanical ventilation, OR = 145, p = 0.001, 95% CI [11.5, 1830]: 66.7% (n = 4) of patients with
bacteremia and 6.9% (n = 10) of participants negative for bacteremia required mechanical ventilation.
• Lab Factors:
o WBC >17,000, OR = 6.1, p = 0.04, 95% CI [1.1, 34.7]: 66.7% (n = 4) of participants with a positive blood
culture had elevated WBC greater than 17,000 per µ/l. 25% (n = 36) of participants with a negative blood
culture had leukocytosis.
o Patchy infiltration, OR = 12.8, p = 0.01, 95% CI [1.5, 113]: 83.3% (n = 5) of participants with bacteremia
had patchy infiltration on the chest x-ray whereas 28.1% (n = 41) of participants with negative blood
cultures had this finding on the chest x-ray.
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Clinical Variables

Total (N = Negative Blood
152)
Culture (n = 152)

History of underlying disease
Yes
57 (37.5)
No
95 (62.5)

Positive Blood
Culture (n = 6)

p- value

Odds Ratio (95%
CI)

55 (37.7)
91(62.3)

2 (33.3)
4 (66.67)

2 (33.3)
4 (66.67)

10 (6.6)
17 (11.2)
37 (24.3)

10 (6.9)
16 (11)
35 (24)

0 (0)
1 (16.7)
2 (33.3)

0.55
0.66
0.60

Median duration (IQR) of
fevers in days

1 (1-3)

1 (1-3)

1.5 (1-3)

0.70

Median duration (IQR) of URI
symptoms in days

3 (1-5)

3 (1-5)

2 (1-3)

0.34

Body temperature
≤38.5ºC
>38.5ºC

122 (80.3)
30 (19.7)

120 (82.2)
26 (17.8)

2 (33.3)
4 (66.7)

0.03

9.2 [1.6, 53.2]

Severe sepsis
No
Yes

148 (97.4)
4 (2.6)

145 (99.3)
1 (0.7)

3 (50)
3 (50)

<0.001

27.2 [4.1, 167]

Mechanical ventilation
No
Yes

138 (90.8)
14 (9.2)

136 (93.2)
10 (6.9)

2 (33.3)
4 (66.7)

0.001

145 [11.5, 1,830]

Respiratory distress
No
Yes

32 (21.1)
120 (79.5)

31 (21.2)
115 (78.8)

1 (16.7)
5 (83.3)

0.79

History of vaccines
Pneumococcal
Hemophilus influenza type B
Influenza

0.83
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Tam et al., 2015
Design

Quantitative Synthesis (meta-analysis)

Objective

In the
1.
2.
3.

Methods

Protocol and registration. No mention of protocol/registration
Eligibility Criteria
Inclusion:
•
Studies involving patients up to 18 years old with diagnosis of CAP (defined as clinical, radiographic, and/or microbiologic
diagnosis of pneumonia at time of or within 48 hours of admission to hospital) who were evaluated in the ED or
hospitalized
•
Studies using an ICD-9 code of pneumonia in patients up to 18yo
Exclusion:
•
Studies based in ambulatory setting
•
Studies that predominantly included patients with comorbidities (underlying chronic heart and lung conditions,
malnutrition, immunodeficiency, immunosuppression)
•
Studies evaluating known positive isolates, e.g. studies evaluating diagnostic methods for detection of S pneumonia in
children with pneumonia
•
Studies focusing on pneumonia or invasive disease caused by particular pathogens
•
Studies that did not sufficiently differentiate total number of BCs from positive BCs
Information sources. (1970-2013), Search terms and strategy listed as table
•
PubMed
•
Scopus
Study Selection.
•
Abstracts were independently scored by two reviewers for relevance using a validated methodology
•
If at least one reviewer judged full text of an article to be clinically relevant, two independent reviewers appraised the
article using a structured data collection form
•
These two reviewers determined by consensus whether each article should be cited in the SR
•
Senior author assessed the identified articles for completeness
Data collection process.
•
Data on total number of BCs collected and rate of positive BCs in patients with a diagnosis of pneumonia were extracted
•
Data extraction was recorded in Microsoft Excel
•
Communications were sent to authors if clarifications from study were needed
Risk of bias (RoB) across studies.
•
Internal validity (bias and confounding) was evaluated using a modified version of the Downs and Black critical appraisal
tool
•
Publication bias was examined and adjusted by the trim and fill method
•
No mention of Risk of Bias tool used to assess other bias

pediatric patient requiring hospitalization for presumed moderate to severe bacterial community acquired pneumonia (CAP),
How often are blood cultures (BCs) positive?
What are the most commonly isolated pathogens?
Is there a link between disease severity and positive blood culture?

* These guidelines do not establish a standard of care to be followed in every case. It is recognized that each case is different, and those individuals involved
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Summary measures.
•
Positive BCs: numbers and percentages
•
Most commonly isolated pathogens: percentages
•
Studies that focus on severity: Estimate (95% CI)
Synthesis of results.
•
Statistical modeling was performed using the “metaphor” package in R statistical software
•
Logistic transformations were used to calculate the 95% CI for study specific rate estimates
•
Meta-analysis of the rate of the positive BCs was conducted using random effects models to incorporate heterogeneity
across studies
•
Pooled proportions were calculated within subgroups using random effects models
•
Meta-analysis done on BC rates (overall) and BC rates (subgroups, see below)
Additional analyses. (meta analyses of subgroups, all include I2)
Subgroups included in meta-analysis included
•
Studies pre/post pneumococcal conjugate vaccine (PCV)
•
Prospective only studies (pre/post PCV)
•
US studies
•
US and Western Europe studies
•
International studies
•
Studies in children </= 5y
•
Studies that do/do not focus on severe CAP
Results

Study Selection.
Number of articles identified: N = 220
a. Full-text articles assessed for eligibility: n = 105
b. Studies included in quantitative synthesis: n = 21
Synthesis of results.
Number
Number of
Results: Estimate
Outcome
of
subjects
[95% CI]
Studies
Positive
21
8621
5.14 [3.61, 7.28]
BCs
Severe
4
2794
9.89 [6.79, 14.19]
CAP
Non severe
17
5827
4.17 [2.79-6.18]
CAP

I2(%)
91.3
61.6
85.4
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in providing health care are expected to use their judgment in determining what is in the best interests of the patient based on the circumstances existing at
the time. It is impossible to anticipate all possible situations that may exist and to prepare guidelines for each. Accordingly, these guidelines should guide
care with the understanding that departures from them may be required at times.

Department of Evidence Based Practice
Service and Performance Excellence
Date Finalized/Revised: 10/2018; 03/2020

127

Most commonly isolated pathogens from all studies (8621 patients, %):
•
S. pneumonia 76.7
•
Hemophilus influenza 3.1
•
Staphylococcus aureus 2.1
•
Klebsiella pneumonia 1.6
•
Streptococcus pyogenes 0.3
•
Hemophilus parainfluenza 0.3
•
Moraxella catarrhalis 0.3
•
Escherichia coli 0.3
•
Neisseria meningitides 0.3
•
Enterobacter spp 0.3
•
Stenotrophomonas maltophilia 0.3
•
Contaminants 14.7
Risk of bias across studies.
•
No mention of Risk of Bias tool used to assess bias other than publication and selection bias
•
Authors report a chance of sampling bias
Additional analysis: Meta-analysis performed on subgroups
•
Studies pre/post pneumococcal conjugate vaccine (PCV)
•
Prospective only studies (pre/post PCV)
•
US studies
•
US and Western Europe studies
•
International studies
•
Studies in children </= 5y
•
Studies that do/do not focus on severe CAP
Discussion

Funding

Summary of evidence.
•
BCs are positive in <10% of subjects, regardless of disease severity
•
Most commonly identified pathogen was Streptococcus pneumonia by a large margin
•
BCs are positive about twice as often in a patient with severe CAP vs a patient with non-severe CAP
Limitations.
•
No risk of bias done on individual studies
•
Diagnostic criteria for severe vs non severe CAP differ from study to study
•
Although studies excluded patients with comorbidities, some studies included patients with asthma
One of the Authors was supported in part by a US Agency for Healthcare Research and Quality grant and a US National Institute of
Allergy and Infectious Diseases grant.
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Cannavino et al., 2016
Methods
Participants

Randomized, multi-center, prospective controlled trial
Setting: 34 study centers in 8 countries (Poland, Spain, United States, Bulgaria, Georgia, Greece, Hungary, and Ukraine)
Randomized into study: N = 161
• Group 1: Ceftaroline n = 122
• Group 2: Ceftriaxone n = 39
Completed Study (Modified Intent-to-Treat): N = 143
• Group 1: n = 107
• Group 2: n = 36
Gender, males:
• Group 1: n = 64 (52.9%)
• Group 2: n = 20 (51.3%)
Age, months/years (median):
Group 1:
• 12-<18 year: 8 (6.6%)
• 6-<12 year: 26 (21.5%)
• 2-<6 year: 64 (52.9%)
• 2 months-<2yr: 23 (19.0%)
Group 2:
• 12-<18 year: 2 (5.1%)
• 6-<12 year: 9 (23.1%)
• 2-<6 year: 21 (53.8%)
• 2 months-<2 year: 7 (17.9%)
Inclusion Criteria:
• Patients ages 2 mos-18 years with community-acquired bacterial pneumonia (CABP) requiring hospitalization and IV
antibacterial therapy
• Must meet CABP definition:
o All children were required to have:
 Fever (temperature >38°C) or hypothermia (temperature <35°C)
 The presence of new infiltrate(s) consistent with bacterial pneumonia, including a new alveolar/lobar
infiltrate or consolidation (based on imaging results)
 Acute onset or worsening within the previous five days of at least two of the following nine clinical
signs and symptoms: cough, tachypnea, dyspnea, grunting, sputum production, chest pain, cyanosis,
evidence of pneumonia with parenchymal consolidation and increased work of breathing.
o Participants needed to have at least one of the five following laboratory findings:
 Bacterial organism consistent with a typical respiratory pathogen identified or isolated from a
respiratory (sputum and pleural fluid) or blood culture,

* These guidelines do not establish a standard of care to be followed in every case. It is recognized that each case is different, and those individuals involved
in providing health care are expected to use their judgment in determining what is in the best interests of the patient based on the circumstances existing at
the time. It is impossible to anticipate all possible situations that may exist and to prepare guidelines for each. Accordingly, these guidelines should guide
care with the understanding that departures from them may be required at times.

Department of Evidence Based Practice
Service and Performance Excellence
Date Finalized/Revised: 10/2018; 03/2020

129

Leukocytosis (>15,000 white blood cells [WBC]/mm3),
Greater than 15% immature neutrophils (bands) regardless of total peripheral white blood cell,
Leukopenia (4500 WBC/mm3) and
Hypoxemia (oxygen saturation <92% on room air)
• Females of reproductive age were required to have a negative urine pregnancy test and agree to remain abstinent or
use dual methods of birth control during treatment and at least 28 days after last study dose
Exclusion Criteria:
• Admission to intensive care unit during study
• Had an infection with a known or suspected ceftriaxone-resistant pathogen
• Infection at baseline with a sole atypical pathogen
• History of hypersensitivity or allergic reaction to β-lactam antimicrobial
• Patients at risk of MRSA infection (included at discretion of treating physician) or with a predominance of Grampositive cocci in clusters on sputum Gram stain
• Confirmed or suspected respiratory tract infection attributed to other sources than CAP pathogens
• Noninfectious causes or suspected sole viral, fungal, or M. tuberculosis causes of pulmonary infiltrates
• Chronic lung disease or neurologic disease that impaired the patient's airway clearance
• Received >24 hours of systemic antibacterial therapy for CABP within 96 hours prior to randomization
• Pregnancy
Power Analysis: Power analysis not completed.






Interventions

•

•
•
Outcomes

Group 1: Ceftaroline fosamil for a minimum of 72 hours or three study days. Dosage: infused over 60 (± 10)
minutes every 8 hour (± 1 hour). Dosages per age follow:
o Less than or equal to 6 months: 8 mg/kg;
o Greater than 6 months and ≤ 33 kg: 12 mg/kg;
o Greater than 6 months and ≥ 33 kg: 400 mg
Group 2: Ceftriaxone 75 mg/kg/day (maximum dose 4 g/day), infused equally in divided doses over 30 (± 10)
minutes every 12 hr.
Both groups: Patients could be switched on study day four to receive oral amoxicillin/clavulanate (up to 90
mg/kg/day divided in two doses)

Primary outcome(s):
• Clinical response at:
o Study day 4, end-of-IV treatment (EOIV) defined as within 24 hours after administration of the last dose of
IV study drug and before the switch to oral amoxymicillin/clavulanate.
o End-of-treatment visit (EOT) defined as within 24 hours after the last dose of oral study drug.
o Test-of-cure visit (TOC) occurred between eight and 15 days after the final dose of study drug.
o Late-follow up visit (LFU) was performed between 21 and 35 days after the last dose of study drug.
• Clinical stability at Study Day 4. Defined as the patient having was defined as having improvement in at least two of
seven symptoms (cough, dyspnea, chest pain, sputum production, chills or rigors, feeling of warmth/feverish and
exercise intolerance or lethargy) and no worsening of any of these symptoms. (Patients had to have a minimum of
two symptoms evaluated at baseline and Study Day 4).
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•
•

•

•

•

Non-responder was defined as a patient who did not have a clinical response or died between baseline and Study Day
4
Clinical outcome at EOIV (clinical cure: defined as resolution of all acute signs and symptoms; clinical improvement:
afebrile for at least 24 hours and no new symptoms with improvement in at least one symptom from baseline and
worsening of none; clinical failure: defined as discontinuation of study drug due to insufficient therapeutic effect
requiring alternative nonstudy antimicrobial therapy, discontinuation of study drug due to an AE and requiring an
alternative nonstudy antimicrobial therapy, or death in which CABP was contributory).
Clinical outcome at EOT (clinical cure: defined as resolution of all acute signs and symptoms of CABP or improvement
of signs and symptoms to an extent that no further antimicrobial therapy was required; clinical improvement: was
not defined for this time frame; clinical failure: defined as a child who has improved but the investigator wished to
continue to provide antibiotic therapy beyond that specified in the protocol or a discontinuation of study drug due to
insufficient therapeutic effect, requiring alternative nonstudy antimicrobial therapy or discontinuation of study drug
due to an AE, requiring an alternative nonstudy antimicrobial therapy, or death in which CABP was contributory.
Clinical outcome at TOC (clinical cure definition is the same as EOT outcome; clinical improvement: was not defined
for this time frame; clinical failure: defined as discontinuation of study drug due to insufficient therapeutic effect,
requiring alternative non-study antimicrobial therapy, or death in which CABP was contributory clinical cure or clinical
failure.
Safety outcomes involved assessment of treatment-emergent adverse events beginning with signing of informed
consent to 30 days after the last dose of the study drug

Risk of bias table
Bias

Scholars’
judgment

Support for judgment

Random sequence generation
(selection bias)

Unclear risk Article states that participants were randomized but does not state how. Participants were randomized in 3:1
(intervention: control) ratio.

Allocation concealment
(selection bias)

Unclear risk

Blinding of participants and
personnel (performance bias)

Low risk

Blinding of outcome
assessment (detection bias)

Low risk

Incomplete outcome data
(attrition bias)

High risk

Selective reporting (reporting
bias)

High risk

Other bias

The authors do not specify if or how allocation concealment was addressed.
It is not explicitly stated if participants and/or personnel were blinded to the allocation. However, the
outcomes measured were objective, leading the review authors to judge that the outcome is not likely to be
influenced by lack of blinding.
The investigators that assessed the clinical outcomes were blinded.
The authors analyzed the data using a modified intent-to-treat population not an actual intent-to-treat.
Reported demographics and outcomes inconsistent based on which group they are reporting on (safety group
or modified intent to treat group). For example, tolerability results reported for safety group, but clinical
outcomes reported for the modified intent-to-treat group.

Unclear risk
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Greenberg et al., 2014
Methods
Participants

single-center, randomized, double-blind, 1:1 placebo-controlled study
Setting: Soroka University Medical Center (SUMC) Pediatric Emergency Room in Beer-Sheva, Israel.
Randomized into study: N = 115
• Group 1: Oral Amoxicillin (10-day course of amoxicillin) n = 59
• Group 2: Oral Amoxicillin + Placebo Powder (5-day course of amoxicillin followed by 5-day course of placebo
powder) n = 56
Completed Study: n = 91
• Group 1: Oral Amoxicillin n = 49
• Group 2: Oral Amoxicillin + Placebo Powder n = 42
Gender, males:
• Group 1: Oral Amoxicillin n = 35 (59.3%)
• Group 2: Oral Amoxicillin + Placebo Powder n = 32 (57.1%)
Age, months (mean + SD):
• Group 1: Oral Amoxicillin 27.9 + 15.5
• Group 2: Oral Amoxicillin + Placebo Powder 27.5 + 14.4
Inclusion Criteria:
• Age 6-59 months
• Alveolar pneumonia based on chest radiography
• Disease symptoms began < 7 days prior to presentation
• Temperature ≥ 38.5°C
• WBC ≥ 15,000/mm3
• Community-acquired disease
• Patient judged to be manageable as outpatient
• Informed consent obtained from parents or legal guardian
Exclusion Criteria:
• Antimicrobial drug received within ≤14 days
• Need of parenteral treatment (ie, impaired perfusion, hypotension, oliguria, lactic acidosis, impaired consciousness,
presence of pleural effusion, vomiting)
• Oxygen saturation < 94%
• Known impaired immunity
• > 2 pneumonia episodes in last year
• Chronic illness (i.e., cystic fibrosis or cerebral palsy) potentially influencing current illness
• Presence of an additional infection necessitating a longer or different antibiotic treatment
• Unavailability for follow up
• Known β-lactam hypersensitivity
• Known allergy to soy milk
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Power Analysis:
• The probability of cure was assumed to be 95% with an α value of 0.05 and a power of 80%. The noninferiority
margin was 10% and the test was 2 sided. Using these parameters, the calculated sample size of 59 in each group.
After achieving > 40 evaluable patients in both groups (5-day and 10-day arms with no failures), the sample size
needed was recalculated against the probability of success of 99%, 98%, or 97%. This recalculation led to a
respective sample size of 12 subjects (3-day), 14 subjects (5-day), and 36 subjects (10-day).
Interventions

•

•

Outcomes

Intervention arms:
o Group 1: Received oral amoxicillin (80mg/kg/day divided to 3 doses) for 10 days (30 total doses).
o Group 2: Received oral amoxicillin (80mg/kg/day divided to 3 doses) for 5 days (15 total doses) then
Placebo powder (Vitamed, Binyamina, Israel) reconstituted with soy milk for 5 days (15 total doses)
Both arms:
o Each participant received 1 kit each including 2 packages at enrollment.
o All participants received amoxicillin for 5 days in their first package (15 doses).
o On the sixth day, all participants opened their second package which either contained:
 amoxicillin for an additional 5 days to complete a 10-day treatment (30 doses altogether) or
 placebo powder.
o To minimize the chance of distinguishing between amoxicillin and the placebo powder in the second package,
the amoxicillin used in the second package looked different than that used in the first package. The first
package contained Moxypen powder syrup (Teva Pharmaceutical Industry, Israel) whereas the second
package contained either Moxyvit suspension (Vitamed, Bynyamina, Israel) or placebo powder.
o Compliance measured by:
 Parents were asked daily about the number of administered doses
 Returned empty bottles were counted
o Evaluation occurred via daily phone calls for the first 14 days and at the end of the study on day 30-35
o Patients evaluated by study physician on days 5-7 and 10-14 who:
 Performed a physical exam
 Obtained a blood sample for WBC count, absolute neutrophil count (ANC) and CRP concentration
determination

Primary outcome:
• Absence of treatment failure within 30 days
Secondary outcome(s)
• Clinical parameters such as:
o Temperature
o Difficult breathing
o Restlessness
o Coughing
o Loss of appetite
o Sleep disturbances
• Laboratory Values (WBC and CRP)
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Notes

*Patients diagnosed with asthma were not considered as meeting exclusion criteria
Stage 1: Compared 3- to 10- day arms. Four patients had treatment failure between days 4 and 10 (all of these patients
were in the 3-day arm). Stage 1 was discontinued and replaced with Stage 2.
Stage 2: Compared 5-day to 10-day treatment regimens.

Risk of bias table
Bias

Scholars’
judgement

Support for judgement

Random sequence generation
(selection bias)

Low risk

The random allocation sequence was done with a computerized random-number generator by the
epidemiologist (N.L.G.). The block length was 10 and the code was known only to the epidemiologist.

Allocation concealment
(selection bias)

Low risk

The allocation numbers were random 4 digit numbers which were in nonconsecutive order in the allocation
list. The epidemiologist handled the allocation list to the pharmacist who concealed the allocation by labeling
the identical opaque study drug containers with allocation numbers. Another allocation list without the
randomization code was given to the investigators. An unblinded research coordinator provided each patient
with the amount of study drug for the first 5 days (depending on the study stage).

Blinding of participants and
personnel (performance bias)

Low risk

Both parents and study researcher (excluding the person in charge of preparing the study drug) were
blinded to the content of the treatment kits

Blinding of outcome
assessment (detection bias)

Low risk

Incomplete outcome data
(attrition bias)

High risk

Study drugs were not handled by physician who collected data and assessed outcomes
The power analysis and sample size needed was changed from needing 59 subjects in each arm to 24
subjects in the 5-day arm and 36 subjects needed in the 10-day arm.

Selective reporting (reporting
bias)

Unclear risk

The study did not disclose data for all secondary outcomes. They only mentioned that the proportions were
similar between the two arms of the study

Other bias

Unclear risk

This study changed it's protocol from 3-day and 10-day amoxicillin courses to 5-day and 10-day amoxicillin
courses due to 3-day study treatment failure.

* These guidelines do not establish a standard of care to be followed in every case. It is recognized that each case is different, and those individuals involved
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ISCAP et al., 2004
Methods
Participants

Randomized, double-blind, placebo-controlled multicenter trial
Setting: Outpatient departments of seven referral hospitals in India from August 2000 to December 2002
Randomized into study: N = 2188
• Group 1: Three day treatment with amoxicillin (amox) n = 1095
• Group 2: Five day treatment with amox n = 1093
Completed Study: N = 2059
• Group 1: n = 1033
• Group 2: n = 1026
Gender, Males
• Group 1: 685 (62.6%)
• Group 2: 676 (61.8%)
Age, months (mean):
• Group 1: 17 (13.3)
• Group 2: 16.9 (13)
Inclusion Criteria:
• Aged 2-59 months
• Complaints of cough, rapid respirations or difficulty breathing
• Non-severe pneumonia
o respiratory rate >50 breaths per minute for ages 2-11 months or >40 for ages 12-59 months
Exclusion Criteria:
• Signs of severe pneumonia or disease
o cyanosis, convulsions, inability to drink, difficult to wake, severe malnutrition, stridor
o other conditions requiring antibiotic treatment
o clinically diagnoses with congenital heart disease, chronic systemic disorders, history of repeated
wheezing or asthma,
o Hospitalized in the previous two weeks
o Taken antibiotics in the past 2 days
o measles in the past month
o history of penicillin allergy
Power Analysis:
• Sample size calculated to test the equivalence hypothesis. Assuming a treatment failure rate of 12% with
five day treatment, the two treatments would be equivalent if the failure rate with the shorter course of
treatment was not more than 17% (that is, a difference of 5% or less). The study team was prepared to
allow this size of difference, because there are other benefits of short course treatment, including lower
cost and less frequent side effects. One planned interim analysis occurred after a third of participants had
been recruited. Using the O’ Brien-Fleming approach. The authors carried out interim analysis at a level of
0.005 and the final analysis at 0.047. One sided testing, with the power set at 90% for the study. The
required number of patients was 950 in each group.
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Interventions

Both Groups:
• Patients with fever or wheeze received symptomatic treatment before enrolment
• received tablets of amox 125mg dissolved in 5 ml of water, and the effective dose per kilogram body
weight for the first three days
• Amox given three times a day
• The next two days participants received amox or placebo
• participants were followed up at three and five days and then again between 12 and 14 days after
enrolment
• Home visits done within 24 hours for those who failed to report on appointed days
• Caregivers asked to categorize their child as completely well, improved but still sick, the same or worse at
each follow up visit
Group 1:
• 3 days amox treatment and 2 days placebo
Group 2:
• 5 days amox treatment

Outcomes

Primary Outcome:
• Treatment failure (development of chest indrawing, convulsions, drowsiness, or inability to drink at any
time, respiratory rate above age specific cut points on day three or later, or oxygen saturation <90% on
day 3.
Primary Objective: Compare the proportion of children recovering after 3 days' treatment and five days'
treatment
• Participants who did not fail on assessment days 3 or 5 were considered clinically cured
Secondary Objectives:
• Compare the proportion:
o who relapsed within the next 6-14 days
o had resistant strains of S pneumomiae of H influenzae in nasopharyngeal cultures at enrolment
and at 14 day follow up
o Direct medical costs of treating clinical failures and relapses
o assess the proportion of participants whose nasopharyngeal aspirates was positive for respiratory
Syncytial virus at enrolment

* These guidelines do not establish a standard of care to be followed in every case. It is recognized that each case is different, and those individuals involved
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Risk of bias table
Scholars’
judgement

Bias

Support for judgement

Random sequence generation (selection
bias)

Low risk

Allocation concealment (selection bias)

Low risk

For both treatment groups, tablets were placed in serially numbered opaque white envelopes,

Blinding of participants and personnel
(performance bias)

Low risk

The opaque white envelopes contained a green envelope containing 11 doses of amoxicillin for
three days and a blue envelope containing eight doses of either amoxicillin or placebo for the
next two days.

Blinding of outcome assessment
(detection bias)

Unclear risk

Incomplete outcome data (attrition
bias)

Low risk

Selective reporting (reporting bias)

Low risk

Other bias

Unclear risk

Block randomization, with variable sized blocks

Not stated
Intention to treat
All outcomes were reported
Did not state how the diagnosis of pneumonia was made (clinically, by x-ray, or labs), did they
really have pneumonia?

Lodha et al., 2013
Design
Objective
Methods

Quantitative Synthesis (meta-analysis)
•

To identify effective antibiotic drug therapies for community-acquired pneumonia (CAP) of varying severity in
children by comparing various antibiotics

Protocol and registration.
•
Protocol first published: Issue 3, 2004
•
Review first published: Issue 3, 2006
Eligibility Criteria.
•
Randomized controlled trials (RCTs) comparing at least two antibiotics for CAP in children, using the definition of
pneumonia (as given by WHO) or radiologically confirmed.
•
Children under 18 years of age with CAP treated in a hospital or ambulatory setting.
Information sources.
•
Cochrane Central Register of Controlled Trials (CENTRAL) 2012
•
MEDLINE (September 2009 to October week 4, 2012);
•
EMBASE (September 2009 to November 2012);
•
CINAHL (2009 to November 2012);
•
Web of Science (2009 to November 2012)
•
LILACS (2009 to November 2012).
•
Bibliographies of selected articles to identify any additional trials not recovered by the electronic searches.

* These guidelines do not establish a standard of care to be followed in every case. It is recognized that each case is different, and those individuals involved
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the time. It is impossible to anticipate all possible situations that may exist and to prepare guidelines for each. Accordingly, these guidelines should guide
care with the understanding that departures from them may be required at times.

Department of Evidence Based Practice
Service and Performance Excellence
Date Finalized/Revised: 10/2018; 03/2020

137

Search.
•
Studies retrieved through a search strategy which included cross-referencing.
Study Selection.
•
A person who was not involved in the review gave all relevant studies a serial number to mask the authors’ names
and institutions, the location of the study, reference lists and any other potential identifiers.
•
Two review authors independently selected potentially relevant studies based on their title and abstract.
•
Two review authors independently reviewed the results for inclusion in the analysis
•
Resolved differences about study quality through discussion.
Data collection process.
•
Retrieved the complete texts of these studies electronically or by contacting the trial authors.
•
Contacted trial authors for missing data .
•
RevMan.
•
For each of the outcome variables, we carried out an assessment of heterogeneity with Breslow’s test of
homogeneity using RevMan.
Risk of bias (RoB) across studies.
•
Assessed publication bias using The Cochrane Collaboration’s ’Risk of bias’ tool.
•
Sequence generation, allocation concealment, blinding of personnel and outcome assessors, incomplete data, and
selective outcome reporting: assessed as yes, no or unclear
•
Other sources of bias
Summary measures.
•
For each comparison, 2 x 2 tables were used
•
Calculated ORs and 95% CIs.
•
Random-effects model for all the comparison
Results

Study Selection.
Number of articles identified: N = 29
o Full-text articles assessed for eligibility: n = 9
o Studies included in quantitative synthesis: n = 9
Synthesis of results.
•
30 comparison forest plots
Risk of bias across studies.
•
In this review one study, (Awasthi 2008) one of the authors of the present review (Kabra) was a co-author.
•
Five out of 29 studies were double-blind and allocation concealment was adequate.
•
Another 12 studies were unblinded but had adequate allocation concealment, classifying them as good-quality
•
Data were fully detailed in 20 studies; selective reporting of data was unclear in 12 studies and 13 studies were
funded by WHO or universities.
•
There was more than one study comparing co-trimoxazole with amoxicillin, oral amoxicillin with injectable
penicillin/ampicillin and chloramphenicol with ampicillin/penicillin and studies were of good quality, suggesting the
evidence for these comparisons was of high quality compared to other comparisons.
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Bias

No. of studies
with high risk

No. of studies
with low risk

No. of studies
with unclear risk

Sequence generation

0

14

15

Allocation concealment

0

15

14

Blinding of personnel
and participants

23

4

2

Blinding of outcome
assessment

21

5

3

Selective reporting

0

20

9

Incomplete outcome
data

0

22

7

Other

0

9

20

Additional analysis.
N/A
Discussion

Summary of evidence.
•
•

•

In ambulatory settings, for treatment of World Health Organization (WHO) defined non-severe CAP, amoxicillin
compared with cotrimoxazole had similar failure rates, OR = 1.18, 95% CI [0.91, 1.51] and cure rates, OR = 1.03,
95% CI [0.56, 1.89]. Three studies involved 3952 children.
In children with severe pneumonia without hypoxemia, oral antibiotics (amoxicillin/co-trimoxazole) compared with
injectable penicillin had similar failure rates OR = 0.84, 95% CI [0.56, 1.24], hospitalization rates OR = 1.13, 95%
CI [0.38, 3.34] and relapse rates OR = 1.28, 95% CI [0.34, 4.82]. Six studies involved 4331 children below 18 years
of age.
In very severe CAP, death rates were higher in children receiving chloramphenicol compared to those receiving
penicillin/ampicillin plus gentamicin OR = 1.25, 95% CI [0.76, 2.07]. One study involved 1116 children.

Limitations.
•
A limited number of RCTs fulfilled the inclusion criteria.
•
Most of the antibiotic comparisons were available in single studies only.
•
Five studies met all the quality assessment criteria and for most comparisons of the efficacy of antibiotics, only one
or two studies were available.
* These guidelines do not establish a standard of care to be followed in every case. It is recognized that each case is different, and those individuals involved
in providing health care are expected to use their judgment in determining what is in the best interests of the patient based on the circumstances existing at
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Funding

•
•

Internal sources
•
All India Institute of Medical Sciences, New Delhi, India.
External sources
•
No sources of support supplied
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Characteristics of Studies
Blumer et al., 2016
Methods
Participants

RCT, multicenter, observer-blinded, active-controlled study
Setting: 11 study centers in Georgia, Ukraine, United States (Hospitals/Clinics in Ohio, Georgia, California) Jan 2013 - May
2014
Randomized into study: N = 38
• Group 1: Ceftaroline fosamil n = 29
• Group 2: Ceftriaxone plus Vacomycin n = 9
Completed study: N = 35
• Group 1: 26
• Group 2: 9
Gender, % males:
• Group 1: 72.4%
• Group 2: 55.6%
Age, years: median (range):
• Group 1: 4.0 (0.3-17.0)
• Group 2: 4.0 (0.3-16.0)
Inclusion Criteria:
• Patients age 2 mouths to 18 years with complicated community acquired bacterial pneumonia (cCABP)
• Patients requiring three days of initial hospitalization
• Diagnosis of CABP required:
1. Presence of fever (Temp > 38C) or hypothermia (Temp < 35C) AND
2. New pulmonary infiltrate compatible with bacterial pneumonia based on diagnostic testing AND
3. One of the following:
 Typical respiratory pathogen isolated from a respiratory or blood culture
 Leukocytosis (> 15,000 white blood cells/mm3, > 15% immature neutrophils regardless of total WBC
count)
 Leucopenia (< 4500 WBC/mm3)
 Hypoxemia (oxygen saturation < 92% on room air)
• The patient had to have at least one of the following indicators to distinguish cCABP from CABP:
1. Empyema
2. Pulmonary abscess
3. Necrotizing pneumonia
4. Pneumatocele
5. Pleural effusion needing chest tube drainage
6. Gram-positive cocci in clusters on Gram stain from a respiratory specimen
7. Requirement for positive pressure-assisted ventilation

* These guidelines do not establish a standard of care to be followed in every case. It is recognized that each case is different, and those individuals involved
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8. Previous influenza like illness (within 28 days before enrolment)
9. Treatment in an intensive care unit.
• In addition, the participant had to have at least two of the following to distinguish cCABP from CABP that occurred or
worsened within the previous 5 days:
1. Cough
2. Tachypnea
3. Dyspnea
4. Grunting
5. Sputum production
6. Chest pain
7. Cyanosis
8. Evidence of pneumonia with parenchymal consolidation
9. Increased work of breathing (WOB)
Exclusion Criteria:
• History of hypersensitivity or allergic reaction to vancomycin or any ß-lactam antibiotic
• Confirmed or suspected infection caused by a pathogen resistant to any of the IV study drugs
• Infection caused by a sole atypical organism at baseline
• Infection caused by bacteria other than CABP pathogens, such as organisms associated with ventilator-associated or
hospital acquired pneumonia
• Non-infectious pulmonary infiltrations on chest radiography
• Pt had received more than 24 hours of any systemic antimicrobial therapy for CABP within 96 hours of randomization
(with the exception of patients who were considered to have failed prior treatment),
• Moderate or severe renal insufficiency
• Patient history of seizure
• Suspected bacterial meningitis
• Elevated AST, ALT, bilirubin labs
• Neutropenia
• Thrombocytopenia
• Patients with HIV and a CD4 count < 250cells/mm3 or history of another immune deficiency syndrome
Power Analysis: Did not occur due to small size of study population
Interventions

Group 1:
• < 6 months old: 10mg/kg infused over 120 (+/- 10) minutes every 8 (+/-1) hours
• > 6 months old: IV ceftaroline fosamil infused over 120 (+/- 10) minutes every 8 (+/-1) hours at a dose of 15mg/kg
(or 600 mg if weight > 40 kg)
Group 2*:
• IV Ceftriaxone: 75 mg/kg/day (up to 4 g/day), divided into two doses, 12 (+/-2) hours apart and infused over 30
(+/- 10) minutes
• IV vancomycin: 15 mg/kg every 6 (+/- 1) hours infused over > 60 minutes (or at a maximum of 10mg/min,
whichever was longer)

* These guidelines do not establish a standard of care to be followed in every case. It is recognized that each case is different, and those individuals involved
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*NOTE for Group 2: Vancomycin could be discontinued on or after day 4 if MRSA or penicillin-resistant or intermediate S
pneumoniae was not confirmed.
Switching from IV to oral antibiotics on or after day 4 for both groups:
A switch from IV study drug to open-label oral study drug (amoxicillin clavulanate, clindamycin, or linezolid) was allowed on
or after study day 4 at the discretion of the investigator if the patient met the following criteria:
• Received > 72 hours of IV study drug therapy
• Had their clinical s/s assessed on Study Day 4
• Were able to maintain oral intake
• Afebrile (< 38º C) for > 24 hours
• Oxygen saturation > 92% on RA
• WBC WNL for age or > 20% improvement from baseline
• Absence or improvement of cough, dyspnea, sputum production or chest pain
Group 1:
• 22/30 patients switched to oral antibiotics on or after day 4 (it is unclear which of these patients were cCABP vs
CABP)
• Patients were switched to the following oral antibiotics: clindamycin (13/30 patients [59%]), amoxicillin clavulanate
(8/30 [36%]) or linezolid (2/30 [9%])
Group 2:
• All patients switched to oral antibiotics on or after day 4
• Patients were switched to the following oral antibiotics: clindamycin (6/10 [60%]) or amoxicillin clavulanate (4/10
[40%]).
Both groups: combined IV plus oral drug or IV study drug was required for 5–21 days
Outcomes

1.

2.

3.

Clinical response and stability at study day 4:
1. Clinical response at study day 4, defined as improvement in at least 2 and worsening of none of the following
symptoms: cough, dyspnea, chest pain, sputum production, chills or rigors, feeling feverish and exercise
intolerance or lethargy.
2. Clinical stability at study day 4, defined as: afebrile (< 38º C) for > 24 hours; normal, age appropriate pulse
and respiratory rates, oxygen saturation > 92% on RA, and no worsening of clinical response symptoms
Clinical cure at end of therapy (EOT) and test of cure (TOC)
1. Clinical cure at EOT and TOC defined as resolution of all acute signs and symptoms of CABP or no further
antimicrobial therapy was required
2. Clinical failure at the EOT visit defined as continuation of study drug beyond the 21 days of therapy,
discontinuation of study drug due to insufficient therapeutic effect or adverse effect and requirement for
alternative non-study antimicrobial therapy for CABP, or death in which CABP was identified as a contributing
factor.
3. Clinical failure at TOC visit defined as incomplete resolution or worsening of CABP signs or symptoms or the
development of new signs or symptoms requiring alternative non-study antimicrobial therapy or death in
which CABP was identified as a contributing factor.
Adverse events

* These guidelines do not establish a standard of care to be followed in every case. It is recognized that each case is different, and those individuals involved
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Notes

Funding: Cerexa, Inc, a wholly owned subsidiary of Forest Laboratories
Prior antibiotic use (within 72 hours of study): 18/29 patients (62%) in Group 1 and 5/9 patients (56%) in Group 2
received prior antibiotics within 96 hours of the first dose of IV study drug.
The most commonly administered prior antibiotics in Group 1 were ceftriaxone (7/29 patients [24%]) and vancomycin and
azithromycin (both 5/29 patients [17%]), and in Group 2 were ceftriaxone and clindamycin (both 3/9 patients [33%]) and
cefotaxime (2/9 patients [22%]).
Adverse Events data is based on the total patient population of 40. Data for Adverse Events is included in a separate table,
below.

Risk of Bias table
Bias

Scholar’s
judgment

Random sequence
generation (selection bias)

Unclear risk

Support for judgment
No mention of how sequence was generated

Allocation concealment
(selection bias)

Low risk

Block randomization using an interactive voice response system was used to assign patients 3:1 to a
study group

Blinding of participants
and personnel
(performance bias)

Low risk

The study was observer blinded. Each hospital had at least one blinded investigator who conducted clinical
assessments

Blinding of outcome
assessment (detection
bias)

High risk

No mention that outcome assessments were blinded

Incomplete outcome data
(attrition bias)

Low risk

Data is given for all 38 patients with cCABP

Selective reporting
(reporting bias)

Low risk

Study's outcomes are given, data for all study outcomes are included

Other bias

Unclear risk

* These guidelines do not establish a standard of care to be followed in every case. It is recognized that each case is different, and those individuals involved
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Cannavino et al., 2016
Methods
Participants

Randomized, multi-center, prospective controlled trial
Setting: 34 study centers in 8 countries (Poland, Spain, United States, Bulgaria, Georgia, Greece, Hungary, and Ukraine)
Randomized into study: N = 161
• Group 1: Ceftaroline n = 122
• Group 2: Ceftriaxone n = 39
Completed Study (Modified Intent-to-Treat): N = 143
• Group 1: n = 107
• Group 2: n = 36
Gender, males:
• Group 1: n = 64 (52.9%)
• Group 2: n = 20 (51.3%)
Age, months/years (median):
Group 1:
• 12-<18 year: 8 (6.6%)
• 6-<12 year: 26 (21.5%)
• 2-<6 year: 64 (52.9%)
• 2 months-<2yr: 23 (19.0%)
Group 2:
• 12-<18 year: 2 (5.1%)
• 6-<12 year: 9 (23.1%)
• 2-<6 year: 21 (53.8%)
• 2 months-<2 year: 7 (17.9%)
Inclusion Criteria:
• Patients ages 2 months-18 years with community-acquired bacterial pneumonia (CABP) requiring hospitalization and
IV antibacterial therapy
• Must meet CABP definition:
o All children were required to have:
 Fever (temperature >38°C) or hypothermia (temperature <35°C)
 The presence of new infiltrate(s) consistent with bacterial pneumonia, including a new alveolar/lobar
infiltrate or consolidation (based on imaging results)
 Acute onset or worsening within the previous five days of at least two of the following nine clinical
signs and symptoms: cough, tachypnea, dyspnea, grunting, sputum production, chest pain, cyanosis,
evidence of pneumonia with parenchymal consolidation and increased work of breathing.
o Participants needed to have at least one of the five following laboratory findings:
 Bacterial organism consistent with a typical respiratory pathogen identified or isolated from a
respiratory (sputum and pleural fluid) or blood culture,
 Leukocytosis (>15,000 white blood cells [WBC]/mm3),
 Greater than 15% immature neutrophils (bands) regardless of total peripheral white blood cell,

* These guidelines do not establish a standard of care to be followed in every case. It is recognized that each case is different, and those individuals involved
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Leukopenia (4500 WBC/mm3) and
Hypoxemia (oxygen saturation <92% on room air)
• Females of reproductive age were required to have a negative urine pregnancy test and agree to remain abstinent or
use dual methods of birth control during treatment and at least 28 days after last study dose
Exclusion Criteria:
• Admission to intensive care unit during study
• Had an infection with a known or suspected ceftriaxone-resistant pathogen
• Infection at baseline with a sole atypical pathogen
• History of hypersensitivity or allergic reaction to β-lactam antimicrobial
• Patients at risk of MRSA infection (included at discretion of treating physician) or with a predominance of Grampositive cocci in clusters on sputum Gram stain
• Confirmed or suspected respiratory tract infection attributed to other sources than CAP pathogens
• Noninfectious causes or suspected sole viral, fungal, or M. tuberculosis causes of pulmonary infiltrates
• Chronic lung disease or neurologic disease that impaired the patient's airway clearance
• Received >24 hours of systemic antibacterial therapy for CABP within 96 hours prior to randomization
• Pregnancy
Power Analysis: Power analysis not completed.




Interventions

•

•
•
Outcomes

Group 1: Ceftaroline fosamil for a minimum of 72 hours or three study days. Dosage: infused over 60 (± 10)
minutes every 8 hours (± 1 hour). Dosages per age follow:
o Less than or equal to 6 months: 8 mg/kg;
o Greater than 6 months and ≤ 33 kg: 12 mg/kg;
o Greater than 6 months and ≥ 33 kg: 400 mg
Group 2: Ceftriaxone 75 mg/kg/day (maximum dose 4 g/day), infused equally in divided doses over 30 (± 10)
minutes every 12 hr.
Both groups: Patients could be switched on study day four to receive oral amoxicillin/clavulanate (up to 90
mg/kg/day divided in two doses)

Primary outcome(s):
• Clinical response at:
o Study day 4, end-of-intravenous treatment (EOIV) defined as within 24 hours after administration of the last
dose of IV study drug and before the switch to oral amoxymicillin/clavulanate.
o End-of-treatment visit (EOT) defined as within 24 hours after the last dose of oral study drug.
o Test-of-cure visit (TOC) occurred between eight and 15 days after the final dose of study drug.
o Late-follow up visit (LFU) was performed between 21 and 35 days after the last dose of study drug.
• Clinical stability at Study Day 4. Defined as the patient having improvement in at least two of seven symptoms
(cough, dyspnea, chest pain, sputum production, chills or rigors, feeling of warmth/feverish and exercise intolerance
or lethargy) and no worsening of any of these symptoms. (Patients had to have a minimum of two symptoms
evaluated at baseline and Study Day 4).
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•
•

•

•

•

Non-responder was defined as a patient who did not have a clinical response or died between baseline and Study Day
4
Clinical outcome at EOIV (clinical cure: defined as resolution of all acute signs and symptoms; clinical improvement:
afebrile for at least 24 hours and no new symptoms with improvement in at least one symptom from baseline and
worsening of none; clinical failure: defined as discontinuation of study drug due to insufficient therapeutic effect
requiring alternative nonstudy antimicrobial therapy, discontinuation of study drug due to an AE and requiring an
alternative nonstudy antimicrobial therapy, or death in which CABP was contributory).
Clinical outcome at EOT (clinical cure: defined as resolution of all acute signs and symptoms of CABP or improvement
of signs and symptoms to an extent that no further antimicrobial therapy was required; clinical improvement: was
not defined for this time frame; clinical failure: defined as a child who has improved but the investigator wished to
continue to provide antibiotic therapy beyond that specified in the protocol or a discontinuation of study drug due to
insufficient therapeutic effect, requiring alternative nonstudy antimicrobial therapy or discontinuation of study drug
due to an AE, requiring an alternative nonstudy antimicrobial therapy, or death in which CABP was contributory.
Clinical outcome at TOC (clinical cure definition is the same as EOT outcome; clinical improvement: was not defined
for this time frame; clinical failure: defined as discontinuation of study drug due to insufficient therapeutic effect,
requiring alternative non-study antimicrobial therapy, or death in which CABP was contributory clinical cure or clinical
failure.
Safety outcomes involved assessment of treatment-emergent adverse events beginning with signing of informed
consent to 30 days after the last dose of the study drug

Risk of Bias table
Bias

Scholars’
judgment

Support for judgment

Random sequence
generation (selection bias)

Unclear risk

Article states that participants were randomized but does not state how. Participants were randomized in 3:1
(intervention: control) ratio.

Allocation concealment
(selection bias)

Unclear risk The authors do not specify if or how allocation concealment was addressed.

Blinding of participants and
personnel (performance
bias)

Low risk

It is not explicitly stated if participants and/or personnel were blinded to the allocation. However, the
outcomes measured were objective, leading the review authors to judge that the outcome is not likely to be
influenced by lack of blinding.

Blinding of outcome
assessment (detection
bias)

Low risk

The investigators that assessed the clinical outcomes were blinded.
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Incomplete outcome data
(attrition bias)

High risk

The authors analyzed the data using a modified intent-to-treat population not an actual intent-to-treat.

Selective reporting
(reporting bias)

High risk

Reported demographics and outcomes inconsistent based on which group they are reporting on (safety group
or modified intent to treat group). For example, tolerability results reported for safety group, but clinical
outcomes reported for the modified intent-to-treat group.

Other bias

Unclear risk
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Lassi, et al., 2014
Design

Quantitative Synthesis (meta-analysis)

Objective

Meta-analysis of RCTs conducted in low and middle income countries (LMICs) to determine the most suitable antibiotic
therapy for treating community acquired pneumonia (very severe, severe and non-severe).

Methods

Inclusion Criteria:
•
Pediatric patients between 2 and 59 months of age
•
Respiratory illness with a clinical diagnosis of community acquired pneumonia
•
Pneumonia classified as: non-severe, severe, very severe
Exclusion Criteria:
•
Method of diagnosis not disclosed
•
Adult patient population
Information sources: Medline, Cochrane Library, PubMed, Google Scholar on March 15th, 2013. English articles only.
Search:
•
Search terms (or combination of); ((‘Pneumonia’ OR ‘very severe pneumonia’ OR ‘severe pneumonia’ OR ‘non-severe
pneumonia’ OR ‘acute respiratory illness’ OR ‘Community acquired pneumonia’) AND (‘child*’ OR ‘infant’ OR
‘preschool*’ OR ‘schoolchild’ OR ‘school age’ OR ‘preschool’ OR ‘kid*’ OR ‘toddler*’) AND (‘treatment’ OR ‘antiinfective agent’ OR ‘anti-bacterial agents’ OR ‘antibitoic’ OR ‘management’)).
Study Selection:
•
Studies that examined a single drug or combination
•
Different drug dose
•
Duration and route of same drug
•
Analysis of clinical cure rate
•
Treatment failure
•
Relapse rate
•
Change in antibiotic therapy
•
Death
Data collection process:
•
All data was entered and analyzed using Review Manager 5 software.
Risk of bias (RoB) across studies:
•
Cochrane methods for risk of bias assessment to assess the quality of included studies.
Summary measures:
•
Risk ratio was utilized.
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Results

Study Selection:
Number of articles identified: N = 8122
a. Full-text articles assessed for eligibility: n = 83
b. Studies included in qualitative synthesis: n = 42
Synthesis of results:
•
3 studies included for very severe pneumonia
•
Failure rate with ampicillin and gentamicin vs chloramphenicol
•
Penicillin plus gentamicin vs chloramphenicol
•
Penicillin and gentamicin vs amoxicillin-clavulanic acid
•
6 studies included for severe pneumonia
•
Chloramphenicol plus penicillin vs ceftriaxone
•
Co-trimoxazole vs amoxicillin
•
Parenteral penicillin vs oral amoxicillin
•
Ampicillin (intravenous) plus oral amoxicillin vs oral amoxicillin
•
Parenteral benzyl penicillin vs oral amoxicillin
•
Oral co-trimoxazole vs intramuscular procaine penicillin
•
Penicillin or cefuroxime
•
13 studies included for non-severe pneumonia
•
oral co-trimoxazole vs oral amoxicillin
•
oral levofloxacin vs oral co-amoxiclavulanic acid
•
oral azithromycin vs oral co-amoxiclavulanic acid
•
amoxicillin vs co-amoxiclavulanic acid
•
parenteral ampicillin vs penicillin plus chloramphenicol
Risk of bias across studies:
•
Out of the 22 included studies, 20 were free of selective reporting, 12 were double-blinded, and 14 had adequate
allocation concealment. Five studies included for very severe and severe pneumonia were free of other bias, while
four studies in non-severe pneumonia mentioned their source of funding.

Discussion

Summary of evidence. See study for full results.
Limitations. Duplicate studies, articles in foreign languages with non-English abstracts, studies which did not include any
acute respiratory illness.

Funding

For this meta-analysis, no source of funding was disclosed. However, as noted above, four studies in non-severe pneumonia
category mentioned their source of funding.
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Lodha et al., 2016
Design
Objective

Quantitative Synthesis (Systematic Review)
To determine the efficacy of oral antibiotics in treatment of severe pneumonia in children under the age of 5 years.
Primary Outcome: Treatment failure rates, relapse rates

Methods

Protocol and registration.
Eligibility Criteria.
•
Severe pneumonia was defined as cough or difficulty breathing for less than two weeks; rapid breathing (respiratory
rate >50 breaths/min in children 2 months-11 months, or >40 breaths/min in children 12 months to 59 months of
age); and lower chest-indrawing.
Inclusion criteria.
•
Randomized controlled trial or quasi randomized study design
•
Studies comparing the efficacy of oral antibiotics with parenteral antibiotics for treatment of community acquired
pneumonia (CAP) with chest-indrawing
•
Studies in patients less than 60 months of age
•
Studies with at least one arm including oral antibiotics in a hospital or community-based setting
Exclusion criteria.
•
Studies on children with chronic pulmonary disease, immunodeficiency disorders, neurological disorders affecting
lung function, and cardiac disorders
Information sources.
Search.
•
Cochrane Central register of Controlled Trials, MEDLINE (1966-2015), EMBASE (1980-April 2015), bibliographies
of selected articles
Study Selection.
•
Abstracts of identified articles were reviewed by two independent readers and selected based on relevance.
Data collection process.
•
A scientist separate from the data extraction concealed the study identifiers and assigned serial numbers to the
studies.
•
The two independent authors extracted data in a pretested Performa, and data discrepancies were resolved by
discussion with a third author.
Risk of bias (RoB) across studies.
The number of included studies (n = 4) was too low to complete a funnel plot to assess for publication bias. Two authors
used the Cochrane Collaboration’s “Risk of bias” tool.
Summary measures.
•
Treatment failure
•
Relapse rates
•
Hospitalization
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•
•
•

Death rates
Serious adverse events
Quality assessment

Synthesis of results.
•
RevMan (ver. 5.2) was used for data management and analyses.
•
Heterogeneity was assessed using RevMan, and it was considered significant if I2 value was greater than 30%.
•
Random effects model was used for all analyses.
Results

Study Selection.
Number of articles identified: N = 1979
Full-text articles assessed for eligibility: n = 12
o Studies included in qualitative synthesis: n = 4
Synthesis of results.
•
Three of four studies used amoxicillin as the oral antibiotic and penicillin/ampicillin as the parenteral antibiotics. One
study used co-trimoxazole as the oral antibiotic.
•
One study was multi-country, conducted in Colombia, Ghana, India, Mexico, Pakistan, South Africa (two sites),
Vietnam, and Zambia. The other three studies were conducted in Pakistan, Gambia, and Kenya, respectively.
•
Three studies were conducted in a hospital or partially in the hospital; one was completed entirely in the ambulatory
setting.
•
Treatment failure: Treatment failure rate for children receiving oral antibiotics was 13%; failure rate for
parenteral antibiotics was 13.8% (OR = .93, 95% CI [.78,1.11]).
Fig. 2
Study
Addo-Yobo
et al.,
2004
Agveyu et
al., 2015
Campbell
et al.,
1988
Hazir et
al., 2008
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•
•

•

Total
287
300
events
Death rates: 5/2208 (0.2%) of children in the oral group and 15/1925 (0.8%) children in the parental group died.
Serious adverse events (SAE): One of the studies reported SAE. SAE was noted in 30 children, eight in the
amoxicillin group and 22 in the penicillin group. Thirteen SAE cases were attributed to the study drug, and
treatment was changed or discontinued in 12 of 13 cases. None of the deaths were associated with the study drug.
The SAE events and number of children affected follow:
o Death: 12
o Rash: 5
o Diarrhea: 5
o Allergy to penicillin: 2
o Anemia and malaria: 1
o Severe malaria: 3
o Unspecified event: 2
Quality assessment: The authors determined the quality of evidence was “High Quality” using the GRADE
framework.

Risk of bias across studies.
•
Three studies were determined to be good quality, but they were not blinded. The authors determined the cotrimoxazole vs parenteral antibiotic did not adequately discuss sequence generation or allocation concealment.
Discussion

Funding

Summary of evidence.
•
The authors determined that there is no significant difference in failure and relapse rates of severe pneumonia for
oral and parenteral antibiotic treatment in children under the age of 5 years.
•
Treatment outcomes were not affected by treatment setting (community versus hospital setting).
•
Relapse rates and SAE were similar in both oral and parenteral antibiotic groups.
Limitations.
•
The authors state that one limitation of the review is the included articles were based on a clinical diagnosis of
pneumonia. Another limitation small sample of articles included; however the overall population included across the
four studies was 4400 study participants. None of the articles included were blinded studies.
Funding.
World Health Organization
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Lodha et al., 2013
Design
Objective
Methods

Quantitative Synthesis (meta-analysis)
•

To identify effective antibiotic drug therapies for CAP of varying severity in children by comparing various antibiotics

Protocol and registration.
•
Protocol first published: Issue 3, 2004
•
Review first published: Issue 3, 2006
Eligibility Criteria.
•
RCTs comparing at least two antibiotics for CAP in children, using the definition of pneumonia (as given by WHO) or
radiologically confirmed.
•
Children under 18 years of age with CAP treated in a hospital or ambulatory setting.
Information sources.
•
Cochrane Central Register of Controlled Trials (CENTRAL) 2012
•
MEDLINE (September 2009 to October week 4, 2012);
•
EMBASE (September 2009 to November 2012);
•
CINAHL (2009 to November 2012);
•
Web of Science (2009 to November 2012)
•
LILACS (2009 to November 2012).
•
Bibliographies of selected articles to identify any additional trials not recovered by the electronic searches.
Search.
•
Studies retrieved through a search strategy which included cross-referencing.
Study Selection.
•
A person who was not involved in the review gave all relevant studies a serial number to mask the authors’ names
and institutions, the location of the study, reference lists and any other potential identifiers.
•
Two review authors independently selected potentially relevant studies based on their title and abstract.
•
Two review authors independently reviewed the results for inclusion in the analysis.
•
Resolved differences about study quality through discussion.
Data collection process.
•
Retrieved the complete texts of these studies electronically or by contacting the trial authors.
•
Contacted trial authors for missing data.
•
RevMan.
•
For each of the outcome variables, assessment of heterogeneity with Breslow’s test of homogeneity using RevMan.
Risk of bias (RoB) across studies.
•
Assessed publication bias using The Cochrane Collaboration’s ’Risk of bias’ tool.
•
Sequence generation, allocation concealment, blinding of personnel and outcome assessors, incomplete data, and
selective outcome reporting: assessed as yes, no or unclear
•
Other sources of bias
Summary measures.
•
For each comparison, 2 x 2 tables were used
•
Calculated ORs and 95% CIs.
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•
Results

Discussion

Random-effects model for all the comparisons

Study Selection.
Number of articles identified: N = 29
o Full-text articles assessed for eligibility: n = 9
o Studies included in quantitative synthesis: n = 9
Synthesis of results.
•
30 comparison forest plots
Risk of bias across studies.

Bias

No. of studies
with high risk

No. of studies
with low risk

No. of studies
with unclear risk

Sequence generation

0

14

15

Allocation concealment

0

15

14

Blinding of personnel
and participants

23

4

2

Blinding of outcome
assessment

21

5

3

Selective reporting

0

20

9

Incomplete outcome
data

0

22

7

Other

0

9

20

Summary of evidence.
•
•

•

In ambulatory settings, for treatment of WHO defined non-severe CAP, amoxicillin compared with cotrimoxazole had
similar failure rates, OR = 1.18, 95% CI [0.91, 1.51] and cure rates, OR = 1.03, 95% CI [0.56, 1.89]. Three studies
involved 3952 children.
In children with severe pneumonia without hypoxemia, oral antibiotics (amoxicillin/co-trimoxazole) compared with
injectable penicillin had similar failure rates OR = 0.84, 95% CI [0.56, 1.24], hospitalization rates OR = 1.13, 95%
CI [0.38, 3.34] and failure rates OR = 1.28, 95% CI [0.34, 4.82]. Six studies involved 4331 children below 18 years
of age.
In very severe CAP, death rates were higher in children receiving chloramphenicol compared to those receiving
penicillin/ampicillin plus gentamicin OR = 1.25, 95% CI [0.76, 2.07]. One study involved 1116 children.
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Limitations.
•
A limited number of RCTs fulfilled the inclusion criteria.
•
Most of the antibiotic comparisons were available in single studies only.
•
Five studies met all the quality assessment criteria. For most comparisons of the efficacy of antibiotics, only one or
two studies were available.
Funding

•
•

Internal sources
•
All India Institute of Medical Sciences, New Delhi, India.
External sources
•
No sources of support supplied

Shah et al., 2016
Methods
Participants

Multicenter retrospective cohort study
Participants: Children > 2 months and <18 years discharged with complicated pneumonia.
Setting: Pediatric hospitals (Information obtained from Pediatric Health Information System (PHIS)
Number enrolled into study: N = 2123
• Oral antibiotics: n = 1842
• Parenteral antibiotics: n = 281
Number completed: N = 2123
Gender, males: Not available
Age, <5 y:
• Oral antibiotics: 61.1%
• PICC: 61.6%
Inclusion criteria:
• Children > 2 years of age and <18 years of age on the date of admission
• Children who were discharged between January 1, 2009 and December 31, 2012
• Had an International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM) discharge diagnosis
code for both pneumonia and pleural effusion where the primary ICD-9-CM code was either pneumonia or pleural
effusion.
*If a child had multiple hospitalizations within a 14-day-period, the first admission was considered the eligible encounter,
whereas subsequent admissions were classified as readmissions.
Exclusion criteria:
• Concurrent or previous ICD-9-CM code for chronic condition(s) that would increase the risk of treatment failure with
either modality or preclude oral antibiotic use (i.e., cardiovascular, respiratory, hematology, immunodeficiency, or
malignancy)
• Children who were not admitted through the ED (including children transferred from another hospital, where pre
transfer data would not be available in PHIS or the medical record)
• Children who did not receive antibiotics on the first day of hospitalization
• Length of stay <4 days (increasing the likely hood of discharge without intravenous antibiotics for prolonged therapy)
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•

Interventions
Outcomes

Notes

•
•

Hospital stay >14 days (Increasing the likely hood of discharge with oral antibiotics as planned antibiotic therapy was
nearly complete)
Transferred to another facility
Expired during their hospitalization

•
•

Group 1: Oral antibiotic
Group 2: Antibiotics via PICC

Primary outcome(s): Treatment failure (defined as an Emergency Department revisit or rehospitalization that resulted in
extension or change of antibiotic therapy or performance of pleural drainage).
Secondary outcome(s):
• PICC complications (fever evaluation, PICC insertion site or bloodstream infections, sepsis, or PICC thrombosis)
• Adverse drug reactions (diarrhea, Clostridium difficile infection, rash, erythema multiforme or Stevens Johnson
Syndrome anaphylaxis, drug-induced neutropenia, drug fever, acute kidney injury, serum sickness, or other drugrelated complications)
• Other related revisits or rehospitalization not classified as treatment failure, PICC complication, or adverse drug
reaction but plausibly related to the index encounter or treatment, and a composite of all four outcomes termed "all
related revisits."
Results:
• 7280 children were identified as eligible encounters from 38 different hospitals, however 4550 were excluded
because they met the exclusion criteria derived from PHIS. 607 additional children were excluded because they met
the exclusion criteria derived from the medical record review.
• Pleural drainage was performed in 931 (43.9%) children. A pathogen was identified in blood or pleural fluid culture in
305 (14.4%) children.
• The most common pathogens found in the cultures were: Streptococcus milleri group bacteria (n = 9), Streptococcus
pneumoniae (n = 175), Staphylococcus aureus (n = 77), and Streptococcus pyogens (n = 21). MRSA comprised 56
(72.7%) of the S aureus isolates.
• The median hospital length of stay was 7 days. The hospital level length of stay median ranged from 5-9.5 days, with
a median of hospital medians of 7 days.
• PICC use post-discharge varied across hospitals, ranging from 0-71%. PICC use also varied based on census regions.
Most common antibiotics administered via PICC:
•
Anti- Methicillin-susceptible Staphylococcus aureus (MSSA) antibiotics alone (n = 117, 41.6%)
•
Anti-MSSA antibiotic + anti-MRSA antibiotic (n = 73, 26.0%)
•
Anti-MRSA antibiotics alone (n = 42, 14.9%)
Most common antibiotics administered orally:
•
Anti-MSSA agents alone (n = 462, 25.1%)
•
Anti-MRSA agents alone (n = 422, 22.9%)
•
Anti-MRSA agent in combination with anti-MSSA agent (n = 261, 14.2%)
•
Amoxicillin alone (n = 214, 11.6%)
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*All post-discharge antibiotics were prescribed for a median of 14 days. 5% of the subjects were prescribed 21 or more days
of antibiotics post-discharge.
Matching (Pre and Post):
Pre:
• Before matching, children with post discharge PICC antibiotic therapy had higher rates of surgical drainage, ICU
admission, and positive cultures. Treatment failure prior to matching occurred in 57 (2.7%) children overall, 3.2% in
those with PICC antibiotic therapy and 2.6% in those with oral antibiotic therapy.
• No treatment failure was seen in the 77 patients with S aureus isolated culture.
• Among the children that were discharged with culture negative infection, treatment failure occurred in 1.4% and
1.9% of those discharged with amoxicillin and anti-MRSA antibiotics.
• Failure was managed with the following interventions: pleural drainage, change in antibiotics, extension of
antibiotics.
• Three children included in the study (two receiving oral antibiotics and one receiving PICC) developed a
bronchopleural fistula.
• PICC complications occurred in 20 children. Complications included PICC thrombosis resulting in malfunction (n =
11), PICC dislodgement or breakage (n = 4), insertion site cellulitis (n = 1), and fever evaluation (n = 1).
• No PICC associated bloodstream infections were reported.
• Adverse drug reactions occurred in 13 (0.6%) children overall; six had a rash, two had GI symptoms (abdominal
pain), and one each developed serum sickness, drug induced neutropenia, drug fever, heparin-induced
thrombocytopenia, and joint pain.
• Other related visits occurred in 73 of children. The most common reasons were respiratory complaints,
vomiting/dehydration, chest pain, chest tube site drainage, abdominal pain, and seizure.
Post:
• Matching resolved differences in patient characteristics, including rates and timing of pleural drainage.
• There were no significant differences in treatment failure rates between PICC and oral antibiotic recipients, OR =
1.26, 95% CI [0.54, 2.94]
• In the matched analysis, adverse drug reactions, other related revisits and all revisits related to complicated
pneumonia remained significantly higher in those receiving antibiotics via PICC compared with oral route.
• Children with complicated pneumonia should preferentially receive oral antibiotics at discharge when effective oral
options are available.
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Stockmann et al., 2015
Methods
Participants

Interventions

Outcomes

Cohort, retrospective review of EHR data
Setting: USA, quaternary pediatric care referral center for 5 intermountain western states, January 2005-October 2014.
Number in study: N = 391
• Group 1 (Oral antibiotic therapy): n = 54
• Group 2 (Outpatient Parenteral Antibiotic Therapy [OPAT]): n = 337
Age, years, median, Interquartile range (IQR):
• Group 1: 4.7 (2.6-9.1)
• Group 2: 3.7 (2.0-7.0
Gender, male: Extracted with data but not specified
Inclusion Criteria: Hospitalization (and all healthcare encounters within 30 days of index hospitalization) with ICD code for
Pediatric Parapneumonic Empyema (PPE) plus ICD code of one or more of the following:
• Thoracentesis
• Chest tube placement
• Video-assisted thoracoscopic surgery
• Thoracotomy
Exclusion Criteria: None specified
Group 1: Oral antibiotic therapy, including
• Amoxicillin alone
• Clindamycin alone
• Clindamycin and rifampin
• Amoxicillin/clavulanate alone
• Lefloxacin alone
• Others
Group 2: OPAT, including
• Ceftriaxone or cefotaxime alone
• Ceftriaxone or cefotaxime and clindamycin
• Ceftriaxone or cefotaxime and other
• Clindamycin alone
• Clindamycin and others
• Others
Primary outcome:
• All cause complications
o Treatment failure*
o Treatment-related complications
 Readmission & unplanned Emergency Department/Urgent Care visit within 30 days
 Adverse drug events*
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*Outcomes of interest to CMH CPG or CAT development team
Notes

Duration and dosage of therapy was not discussed
Patients with chronic/complex medical conditions made up 54% of group 1 and 49% of group 2, (and thus were not excluded
from study), including:
• Neurologic/neuromuscular conditions
• Cardiovascular
• Respiratory
• Renal/urologic
• Gastrointestinal
• Hematologic/immunologic
• Metabolic
• Premature/neonatal
Results:
1. Treatment Failure (defined as readmission with re-accumulation of pleural fluid or abscess require drainage, or hospital
readmission/ED/Urgent care visit related to antibiotic therapy), n (%)
• Group 1: 0
• Group 2: 2 (0.6%)
2. Adverse Events (defined as either pneumonia-related, treatment-related, or catheter related complication), n(%)
• Group 1, pneumonia related: 2 (3.7%)
• Group 1, treatment related: 3 (5.6%)
• Group 2, pneumonia related: 5 (1.5%)
• Group 2, treatment related: 26 (7.7%)
• Group 2, catheter related: 17 (5.0%)
Pneumonia related complication: OR = 2.55, 95% CI [0.24, 16.05]
Treatment related complication: OR = 0.70, 95% CI [0.13, 2.43]
3. Length of stay, days, median [IQR]
• Group 1: 10.0 (7.6-15.4)
• Group 2: 8.7 (6.9-11.0)

* These guidelines do not establish a standard of care to be followed in every case. It is recognized that each case is different, and those individuals involved
in providing health care are expected to use their judgment in determining what is in the best interests of the patient based on the circumstances existing at
the time. It is impossible to anticipate all possible situations that may exist and to prepare guidelines for each. Accordingly, these guidelines should guide
care with the understanding that departures from them may be required at times.
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Characteristics of Studies 5c
Amarilyo et al., 2014
Methods
Participants

Randomized Controlled Trial
Setting: Children's Hospital, Tel Aviv, November 2004-January 2007
Randomized into study: N = 58
• Group 1 (low dose penicillin): n = not disclosed, group 1 and group 2 together total 35
• Group 2 (high dose penicillin): n = not disclosed, group 1 and group 2 together total 35
• Group 3 (cefurodime): n = 23
Completed Study: N = 58
• Group 1 (low dose penicillin): n = not disclosed, group 1 and group 2 together total 35
• Group 2 (high dose penicillin): n = not disclosed, group 1 and group 2 together total 35
• Group 3 (cefurodime): n = 23
Gender, males:
• Group 1 (low dose penicillin): not disclosed
• Group 2 (high dose penicillin): not disclosed
• Group 3 (cefurodime): not disclosed
Age, months/years (mean) (SD): "Aged 3 months to 15 years"
• Group 1 (low dose penicillin): not disclosed
• Group 2 (high dose penicillin): not disclosed
• Group 3 (cefurodime): not disclosed
Inclusion Criteria:
• fever >38 degrees Celsius
• chest radiograph evidence lobar segmental pneumonia confirmed by Radiologist
• clinically and hemodynamically stable on admission but judged by the clinician to be ill enough to warrant admission.
Exclusion Criteria:
• previous hospitalization
• ingestion of antibiotics within 2 weeks of admission
• significant pleural effusion that needed to be tapped on admission
• severe chronic disease or immune deficiency
• nasal swab positive for common viruses that are associated with CAP (Community-acquired pneumonia).
Power Analysis: The authors did not describe if power analysis was performed

* These guidelines do not establish a standard of care to be followed in every case. It is recognized that each case is different, and those individuals involved
in providing health care are expected to use their judgment in determining what is in the best interests of the patient based on the circumstances existing at
the time. It is impossible to anticipate all possible situations that may exist and to prepare guidelines for each. Accordingly, these guidelines should guide
care with the understanding that departures from them may be required at times.
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Interventions

Outcomes

Notes

Both:

•

Before receiving antibiotic therapy, each patient underwent a complete history and physical examination in the
emergency department. Nasal swabs were performed on all the patients. Chest radiograph, a complete blood count,
serum electrolytes, C-reactive protein (CRP) levels, and blood cultures were obtained and repeated before discharge.
• Approximately 48 hours after significant clinical improvement was observed, with normalization of body temperature
(defined as 38.0C), oral amoxicillin (80 mg/kg-1/d-1 divided into 3 doses) was initiated to complete a total of 14 days
of treatment. Each patient was monitored and followed up in an outpatient clinic 1 month later.
Group 1: low dose penicillin G (200,000 U/kg-1/d-1) intravenously (IV) divided into 4 doses,
Group 2: high-dose penicillin G (400,000 U/kg-1/d-1) IV divided into 4 doses
Group 3: cefuroxime (100 mg/kg-1/d-1) IV divided in 3 doses.
Primary Outcome:
Length of hospital duration*
Secondary Outcome:
Time to defervescence
Safety Outcome:
Adverse reactions
A table containing data is inserted in the background section above. Since the authors did not provide group participant
values, analysis author was unable to use the standard data table.

Risk of bias table
Bias
Random sequence
generation (selection bias)
Allocation concealment
(selection bias)

Scholar’s
judgment
High risk

Unclear risk

Blinding of participants and
personnel (performance
bias)

High risk

Blinding of outcome
assessment (detection bias)

Unclear risk

Support for judgement
Randomization not described

Allocation Concealment not described

Blinding not described

Outcome measurement not likely to be influenced by lack of blinding

* These guidelines do not establish a standard of care to be followed in every case. It is recognized that each case is different, and those individuals involved
in providing health care are expected to use their judgment in determining what is in the best interests of the patient based on the circumstances existing at
the time. It is impossible to anticipate all possible situations that may exist and to prepare guidelines for each. Accordingly, these guidelines should guide
care with the understanding that departures from them may be required at times.
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Incomplete outcome data
(attrition bias)

Low risk

All randomized patients completed study

Selective reporting
(reporting bias)

High risk

Number of patients in each group not disclosed, age not disclosed

Other bias

Unclear risk

* These guidelines do not establish a standard of care to be followed in every case. It is recognized that each case is different, and those individuals involved
in providing health care are expected to use their judgment in determining what is in the best interests of the patient based on the circumstances existing at
the time. It is impossible to anticipate all possible situations that may exist and to prepare guidelines for each. Accordingly, these guidelines should guide
care with the understanding that departures from them may be required at times.
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Blumer et al., 2016
Methods
Participants

Randomized Control Trial, multicenter, observer-blinded, active-controlled study
Setting: 11 study centers in Georgia, Ukraine, United States (Hospitals/Clinics in Ohio, Georgia, California) Jan 2013 - May
2014
Randomized into study: N = 38
• Group 1: Ceftaroline fosamil n = 29
• Group 2: Ceftriaxone plus Vancomycin n = 9
Completed study: N = 35
• Group 1: 26
• Group 2: 9
Gender, % males:
• Group 1: 72.4%
• Group 2: 55.6%
Age, years: median (range):
• Group 1: 4.0 (0.3-17.0)
• Group 2: 4.0 (0.3-16.0)
Inclusion Criteria:
• Patients age 2 mouths to 18 years with complicated community acquired bacterial pneumonia (cCABP)
• Patients requiring three days of initial hospitalization
• Diagnosis of CABP required:
4. Presence of fever (Temp > 38 º C) or hypothermia (Temp < 35 º C) AND
5. New pulmonary infiltrate compatible with bacterial pneumonia based on diagnostic testing AND
6. One of the following:
 Typical respiratory pathogen isolated from a respiratory or blood culture
 Leukocytosis (> 15,000 white blood cells/mm3, > 15% immature neutrophils regardless of total WBC
count)
 Leucopenia (< 4500 WBC/mm3)
 Hypoxemia (oxygen saturation < 92% on room air)
• The patient had to have at least one of the following indicators to distinguish cCABP from CABP:
10. Empyema
11. Pulmonary abscess
12. Necrotizing pneumonia
13. Pneumatocele
14. Pleural effusion needing chest tube drainage
15. Gram-positive cocci in clusters on Gram stain from a respiratory specimen
16. Requirement for positive pressure-assisted ventilation
17. Previous influenza like illness (within 28 days before enrolment)
18. Treatment in an intensive care unit.

* These guidelines do not establish a standard of care to be followed in every case. It is recognized that each case is different, and those individuals involved
in providing health care are expected to use their judgment in determining what is in the best interests of the patient based on the circumstances existing at
the time. It is impossible to anticipate all possible situations that may exist and to prepare guidelines for each. Accordingly, these guidelines should guide
care with the understanding that departures from them may be required at times.
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•

In addition, the participant had to have at least two of the following to distinguish cCABP from CABP that occurred or
worsened within the previous 5 days:
10. Cough
11. Tachypnea
12. Dyspnea
13. Grunting
14. Sputum production
15. Chest pain
16. Cyanosis
17. Evidence of pneumonia with parenchymal consolidation
18. Increased work of breathing (WOB)
Exclusion Criteria:
• History of hypersensitivity or allergic reaction to vancomycin or any ß-lactam antibiotic
• Confirmed or suspected infection caused by a pathogen resistant to any of the IV study drugs
• Infection caused by a sole atypical organism at baseline
• Infection caused by bacteria other than CABP pathogens, such as organisms associated with ventilator-associated or
hospital acquired pneumonia
• Non-infectious pulmonary infiltrations on chest radiography
• Pt had received more than 24 hours of any systemic antimicrobial therapy for CABP within 96 hours of randomization
(with the exception of patients who were considered to have failed prior treatment),
• Moderate or severe renal insufficiency
• Patient history of seizure
• Suspected bacterial meningitis
• Elevated AST, ALT, bilirubin labs
• Neutropenia
• Thrombocytopenia
• Patients with HIV and a CD4 count < 250cells/mm3 or history of another immune deficiency syndrome
Power Analysis: Did not occur due to small size of study population
Interventions

Group 1:
• < 6 months old: 10mg/kg infused over 120 (+/- 10) minutes every 8 (+/-1) hours
• > 6 months old: IV ceftaroline fosamil infused over 120 (+/- 10) minutes every 8 (+/-1) hours at a dose of 15mg/kg
(or 600 mg if weight > 40 kg)
Group 2*:
• IV Ceftriaxone: 75 mg/kg/day (up to 4 g/day), divided into two doses, 12 (+/-2) hours apart and infused over 30
(+/- 10) minutes
• IV vancomycin: 15 mg/kg every 6 (+/- 1) hours infused over > 60 minutes (or at a maximum of 10mg/min,
whichever was longer)
*NOTE for Group 2: Vancomycin could be discontinued on or after day 4 if MRSA or penicillin-resistant or intermediate S
pneumoniae was not confirmed.

* These guidelines do not establish a standard of care to be followed in every case. It is recognized that each case is different, and those individuals involved
in providing health care are expected to use their judgment in determining what is in the best interests of the patient based on the circumstances existing at
the time. It is impossible to anticipate all possible situations that may exist and to prepare guidelines for each. Accordingly, these guidelines should guide
care with the understanding that departures from them may be required at times.
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Switching from IV to oral antibiotics on or after day 4 for both groups:
A switch from IV study drug to open-label oral study drug (amoxicillin clavulanate, clindamycin, or linezolid) was allowed on
or after study day 4 at the discretion of the investigator if the patient met the following criteria:
• Received > 72 hours of IV study drug therapy
• Had their clinical signs and symptoms assessed on Study Day 4
• Were able to maintain oral intake
• Afebrile (< 38º C) for > 24 hours
• Oxygen saturation > 92% on RA
• WBC WNL for age or > 20% improvement from baseline
• Absence or improvement of cough, dyspnea, sputum production or chest pain
Group 1:
• 22/30 patients switched to oral antibiotics on or after day 4 (it is unclear which of these patients were cCABP vs
CABP)
• Patients were switched to the following oral antibiotics: clindamycin (13/30 patients [59%]), amoxicillin clavulanate
(8/30 [36%]) or linezolid (2/30 [9%])
Group 2:
• All patients switched to oral antibiotics on or after day 4
• Patients were switched to the following oral antibiotics: clindamycin (6/10 [60%]) or amoxicillin clavulanate (4/10
[40%]).
Both groups: combined IV plus oral drug or IV study drug was required for 5–21 days
Outcomes

4.

5.

6.
Notes

Clinical response and stability at study day 4:
1. Clinical response at study day 4, defined as improvement in at least 2 and worsening of none of the following
symptoms: cough, dyspnea, chest pain, sputum production, chills or rigors, feeling feverish and exercise
intolerance or lethargy.
2. Clinical stability at study day 4, defined as: afebrile (< 38º C) for > 24 hours; normal, age appropriate pulse
and respiratory rates, oxygen saturation > 92% on RA, and no worsening of clinical response symptoms
Clinical cure at end of therapy (EOT) and test of cure (TOC)
1. Clinical cure at EOT and TOC defined as resolution of all acute signs and symptoms of CABP or no further
antimicrobial therapy was required
2. Clinical failure at the EOT visit defined as continuation of study drug beyond the 21 days of therapy,
discontinuation of study drug due to insufficient therapeutic effect or adverse effect and requirement for
alternative non-study antimicrobial therapy for CABP, or death in which CABP was identified as a contributing
factor.
3. Clinical failure at TOC visit defined as incomplete resolution or worsening of CABP signs or symptoms or the
development of new signs or symptoms requiring alternative non-study antimicrobial therapy or death in
which CABP was identified as a contributing factor.
Adverse events

Funding: Cerexa, Inc, a wholly owned subsidiary of Forest Laboratories

* These guidelines do not establish a standard of care to be followed in every case. It is recognized that each case is different, and those individuals involved
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Prior antibiotic use (within 72 hours of study): 18/29 patients (62%) in Group 1 and 5/9 patients (56%) in Group 2
received prior antibiotics within 96 hours of the first dose of IV study drug.
The most commonly administered prior antibiotics in Group 1 were ceftriaxone (7/29 patients [24%]) and vancomycin and
azithromycin (both 5/29 patients [17%]), and in Group 2 were ceftriaxone and clindamycin (both 3/9 patients [33%]) and
cefotaxime (2/9 patients [22%]).
Adverse Events data is based on the total patient population of 40. Data for Adverse Events is included in a separate table,
below.
Risk of Bias table
Bias

Random sequence
generation (selection bias)

Scholar’s
judgment
Unclear risk

Support for judgment

No mention of how sequence was generated

Allocation concealment
(selection bias)

Low risk

Block randomization using an interactive voice response system was used to assign patients 3:1 to a
study group

Blinding of participants
and personnel
(performance bias)

Low risk

The study was observer blinded. Each hospital had at least one blinded investigator who conducted clinical
assessments

Blinding of outcome
assessment (detection
bias)

High risk

No mention that outcome assessments were blinded

Incomplete outcome data
(attrition bias)

Low risk

Data is given for all 38 patients with cCABP

Selective reporting
(reporting bias)

Low risk

Study's outcomes are given, data for all study outcomes are included

Other bias

Unclear risk

* These guidelines do not establish a standard of care to be followed in every case. It is recognized that each case is different, and those individuals involved
in providing health care are expected to use their judgment in determining what is in the best interests of the patient based on the circumstances existing at
the time. It is impossible to anticipate all possible situations that may exist and to prepare guidelines for each. Accordingly, these guidelines should guide
care with the understanding that departures from them may be required at times.
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Breuer et al., 2015
Methods
Participants

Retrospective, cohort study to analyze the clinical outcome of treatment with narrow versus broad spectrum antibiotics
Participants: Previously healthy children with non-complicated community acquired pneumonia (CAP) who needed to be
hospitalized despite outpatient treatment with oral antibiotics
Setting: Pediatric Departments of the Hadassah Hebrew University Medical Center in Jerusalem, Israel from 2003 to 2008
Number enrolled into study: N = 337
• Group 1: narrow spectrum antibiotic, n = 102
o Penicillin n = 93
o Ampicillin n = 7
o Amoxicillin n = 2
• Group 2: broad spectrum antibiotic, n = 235
o Cefuroxime n = 226
o Ceftriaxone n = 7
o Cefazolin n = 2
Number completed: N = 337
• Group 1: n = 102
• Group 2: n = 235
Gender, males:
• Group 1: n = 63 (62%)
• Group 2: n = 130 (55.3%)
Age, years, mean:
• Group 1: n = 3.4 (3.3)
• Group 2: n = 3.1 (3.5)
Inclusion criteria:
• Age 3 months to 18 years
• Admitted with a first episode of CAP
• Received greater than 24 hours of oral antibiotics in the community prior to admission
o Oral antibiotic history as reported by participant’s parents
• International Classification of Diseases, Ninth Revision (ICD-9) primary or secondary diagnosis code pneumonia
• Presenting symptoms and imaging reviewed by a pulmonologist (who was blinded to the in-hospital treatment) only
participants with all three criteria were included in the study:
o Presence of fever > 38ºC
o Clinical signs of a lower respiratory tract infection (tachypnea and/or cough and/or findings of crackles,
bronchial breathing, or diminished breath sounds on auscultation)
o Presence of a consolidation on a chest radiograph
Exclusion criteria:
• Known chronic disease or disability
• Chronic neurological impairment
• Patient receiving chronic medication

* These guidelines do not establish a standard of care to be followed in every case. It is recognized that each case is different, and those individuals involved
in providing health care are expected to use their judgment in determining what is in the best interests of the patient based on the circumstances existing at
the time. It is impossible to anticipate all possible situations that may exist and to prepare guidelines for each. Accordingly, these guidelines should guide
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•
•

Patient with previous episode of pneumonia
Any of the following pneumonia complications at any point during the hospital stay
o Pleural effusion
o Necrotizing pneumonia
o Admitted to the intensive care unit
• Children not receiving penicillin, ampicillin, amoxicillin, ceftriaxone, cefuroxime, or cefazolin during the first 24 hours
of hospitalization
Covariates identified:
• Patient demographics
• Clinical characteristics on presentation
• Laboratory indices on presentation
• Type and duration of oral antibiotic therapy prior to admission
Interventions

Outcomes
Results

Group 1: Narrow spectrum antibiotic therapy defined as the use of parenteral penicillin, parenteral ampicillin, or orally
administered amoxicillin
Group 2: Broad spectrum antibiotic therapy defined as the use of a parenteral cephalosporin agent (ceftriaxone, cefuroxime,
cefazolin)
Secondary outcomes:
• Treatment failure defined as a change in the antibiotic therapy after the first 24 hours of treatment

•
•
•

•

Decision to change antibiotic treatment p = 0.21
o Group 1, narrow antibiotic therapy: n = 15 (14.4%)
o Group 2, broad spectrum antibiotic therapy: n = 23 (9.8%)
Duration of oral antibiotic treatment before admission was not statistically different between groups p = 0.12
Types of antibiotic administered at home, before admission, was not statistically different between groups for the
following
o Penicillin or amoxicillin + clavulanate
o Penicillin or amoxicillin + macrolide
o Penicillin or amoxicillin + cephalosporin
o Penicillin or amoxicillin + macrolide + cephalosporin
o Cephalosporin only
o Cephalosporin + macrolide
o Trimethoprim and sulfamethoxazole, metronidazole, or unknown
Use of a macrolide antibiotic administered at home, before admission, was statistically different between the two
groups p = 0.002
o Group 1, narrow antibiotic therapy: n = 11 (11%)
o Group 2, broad spectrum antibiotic therapy: n = 62 (26%)

* These guidelines do not establish a standard of care to be followed in every case. It is recognized that each case is different, and those individuals involved
in providing health care are expected to use their judgment in determining what is in the best interests of the patient based on the circumstances existing at
the time. It is impossible to anticipate all possible situations that may exist and to prepare guidelines for each. Accordingly, these guidelines should guide
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Cannavino et al., 2016
Methods
Participants

Randomized, multi-center, prospective controlled trial
Setting: 34 study centers in 8 countries (Poland, Spain, United States, Bulgaria, Georgia, Greece, Hungary, and Ukraine)
Randomized into study: N = 161
• Group 1: Ceftaroline n = 122
• Group 2: Ceftriaxone n = 39
Completed Study (Modified Intent-to-Treat): N = 143
• Group 1: n = 107
• Group 2: n = 36
Gender, males:
• Group 1: n = 64 (52.9%)
• Group 2: n = 20 (51.3%)
Age, months/years (median):
Group 1:
• 12-<18 year: 8 (6.6%)
• 6-<12 year: 26 (21.5%)
• 2-<6 year: 64 (52.9%)
• 2 months-<2yr: 23 (19.0%)
Group 2:
• 12-<18 year: 2 (5.1%)
• 6-<12 year: 9 (23.1%)
• 2-<6 year: 21 (53.8%)
• 2 months-<2 year: 7 (17.9%)
Inclusion Criteria:
• Patients ages 2 months-18 years with community-acquired bacterial pneumonia (CABP) requiring hospitalization and
IV antibacterial therapy
• Must meet CABP definition:
o All children were required to have:
 Fever (temperature >38°C) or hypothermia (temperature <35°C)
 The presence of new infiltrate(s) consistent with bacterial pneumonia, including a new alveolar/lobar
infiltrate or consolidation (based on imaging results)
 Acute onset or worsening within the previous five days of at least two of the following nine clinical
signs and symptoms: cough, tachypnea, dyspnea, grunting, sputum production, chest pain, cyanosis,
evidence of pneumonia with parenchymal consolidation and increased work of breathing.
o Participants needed to have at least one of the five following laboratory findings:
 Bacterial organism consistent with a typical respiratory pathogen identified or isolated from a
respiratory (sputum and pleural fluid) or blood culture,
 Leukocytosis (>15,000 white blood cells [WBC]/mm3),
 Greater than 15% immature neutrophils (bands) regardless of total peripheral white blood cell,

* These guidelines do not establish a standard of care to be followed in every case. It is recognized that each case is different, and those individuals involved
in providing health care are expected to use their judgment in determining what is in the best interests of the patient based on the circumstances existing at
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Leukopenia (4500 WBC/mm3) and
Hypoxemia (oxygen saturation <92% on room air)
• Females of reproductive age were required to have a negative urine pregnancy test and agree to remain abstinent or
use dual methods of birth control during treatment and at least 28 days after last study dose
Exclusion Criteria:
• Admission to intensive care unit during study
• Had an infection with a known or suspected ceftriaxone-resistant pathogen
• Infection at baseline with a sole atypical pathogen
• History of hypersensitivity or allergic reaction to β-lactam antimicrobial
• Patients at risk of MRSA infection (included at discretion of treating physician) or with a predominance of Grampositive cocci in clusters on sputum Gram stain
• Confirmed or suspected respiratory tract infection attributed to other sources than CAP pathogens
• Noninfectious causes or suspected sole viral, fungal, or M. tuberculosis causes of pulmonary infiltrates
• Chronic lung disease or neurologic disease that impaired the patient's airway clearance
• Received >24 hours of systemic antibacterial therapy for CABP within 96 hours prior to randomization
• Pregnancy
Power Analysis: Power analysis not completed.




Interventions

•

•
•
Outcomes

Group 1: Ceftaroline fosamil for a minimum of 72 hours or three study days. Dosage: infused over 60 (± 10)
minutes every 8 hours (± 1 hour). Dosages per age follow:
o Less than or equal to 6 months: 8 mg/kg;
o Greater than 6 months and ≤ 33 kg: 12 mg/kg;
o Greater than 6 months and ≥ 33 kg: 400 mg
Group 2: Ceftriaxone 75 mg/kg/day (maximum dose 4 g/day), infused equally in divided doses over 30 (± 10)
minutes every 12 hr.
Both groups: Patients could be switched on study day four to receive oral amoxicillin/clavulanate (up to 90
mg/kg/day divided in two doses)

Primary outcome(s):
• Clinical response at:
o Study day 4, end-of-intravenous treatment (EOIV) defined as within 24 hours after administration of the last
dose of IV study drug and before the switch to oral amoxymicillin/clavulanate.
o End-of-treatment visit (EOT) defined as within 24 hours after the last dose of oral study drug.
o Test-of-cure visit (TOC) occurred between eight and 15 days after the final dose of study drug.
o Late-follow up visit (LFU) was performed between 21 and 35 days after the last dose of study drug.
• Clinical stability at Study Day 4. Defined as the patient having improvement in at least two of seven symptoms
(cough, dyspnea, chest pain, sputum production, chills or rigors, feeling of warmth/feverish and exercise intolerance
or lethargy) and no worsening of any of these symptoms. (Patients had to have a minimum of two symptoms
evaluated at baseline and Study Day 4).

* These guidelines do not establish a standard of care to be followed in every case. It is recognized that each case is different, and those individuals involved
in providing health care are expected to use their judgment in determining what is in the best interests of the patient based on the circumstances existing at
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•
•

•

•

•

Non-responder was defined as a patient who did not have a clinical response or died between baseline and Study Day
4
Clinical outcome at EOIV (clinical cure: defined as resolution of all acute signs and symptoms; clinical improvement:
afebrile for at least 24 hours and no new symptoms with improvement in at least one symptom from baseline and
worsening of none; clinical failure: defined as discontinuation of study drug due to insufficient therapeutic effect
requiring alternative nonstudy antimicrobial therapy, discontinuation of study drug due to an AE and requiring an
alternative nonstudy antimicrobial therapy, or death in which CABP was contributory).
Clinical outcome at EOT (clinical cure: defined as resolution of all acute signs and symptoms of CABP or improvement
of signs and symptoms to an extent that no further antimicrobial therapy was required; clinical improvement: was
not defined for this time frame; clinical failure: defined as a child who has improved but the investigator wished to
continue to provide antibiotic therapy beyond that specified in the protocol or a discontinuation of study drug due to
insufficient therapeutic effect, requiring alternative nonstudy antimicrobial therapy or discontinuation of study drug
due to an AE, requiring an alternative nonstudy antimicrobial therapy, or death in which CABP was contributory.
Clinical outcome at TOC (clinical cure definition is the same as EOT outcome; clinical improvement: was not defined
for this time frame; clinical failure: defined as discontinuation of study drug due to insufficient therapeutic effect,
requiring alternative non-study antimicrobial therapy, or death in which CABP was contributory clinical cure or clinical
failure.
Safety outcomes involved assessment of treatment-emergent adverse events beginning with signing of informed
consent to 30 days after the last dose of the study drug

Risk of Bias table
Bias

Scholars’
judgment

Support for judgment

Random sequence
generation (selection bias)

Unclear risk

Article states that participants were randomized but does not state how. Participants were randomized in 3:1
(intervention: control) ratio.

Allocation concealment
(selection bias)

Unclear risk The authors do not specify if or how allocation concealment was addressed.

Blinding of participants and
personnel (performance
bias)

Low risk

It is not explicitly stated if participants and/or personnel were blinded to the allocation. However, the
outcomes measured were objective, leading the review authors to judge that the outcome is not likely to be
influenced by lack of blinding.

Blinding of outcome
assessment (detection
bias)

Low risk

The investigators that assessed the clinical outcomes were blinded.

* These guidelines do not establish a standard of care to be followed in every case. It is recognized that each case is different, and those individuals involved
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Incomplete outcome data
(attrition bias)

High risk

The authors analyzed the data using a modified intent-to-treat population not an actual intent-to-treat.

Selective reporting
(reporting bias)

High risk

Reported demographics and outcomes inconsistent based on which group they are reporting on (safety group
or modified intent to treat group). For example, tolerability results reported for safety group, but clinical
outcomes reported for the modified intent-to-treat group.

Other bias

Unclear risk

* These guidelines do not establish a standard of care to be followed in every case. It is recognized that each case is different, and those individuals involved
in providing health care are expected to use their judgment in determining what is in the best interests of the patient based on the circumstances existing at
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Lassi et al., 2014
Design

Quantitative Synthesis (meta-analysis)

Objective

Meta-analysis of RCTs conducted in low and middle income countries (LMICs) to determine the most suitable antibiotic
therapy for treating community acquired pneumonia (very severe, severe and non-severe).

Methods

Inclusion Criteria:
•
Pediatric patients between 2 and 59 months of age
•
Respiratory illness with a clinical diagnosis of community acquired pneumonia
•
Pneumonia classified as: non-severe, severe, very severe
Exclusion Criteria:
•
Method of diagnosis not disclosed
•
Adult patient population
Information sources: Medline, Cochrane Library, PubMed, Google Scholar on March 15th, 2013. English articles only.
Search:
•
Search terms (or combination of); ((‘Pneumonia’ OR ‘very severe pneumonia’ OR ‘severe pneumonia’ OR ‘non-severe
pneumonia’ OR ‘acute respiratory illness’ OR ‘Community acquired pneumonia’) AND (‘child*’ OR ‘infant’ OR
‘preschool*’ OR ‘schoolchild’ OR ‘school age’ OR ‘preschool’ OR ‘kid*’ OR ‘toddler*’) AND (‘treatment’ OR ‘antiinfective agent’ OR ‘anti-bacterial agents’ OR ‘antibitoic’ OR ‘management’)).
Study Selection:
•
Studies that examined a single drug or combination
•
Different drug dose
•
Duration and route of same drug
•
Analysis of clinical cure rate
•
Treatment failure
•
Relapse rate
•
Change in antibiotic therapy
•
Death
Data collection process:
•
All data was entered and analyzed using Review Manager 5 software.
Risk of bias (RoB) across studies:
•
Cochrane methods for risk of bias assessment to assess the quality of included studies.
Summary measures:
•
Risk ratio was utilized.

Results

Study Selection:
Number of articles identified: N = 8122
a. Full-text articles assessed for eligibility: n = 83
b. Studies included in qualitative synthesis: n = 42
Synthesis of results:
•
Three studies included for very severe pneumonia

* These guidelines do not establish a standard of care to be followed in every case. It is recognized that each case is different, and those individuals involved
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•
Failure rate with ampicillin and gentamicin vs chloramphenicol
•
Penicillin plus gentamicin vs chloramphenicol
•
Penicillin and gentamicin vs amoxicillin-clavulanic acid
•
Six studies included for severe pneumonia
•
Chloramphenicol plus penicillin vs ceftriaxone
•
Co-trimoxazole vs amoxicillin
•
Parenteral penicillin vs oral amoxicillin
•
Ampicillin (intravenous) plus oral amoxicillin vs oral amoxicillin
•
Parenteral benzyl penicillin vs oral amoxicillin
•
Oral co-trimoxazole vs intramuscular procaine penicillin
•
Penicillin or cefuroxime
•
Thirteen studies included for non-severe pneumonia
•
Oral co-trimoxazole vs oral amoxicillin
•
oral levofloxacin vs oral co-amoxiclavulanic acid
•
oral azithromycin vs oral co-amoxiclavulanic acid
•
amoxicillin vs co-amoxiclavulanic acid
•
parenteral ampicillin vs penicillin plus chloramphenicol
Risk of bias across studies:
•
Out of the 22 included studies, 20 were free of selective reporting, 12 were double-blinded, and 14 had adequate
allocation concealment. Five studies included for very severe and severe pneumonia were free of other bias, while
four studies in non-severe pneumonia mentioned their source of funding.
Discussion
Funding

Limitations. Duplicate studies, articles in foreign languages with non-English abstracts, studies which did not include any
acute respiratory illness.
For this meta-analysis, no source of funding was disclosed. However, as noted above, four studies in non-severe pneumonia
category mentioned their source of funding.

* These guidelines do not establish a standard of care to be followed in every case. It is recognized that each case is different, and those individuals involved
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Leyenaar et al., 2014
Methods

Retrospective cohort study to evaluate effectiveness of ceftriaxone alone compared to ceftriaxone with a macrolide
for treatment of community acquired pneumonia (CAP) in children 1-17 years of age with respect to total length of
stay (LOS) and total hospital costs

Participants

Participants: Children aged 1 to 17 years with pneumonia, admitted between July 1, 2007 and June 30, 2010
Setting: Hospitals that contribute data to the Perspective Data Warehouse which captures approximately 15% of
all US hospitalizations
Number enrolled into study: N = 13,593
• Group 1: Ceftriaxone alone, n = 8,892
• Group 2: Ceftriaxone + macrolide, n = 4,701
Gender, males:
• Group 1: n = 4,814 (54.1%)
• Group 2: n = 2,574 (54.8%)
Age, years (median, [IQR]):
• Group 1: 3 [1-5]
• Group 2: 5 [2-8]
Inclusion criteria:
• Children aged 1 to 17 years old
• Principal diagnosis of pneumonia (ICD-9 codes 480-483 or 485-487.0)
• Received treatment of ceftriaxone alone or ceftriaxone and a macrolide (oral or parenteral azithromycin,
erythromycin, or clarithromycin) on first day of presentation to emergency department (E.D.) or admission
to hospital
Exclusion criteria:
• Children less than 1 year old
• Concurrent diagnosis of bronchiolitis
• Children with complex chronic conditions
• Patients transferred to or from other acute care facilities
• Patients who left against medical advice
Covariates identified:
• Patient: age, gender, race/ethnicity, insurance status, comorbid conditions including asthma, influenza,
and disorders of fluids and electrolytes
• Hospital: geographic region, bed size, urban/rural location, children’s hospital versus general community
hospital, teaching status

Interventions

•
•

Group 1: Received treatment for CAP with ceftriaxone alone
Group 2: Received treatment for CAP with ceftriaxone and macrolide therapy

* These guidelines do not establish a standard of care to be followed in every case. It is recognized that each case is different, and those individuals involved
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Outcomes

Results

Primary outcome(s):
• LOS, reported in days
• Total costs of hospitalization, reported in United States dollars (USD)
Secondary outcome(s)
• Transfer to the intensive care unit (ICU) on or after the second day of hospitalization
• Inpatient mortality
• Readmission to the hospital within 30 days of hospital discharge including all-cause readmissions and
pneumonia-related readmissions

•
•
•
•

Poisson regression used to assess the associations between the antibiotic regimen and the LOS and were
adjusted for patient and hospital characteristics and initial investigations and therapies.
Multivariable linear regression models were used to assess the total hospital costs of each antibiotic
regimen and were adjusted for patient and hospital characteristics and initial investigations and therapies.
A propensity score model was used to predict the initial antibiotic therapy for each age group in order to
address the confounding issue of more severe pneumonia presentations increasing the likelihood of
receiving combination treatment.
There was no significant difference in the unadjusted and adjusted models for the total LOS in children
ages 1 to 4 years between the two groups. Children 5 to 17 years of age who received the combination
therapy had a shorter length of stay (about 5% less) compared to the ceftriaxone alone group in the
unadjusted and adjusted models. See tables below.
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Lodha et al., 2013
Design
Objective
Methods

Quantitative Synthesis (meta-analysis)
•

To identify effective antibiotic drug therapies for CAP of varying severity in children by comparing various antibiotics

Protocol and registration.
•
Protocol first published: Issue 3, 2004
•
Review first published: Issue 3, 2006
Eligibility Criteria.
•
RCTs comparing at least two antibiotics for CAP in children, using the definition of pneumonia (as given by WHO) or
radiologically confirmed.
•
Children under 18 years of age with CAP treated in a hospital or ambulatory setting.
Information sources.
•
Cochrane Central Register of Controlled Trials (CENTRAL) 2012
•
MEDLINE (September 2009 to October week 4, 2012);
•
EMBASE (September 2009 to November 2012);
•
CINAHL (2009 to November 2012);
•
Web of Science (2009 to November 2012)
•
LILACS (2009 to November 2012).
•
Bibliographies of selected articles to identify any additional trials not recovered by the electronic searches.
Search.
•
Studies retrieved through a search strategy which included cross-referencing.
Study Selection.
•
A person who was not involved in the review gave all relevant studies a serial number to mask the authors’ names
and institutions, the location of the study, reference lists and any other potential identifiers.
•
Two review authors independently selected potentially relevant studies based on their title and abstract.
•
Two review authors independently reviewed the results for inclusion in the analysis.
•
Resolved differences about study quality through discussion.
Data collection process.
•
Retrieved the complete texts of these studies electronically or by contacting the trial authors.
•
Contacted trial authors for missing data.
•
RevMan.
•
For each of the outcome variables, assessment of heterogeneity with Breslow’s test of homogeneity using RevMan.
Risk of bias (RoB) across studies.
•
Assessed publication bias using The Cochrane Collaboration’s ’Risk of bias’ tool.
•
Sequence generation, allocation concealment, blinding of personnel and outcome assessors, incomplete data, and
selective outcome reporting: assessed as yes, no or unclear
•
Other sources of bias

* These guidelines do not establish a standard of care to be followed in every case. It is recognized that each case is different, and those individuals involved
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Summary measures.
•
For each comparison, 2 x 2 tables were used
•
Calculated ORs and 95% CIs.
•
Random-effects model for all the comparisons
Results

Discussion

Study Selection.
Number of articles identified: N = 29
o Full-text articles assessed for eligibility: n = 9
o Studies included in quantitative synthesis: n = 9
Synthesis of results.
•
30 comparison forest plots
Risk of bias across studies.

Bias

No. of studies
with high risk

No. of studies
with low risk

No. of studies
with unclear risk

Sequence generation

0

14

15

Allocation concealment

0

15

14

Blinding of personnel
and participants

23

4

2

Blinding of outcome
assessment

21

5

3

Selective reporting

0

20

9

Incomplete outcome
data

0

22

7

Other

0

9

20

Summary of evidence.
•
In ambulatory settings, for treatment of WHO defined non-severe CAP, amoxicillin compared with cotrimoxazole had
similar failure rates, OR = 1.18, 95% CI [0.91, 1.51] and cure rates, OR = 1.03, 95% CI [0.56, 1.89]. Three studies
involved 3952 children.
•
In children with severe pneumonia without hypoxemia, oral antibiotics (amoxicillin/co-trimoxazole) compared with
injectable penicillin had similar failure rates OR = 0.84, 95% CI [0.56, 1.24], hospitalization rates OR = 1.13, 95%
CI [0.38, 3.34] and failure rates OR = 1.28, 95% CI [0.34, 4.82]. Six studies involved 4331 children below 18 years
of age.
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the time. It is impossible to anticipate all possible situations that may exist and to prepare guidelines for each. Accordingly, these guidelines should guide
care with the understanding that departures from them may be required at times.

Department of Evidence Based Practice
Service and Performance Excellence
Date Finalized/Revised: 10/2018; 03/2020

179

In very severe CAP, death rates were higher in children receiving chloramphenicol compared to those receiving
penicillin/ampicillin plus gentamicin OR = 1.25, 95% CI [0.76, 2.07]. One study involved 1116 children.
Limitations.
•
A limited number of RCTs fulfilled the inclusion criteria.
•
Most of the antibiotic comparisons were available in single studies only.
•
Five studies met all the quality assessment criteria. For most comparisons of the efficacy of antibiotics, only one or
two studies were available.
•

Funding

Internal sources
•
All India Institute of Medical Sciences, New Delhi, India.
External sources
•
No sources of support supplied

Williams, 2013
Methods
Participants

Cohort, retrospective data from EHR
Setting: USA, data from 43 children's hospitals, 2005-2011
Number in study:
• Total: N = 15,564
• Group 1, Ceftriaxone/Cefotaxime: n = 13,954
• Group 2, Penicillin/Ampicillin: n = 1610
Gender, male:
• Group 1, Ceftriaxone/Cefotaxime: 51.7%
• Group 2, Penicillin/Ampicillin: 48.8%
Age, median, [range]:
• Group 1, Ceftriaxone/Cefotaxime: 2 [1-5]
• Group 2, Penicillin/Ampicillin: 2 [1-4]
Inclusion Criteria:
• Children: 6 months-10 years old
• Hospitalized July 2005-June 2011
• ICD-9 diagnosis of pneumonia
• >/= 2 calendar days of hospitalization
Exclusion Criteria:
• Potentially severe pneumonia
• Patients at risk for healthcare associated infection
• >/= 1 complex chronic condition
• Interhospital transfers
• Previous hospitalization at a same-system hospital within 30 days of index stay
• Children with any of the following during first 2 calendar days of hospitalization:

* These guidelines do not establish a standard of care to be followed in every case. It is recognized that each case is different, and those individuals involved
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Pleural drainage procedure
Admission to ICU
Mechanical ventilation
Death
• Children receiving other antimicrobial agents during the first 2 calendar days of hospitalization (with the exception
of macrolides or oseltamivir)
• Children switching between broad/narrow spectrum antibiotics
Interventions
Outcomes
Notes

Group 1: Broad spectrum antibiotic agent (ceftriaxone or cefotaxime)
Group 2: Narrow spectrum antibiotic agent (penicillin or ampicillin)
14-day Readmission
No dosage information included in study
•
PICU admission: OR = 0.85, 95% CI [0.27, 2.73]
•
14-day readmission: OR = 0.85, 95% CI [0.45, 1.63]

* These guidelines do not establish a standard of care to be followed in every case. It is recognized that each case is different, and those individuals involved
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Guo et al., 2015
Methods
Participants

Retrospective case study
Participants: Pediatric patients with CAP, with lobe or multi foci infiltration
Setting: Retrospective chart review of CAP cases at a large university teaching hospital (Soochow University, Suzhou,
China) between May 2012 and April 2013
Number enrolled into study: N = 126 consecutive cases
•
Proven viral or mycoplasma CAP: n = 88 cases
Gender, males: n = 71 (56%)
Age, years [range]: 4 [11 days to 14 years]
Inclusion criteria:
•
Previously healthy children with radiologically confirmed lobar or multi focal lung infiltrates
o Lobar distribution defined as involvement of a single lobe
o Two or more foci (unilateral or bilateral) was considered multi focal
o Radiographic findings were independently reviewed by two radiologists; differences in diagnosis
conclusions was reached through consensus resolution
•
Diagnosis of CAP
o Mycoplasma pneumonia diagnosis defined as acute respiratory disease with abnormal chest radiograph
findings and positive laboratory tests combined with real-time PCR using DNA extracted from
nasopharyngeal swab specimens
o Viral pneumonia diagnosis defined as acute respiratory disease with abnormal chest radiograph findings
and positive viral growth (including influenza A and B; adenovirus; respiratory syncytial virus; bocavirus;
human metapneumovirus; and parainfluenza virus 1, 2, and 3) from respiratory cultures obtained from
either nasopharyngeal swab or bronchial-aspirate sampling
o Medical charts, radiographs, and laboratory findings were retrospectively reviewed by both a respiratory
physician and radiologist
Exclusion criteria:
•
History of asthma
•
Patients with simultaneous viral and mycoplasma infections
Covariates identified to influence diagnosing atypical pneumonia:
•
Increased respiratory rate (p = .0053)
•
Wheeze (p < .0001)
•
Gender, males (p = .0197)
•
Increased lymphocyte percentage (p = .0184)
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Interventions

Outcomes

Results

•

Factors analyzed included fever; wheeze; increase of respiratory rate; cough; CRP; white blood cell count (WBC);
and radiological findings among three different age groups: 0 to 23 months, 2 to 4 years, and older than 5 years

Primary outcome(s):
•
Factors allowing differential diagnosis of viral and mycoplasma CAP with lobe or multi foci infiltration
CAP cases:
•
M. pneumoniae: n = 70
•
Viral: n = 18
•
Unknown: n = 38
Variables found to be more frequent in children with atypical pneumonia were further analyzed by logistic regression and
the following were significantly associated with atypical pneumonia
Variable
Odds Ratio
95% Wald Confidence
p value
[OR]
Interval [CI]
Wheeze
.063
0.010 – 0.271
p < .0001
Increased
.093
0.013 – 0.653
p = .0095
respiratory rate
Increased
.053
0.012 – 0.337
p = .0027
lymphocyte %
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Medjo et al., 2014
Methods

Participants

Interventions

Outcomes

Results

Prospective, cohort study to assess the incidence of Mycoplasma pneumoniae pneumonia to determine the clinical,
radiological, and laboratory features specific for M. pneumoniae and to evaluate which diagnostic tests (serology, realtime polymerase chain reaction (RT-PCR) and culture) provide increased accuracy in the diagnosis of M. pneumoniae.
Participants: Previously healthy children aged between 1 and 15 years with symptoms, signs and chest radiographs
consistent with community-acquired pneumonia
Setting: University Children’s Hospital Emergency Department in Belgrade, Serbia from April 2012 to March 2014
Number enrolled into study: N = 166
Number completed: N = 166
Gender, males: N = 86
Age, years (mean, SD): 6.35, 4.52
Inclusion criteria:
• Aged between 1 and 15 years
• Presence of fever, acute respiratory symptoms (cough, tachypnea, difficult breathing) or both, and a new
infiltrate on chest radiography or a consolidation not attributable to some other etiology
Exclusion criteria:
•
Children who received anti-mycoplasma therapy
Covariates identified to influence diagnosing M. pneumoniae pneumonia:
•
Gender, males; p = .014
•
Age, years—mean (SD); p = .001
•
Fever duration before enrollment (days): p = .021
•
Cough duration before enrollment (days): p = .026
Group 1: Patients with M. pneumoniae pneumonia – Acute M. pneumoniae was defined if at least one method was
positive among detection of M. pneumoniae by culture or by PCR or detection of M. pneumoniae -specific antibodies by
serology
Group 2: Patient with non- M. pneumoniae pneumonia
Primary outcome(s):
•
Variables identified from the logistic regression
•
Sensitivity and specificity of laboratory tests serology (IgM antibodies > 1.1 detected and fourfold increase of IgG
antibodies) and RT-PCR
Variables found to be more frequent in children with M. pneumoniae pneumonia were further analyzed by logistic
regression and the following were significantly associated with M. pneumoniae pneumonia
Variable
Odds Ratio
95% Confidence Interval
p value
[OR]
[CI]
Headache
36.077
4.897 – 265.811
p = 0.001
Wheezing
5.681
1.776 – 18.175
p = 0.003
Male gender
.162
0.048 – 0.548
p = 0.003
Age 5 and older
3.067
1.016 – 9.251
p = 0.047
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Sensitivity and specificity of laboratory tests
o Diagnostic values when using fourfold or greater increase of IgG antibody in paired sera as the gold standard
Test
Sensitivity
Specificity
Positive
Negative
(%)
(%)
Predictive
Predictive
Value (%)
Value (%)
Serology (IgM antibodies)
81.82
100
100
97.30
RT-PCR
81.82
98.61
90
97.26
o Diagnostic values when using RT-PCR as the gold standard
Test
Sensitivity
Specificity
(%)
(%)
Serology (IgM antibodies)
Serology (fourfold
increase IgG antibodies)

80
90

98.63
97.26

Positive
Predictive
Value (%)
88.89
81.82

Negative
Predictive
Value (%)
97.30
98.61
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Wang et al., 2012
Design
Objective

Methods

Diagnostic Quantitative Synthesis and Meta-analysis
There were two objectives of this SR/MA. They are (a) to assess the diagnostic accuracy of the signs and symptoms of M.
pneumoniae infection in children and adolescents, and (b) to assess the sources of heterogeneity.
Protocol and registration. It is a Cochrane systematic review and meta-analysis. It has gone through a development
process from protocol to report.
Types of studies. Published peer reviewed trials of diagnostic test accuracy that recruited subjects in a prospective and
consecutive manner. The presence of M. pneumoniae confirmed by serology. Data had to be available to construct 2X2
tables.
Participants. Children and adolescents aged less than or greater than 18 years with clinical or radiological diagnosis of
CAP. Subjects were excluded if a co-morbidity was present, such as cystic fibrosis or bronchiectasis; HIV or
immunosuppressant medication;
Index
•
•
•
•
•
•
•
•
•
•
•

tests. Clinical symptoms and signs including
Cough
Wheeze
Coryza
Crepitations
Fever (different definitions per each study)
Rhonchi
Shortness of breath
Chest pain
Diarrhea
Myalgia
Headache

Target Condition. M. pneumoniae in children and adolescents with CAP
Reference Standards. M. pneumoniae with or without the use of additional laboratory tests such as culture or PCR.
Serology is the most used test.
Information sources. There were no language or publication restrictions.
•
MEDLINE
•
EMBASE

* These guidelines do not establish a standard of care to be followed in every case. It is recognized that each case is different, and those individuals involved
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Search. An extensive search strategy is published in the paper’s appendix. The electronic search was augmented by handsearching references from the included studies reference lists. Medion database, Databases of Reviews of Effects 2012, and
the Cochrane Register of Diagnostic Test Accuracy studies were searched. The list of included studies was reviewed by
content experts to detect any studies that may have been omitted.
Study Selection. Peer reviewed studies of any design which included subjects who were prospectively and consecutively
enrolled into the study. Also, studies had to report data in enough detail to enable the construction of 2X2 tables.
Data collection process. Two authors collected data independently. The following data was collected: study
characteristics, where the study took place, health care setting, criteria for CAP diagnosis, and specifically M. pneumoniae
diagnosis. All discrepancies were resolved with a third author.
Methodological quality (Risk of Bias). The QUADAS tool was the basis for the assessment of bias.
Summary measures.
•
2X2 table were constructed for each study. Presence of M. pneumoniae
or sign.

versus the presence of a clinical symptom

Synthesis of results.
•
Included the prevalence of M. pneumoniae in the study population, and the influence on post-test probability of M.
pneumoniae.
•
Pooled sensitivities, specificities, negative and positive likelihood ratios with 95% confidence intervals, if at least
four studies were available for that sign or symptom.
•
Heterogeneity was explored evaluated by using mixed-effects logistic regression.
•
Covariates identified: age, health care setting, clinical versus clinical and radiological diagnosis, diagnosis of M.
pneumoniae by serology, and other laboratory investigations.

Results

Study Selection.
Number of articles identified: N = 8299
Full-text articles assessed for eligibility: n = 97
o Studies included in qualitative synthesis: n = 7
Synthesis of results.
•
Sensitivity & Specificity
•
+ Likelihood ratio, and – Likelihood ratio
•
Prevalence of M. pneumoniae assessed at 10% to 36%
Methodological quality of included studies (Risk of Bias).
•
Overall methodological quality was strong. Exceptions include:

* These guidelines do not establish a standard of care to be followed in every case. It is recognized that each case is different, and those individuals involved
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Five studies did not clearly report the exclusion of subjects with underlying co-morbidity, or
immunocompromise
One study did not use a suitable reference standard for the diagnosis of M. pneumoniae
Explicit description of blinding of either index or reference test results was not found in any study
Delay between index tests and reference tests was not reported well in 5/7 studies.
o

•
•
•
Discussion

Summary of evidence.
•
Overall, the signs and symptoms of CAP are not reliable in diagnosing pneumonia caused by M. pneumoniae.
•
Pooled estimates for presence of M. pneumoniae:
o Cough – Sensitive, but poorly specific
o Crepitations-Sensitive, but poorly specific
o Coryza- No better than chance
o Wheeze - Wheeze was 12% more likely to be absent in patients with M. pneumoniae (pooled LR+ = 0.76,
95% CI 0.60 to 0.97; pooled LR1- = 12, 95% CI 1.02 to 1.23).

Cough
Crepitations
Coryza
Wheeze
•

•
•

Pooled
Sensitivity
.89
.84
.32
.25

95% CI
[.67,
[.78,
[.08,
[.17,

.97]
.88]
.72]
.36]

Pooled
Specificity
.15
.22
.66
.67

95% CI
[.05,
[.14,
[.28,
[.56,

.37]
.32]
.91]
.76]

The following signs and symptoms could not be pooled and did not discriminate patients with or without M.
pneumoniae:
o Fever
o Rhonchi
o Shortness of breath
o Headache
o Chest pain
o Diarrhea
o Myalgia
The strongest symptom is absence of wheeze. It is a statistically significant diagnostic indicator, but errors of
classification can occur.
Based on a prevalence of 10-36%
o If empirical antibiotic were given to patients with CAP in whom wheeze was not reported, 61% to 89%
would not have M. pneumoniae positive serology or culture.
o Also, antibiotics would have been withheld from 25% of patients who were M. pneumoniae positive by
serology or culture.

* These guidelines do not establish a standard of care to be followed in every case. It is recognized that each case is different, and those individuals involved
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the time. It is impossible to anticipate all possible situations that may exist and to prepare guidelines for each. Accordingly, these guidelines should guide
care with the understanding that departures from them may be required at times.
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Limitations.
•
Few studies, and low number of subjects.
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